0001493152-21-020241.txt : 20210816 0001493152-21-020241.hdr.sgml : 20210816 20210816170316 ACCESSION NUMBER: 0001493152-21-020241 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210816 DATE AS OF CHANGE: 20210816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protagenic Therapeutics, Inc.\new CENTRAL INDEX KEY: 0001022899 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 061390025 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12555 FILM NUMBER: 211179547 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 994-8200 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Atrinsic, Inc. DATE OF NAME CHANGE: 20090630 FORMER COMPANY: FORMER CONFORMED NAME: NEW MOTION, INC. DATE OF NAME CHANGE: 20070504 FORMER COMPANY: FORMER CONFORMED NAME: MPLC, Inc. DATE OF NAME CHANGE: 20050608 10-Q 1 form10-q.htm
0001022899 false --12-31 Q2 Protagenic Therapeutics, Inc.\new 0001022899 2021-01-01 2021-06-30 0001022899 2021-08-13 0001022899 2021-06-30 0001022899 2020-12-31 0001022899 us-gaap:PreferredStockMember 2021-06-30 0001022899 us-gaap:PreferredStockMember 2020-12-31 0001022899 us-gaap:PreferredStockMember 2021-06-30 0001022899 us-gaap:PreferredStockMember 2020-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-06-30 0001022899 2021-04-01 2021-06-30 0001022899 2020-04-01 2020-06-30 0001022899 2020-01-01 2020-06-30 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2019-12-31 0001022899 us-gaap:CommonStockMember 2019-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001022899 us-gaap:RetainedEarningsMember 2019-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001022899 2019-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001022899 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001022899 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001022899 2020-01-01 2020-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-03-31 0001022899 us-gaap:CommonStockMember 2020-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001022899 us-gaap:RetainedEarningsMember 2020-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001022899 2020-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-04-01 2020-06-30 0001022899 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001022899 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-06-30 0001022899 us-gaap:CommonStockMember 2020-06-30 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001022899 us-gaap:RetainedEarningsMember 2020-06-30 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001022899 2020-06-30 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-12-31 0001022899 us-gaap:CommonStockMember 2020-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001022899 us-gaap:RetainedEarningsMember 2020-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001022899 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001022899 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001022899 2021-01-01 2021-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-03-31 0001022899 us-gaap:CommonStockMember 2021-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001022899 us-gaap:RetainedEarningsMember 2021-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001022899 2021-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-04-01 2021-06-30 0001022899 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001022899 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001022899 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-06-30 0001022899 us-gaap:CommonStockMember 2021-06-30 0001022899 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001022899 us-gaap:RetainedEarningsMember 2021-06-30 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001022899 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0001022899 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001022899 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001022899 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001022899 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001022899 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:PrivatePlacementMember 2021-06-30 0001022899 us-gaap:PrivatePlacementMember 2021-01-01 2021-06-30 0001022899 us-gaap:MeasurementInputExercisePriceMember 2020-12-31 0001022899 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001022899 us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001022899 us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001022899 us-gaap:MeasurementInputExpectedTermMember 2020-01-01 2020-12-31 0001022899 us-gaap:MeasurementInputExpectedDividendRateMember 2021-06-30 0001022899 PTIX:ConversionFeatureSharesMember 2021-01-01 2021-06-30 0001022899 PTIX:ConversionFeatureSharesMember 2020-01-01 2020-06-30 0001022899 us-gaap:StockOptionMember 2021-01-01 2021-06-30 0001022899 us-gaap:StockOptionMember 2020-01-01 2020-06-30 0001022899 us-gaap:WarrantMember 2021-01-01 2021-06-30 0001022899 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001022899 PTIX:ConvertibleNotesMember 2021-01-01 2021-06-30 0001022899 PTIX:ConvertibleNotesMember 2020-01-01 2020-06-30 0001022899 2021-09-28 2021-10-01 0001022899 PTIX:ConsultantMember 2019-10-02 0001022899 PTIX:ToxicologyStudiesMember 2021-01-01 2021-06-30 0001022899 PTIX:ToxicologyStudiesMember 2020-12-30 2020-12-31 0001022899 PTIX:ToxicologyStudiesMember 2021-06-30 0001022899 PTIX:ToxicologyStudiesMember 2020-12-31 0001022899 PTIX:PromissoryNoteMember 2021-03-01 0001022899 PTIX:PromissoryNoteMember 2021-01-01 2021-06-30 0001022899 PTIX:PromissoryNoteMember srt:MaximumMember 2021-03-01 0001022899 PTIX:PromissoryNoteMember 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesMember 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesMember 2020-12-31 0001022899 PTIX:UnsecuredConvertibleNotesMember 2021-01-01 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesMember 2020-01-01 2020-06-30 0001022899 PTIX:ConvertibleNotesMember 2021-06-30 0001022899 PTIX:ConvertibleNotesMember 2020-12-31 0001022899 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-06-30 0001022899 us-gaap:ConvertibleNotesPayableMember 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2021-01-01 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2020-01-01 2020-06-30 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2020-12-31 0001022899 PTIX:ConvertibleNotesPayableRelatedPartyMember 2021-01-01 2021-06-30 0001022899 PTIX:ConvertibleNotesPayableRelatedPartyMember 2021-06-30 0001022899 us-gaap:IPOMember 2021-04-28 2021-04-29 0001022899 us-gaap:IPOMember 2021-04-29 0001022899 us-gaap:IPOMember PTIX:FourtyFiveDayOptionMember 2021-04-29 0001022899 2021-04-28 2021-04-29 0001022899 PTIX:SeriesBPreferedStockMember 2021-06-30 0001022899 us-gaap:CommonStockMember 2021-06-30 0001022899 PTIX:TwoThousandSixteenPlanMember 2017-01-01 2017-01-02 0001022899 PTIX:TwoThousandSixteenPlanMember 2017-01-02 0001022899 PTIX:TwoThousandSixteenPlanMember 2020-12-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2021-06-30 0001022899 srt:MinimumMember 2021-06-30 0001022899 srt:MaximumMember 2021-06-30 0001022899 srt:MinimumMember 2021-01-01 2021-06-30 0001022899 srt:MaximumMember 2021-01-01 2021-06-30 0001022899 2020-01-01 2020-12-31 0001022899 srt:MinimumMember 2020-01-01 2020-12-31 0001022899 srt:MaximumMember 2020-01-01 2020-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001022899 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001022899 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001022899 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001022899 PTIX:EmployeesMember 2020-04-01 2020-06-30 0001022899 PTIX:NonEmployeesMember 2020-04-01 2020-06-30 0001022899 us-gaap:StockOptionMember 2021-01-01 2021-06-30 0001022899 us-gaap:StockOptionMember 2020-01-01 2020-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001022899 PTIX:NonEmployeesMember 2021-01-01 2021-06-30 0001022899 us-gaap:StockOptionMember 2021-06-30 0001022899 PTIX:EmployeesMember 2021-06-30 0001022899 PTIX:NonEmployeesMember 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember PTIX:FiveIndividualsMember 2021-02-24 2021-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:RelatedPartiesMember 2020-02-24 2020-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:SettlementOfAccruedCompensationMember 2020-02-24 2020-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:SettlementOfAccruedCompensationMember srt:MaximumMember 2020-02-24 2020-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:SettlementOfAccruedCompensationMember srt:MinimumMember 2020-02-24 2020-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:OptionsVestedOverFourtyEightMonthsMember 2021-02-24 2021-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:OptionsVestedOverFourtyEightMonthsMember 2020-02-24 2020-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:SettlementOfAccruedCompensationMember 2021-05-25 2021-05-26 0001022899 PTIX:OptionsToRelatedPartyMember 2021-06-30 0001022899 PTIX:OptionsToRelatedPartyMember 2021-01-01 2021-06-30 0001022899 us-gaap:WarrantMember 2021-06-30 0001022899 us-gaap:WarrantMember 2021-03-31 0001022899 us-gaap:WarrantMember 2021-04-01 2021-06-30 0001022899 PTIX:OptionsToRelatedPartyMember us-gaap:CommonStockMember 2021-06-30 0001022899 PTIX:UniversityOfTorontoMember 2015-01-01 2015-12-31 0001022899 PTIX:UniversityOfTorontoMember 2015-12-31 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember 2021-06-30 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-06-30 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-06-30 0001022899 PTIX:ResearchAgreementsMember 2021-01-01 2021-06-30 0001022899 PTIX:ResearchAgreementsMember 2020-01-01 2020-06-30 0001022899 us-gaap:LicensingAgreementsMember 2021-06-30 0001022899 us-gaap:SubsequentEventMember 2021-08-16 0001022899 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-08-16 0001022899 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2021-07-25 2021-07-26 0001022899 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2021-07-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended June 30, 2021

 

or

 

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from _________to___________

 

Commission File Number: 000-51353

 

PROTAGENIC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   06-1390025
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

149 Fifth Avenue, Suite 500, New York, New York 10010

(Address of Principal Executive Office) (Zip Code)

 

(212) 994-8200

Registrant’s Telephone Number Including Area Code

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Ticker symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001   PTIX   Nasdaq Capital Market
Common Stock Purchase Warrant   PTIXW   Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period

that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
Emerging Growth Company ☐    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 126-2 of the Exchange Act).

☐ Yes ☒ No

 

As of August 13, 2021 there were 16,699,651 shares of common stock outstanding.

 

 

 

 

 

 

PROTAGENIC THERAPEUTICS, INC.

Form 10-Q Report

For the Fiscal Quarter Ended June 30, 2021

TABLE OF CONTENTS

 

    Page
Part I. Financial Information  
     
Item 1 Financial Statements:  
     
  Consolidated Balance Sheets at June 30, 2021 (unaudited) and December 31, 2020 3
     
  Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2021 and 2020 (unaudited) 4
     
  Consolidated Statements of Changes in Stockholders’ Deficit for the three and six months ended June 30, 2021 and 2020 (unaudited) 5
     
  Consolidated Statements of Cash Flows for six months ended June 30, 2021 and 2020 (unaudited) 6
     
  Notes to Consolidated Financial Statements (unaudited) 7
     
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
     
Item 3 Quantitative and Qualitative Disclosures about Market Risk 19
     
Item 4 Controls and Procedures 19
     
Part II. Other Information  
     
Item 1 Legal Proceedings 21
     
Item 1A Risk Factors 21
     
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 21
     
Item 3 Defaults upon Senior Securities 21
     
Item 4 Mine Safety Disclosures 21
     
Item 5 Other Information 21
     
Item 6 Exhibits 22
     
Signatures 23

 

 

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

   June 30,   December 31, 
   2021   2020 
ASSETS          
           
CURRENT ASSETS          
           
Cash  $11,932,973   $671,091 
Prepaid expenses   129,167    208,156 
           
TOTAL CURRENT ASSETS   12,062,140    879,247 
           
TOTAL ASSETS  $12,062,140   $879,247 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
           
CURRENT LIABILITIES          
           
Accounts payable and accrued expenses  $602,587   $571,517 
Derivative liability   -    83,670 
           
TOTAL CURRENT LIABILITIES   602,587    655,187 
           
PIK convertible notes payable, net of debt discount   350,279    1,081,384 
PIK convertible notes payable, net of debt discount - related parties   311,136    292,412 
           
TOTAL LIABILITIES   1,264,002    2,028,983 
           
STOCKHOLDERS’ EQUITY (DEFICIT)          
Preferred stock, $0.000001 par value; 20,000,000 shares authorized; 872,766 shares issued and outstanding in the following classes:   -    - 
Preferred stock; par value $0.000001; 2,000,000 shares authorized; none issued and outstanding   -    - 
Series B convertible preferred stock, $0.000001 par value; 18,000,000 shares authorized;          
436,017 and 872,766 shares issued and outstanding at June 30, 2021, and December 31, 2020   1    1 
Common stock, $.0001 par value, 100,000,000 shares authorized, 16,263,634 and 10,360,480 shares issued and outstanding at June 30, 2021, and December 31, 2020   1,627    1,036 
Additional paid-in-capital   31,420,307    16,719,749 
Accumulated deficit   (20,453,184)   (17,698,936)
Accumulated other comprehensive loss   (170,613)   (171,586)
           
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)   10,798,138    (1,149,736)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)  $12,062,140   $879,247 

 

See accompanying notes to the unaudited consolidated financial statements

 

3 

 

 

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

 

   2021   2020   2021   2020 
   For the three months ended
June 30,		   For the six months ended
June 30,		 
   2021   2020   2021   2020 
OPERATING AND ADMINISTRATIVE EXPENSES                    
Research and development   140,592    52,008    732,943    117,967 
General and administrative   1,168,241    436,935    1,782,080    891,712 
                     
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES   1,308,833    488,943    2,515,023    1,009,679 
                     
LOSS FROM OPERATIONS   (1,308,833)   (488,943)   (2,515,023)   (1,009,679)
                     
OTHER (EXPENSE) INCOME                    
                     
Interest income   227    93    232    477 
Interest expense   (239,190)   (54,944)   (323,127)   (93,930)
Change in fair value of derivative liability   -    (23,560)   83,670    37,189 
                     
TOTAL OTHER INCOME (EXPENSES)   (238,963)   (78,411)   (239,225)   (56,264)
                     
LOSS BEFORE TAX   (1,547,796)   (567,354)   (2,754,248)   (1,065,943)
                     
INCOME TAX EXPENSE   -    -    -    - 
                     
NET LOSS  $(1,547,796)  $(567,354)  $(2,754,248)  $(1,065,943)
                     
COMPREHENSIVE LOSS                    
                     
Other Comprehensive Loss - net of tax                    
Foreign exchange translation income (loss)   482    1,084    973    (1,335)
                     
TOTAL COMPREHENSIVE LOSS  $(1,547,314)  $(566,270)  $(2,753,275)  $(1,067,278)
                     
Net loss per common share - Basic and Diluted  $(0.11)  $(0.06)  $(0.22)  $(0.10)
                     
Weighted average common shares - Basic and Diluted   14,487,277    10,261,419    12,488,906    10,261,419 

 

See accompanying notes to the unaudited consolidated financial statements

 

4 

 

 

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

For the Three and Six Months Ended June 30, 2021 and 2020

(Unaudited)

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Loss   Deficit 
   Series B Convertible           Additional       Accumulated Other     
   Preferred Stock   Common Stock   Paid-in-   Accumulated   Comprehensive   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Loss   Deficit 
                                 
For the six months ended June 30, 2020                                        
                                         
BALANCE -December 31, 2019   872,766   $1    10,261,419   $1,026   $14,687,172   $(15,150,201)  $(172,364)  $        (634,366)
                                         
Foreign currency translation loss   -    -    -    -    -    -    (2,419)   (2,419)
Stock compensation - stock options   -    -    -    -    360,436    -    -    360,436 
Debt discount from beneficial conversion feature   -    -    -    -    89,204    -    -    89,204 
Issuance of options for settlement of accrued payroll   -    -    -    -    93,950    -    -    93,950 
Modification of warrants   -    -    -    -    5,861    -    -    5,861 
                                         
Net loss   -    -    -    -    -    (498,589)   -    (498,589)
                                         
BALANCE -March 31, 2020   872,766   $1    10,261,419   $1,026   $15,236,623   $(15,648,790)  $(174,783)  $(585,923)
                                         
Foreign currency translation loss   -    -    -    -    -    -    1,084    1,084 
Stock compensation - stock options   -    -    -    -    304,148    -    -    304,148 
Debt discount from beneficial conversion feature   -    -    -    -    86,968    -    -    86,968 
Issuance of options for settlement of accrued payroll   -    -    -    -    15,000    -    -    15,000 
                                         
Net loss   -    -    -    -    -    (567,354)   -    (567,354)
                                         
BALANCE - June 30, 2020   872,766   $1    10,261,419   $1,026   $15,642,739   $(16,216,144)  $(173,699)  $(746,077)
                                         
For the six months ended June 30, 2021                                        
                                         

BALANCE -December 31 , 2020

   872,766   $1    10,360,480   $1,036   $16,719,749   $(17,698,936)  $(171,586)  $(1,149,736)
                                         
Foreign currency translation loss   -    -    -    -    -    -    491    491 
Stock compensation - stock options   -    -    -    -    345,975    -    -    345,975 
Exercise of options   -    -    10,000    1    (1)   -    -    - 
Exercise of warrants   -    -    240,123    24    27,101    -    -    27,125 
                                         
Net loss   -    -    -    -    -    (1,206,452)   -    (1,206,452)
                                         
BALANCE -March 31, 2021   872,766   $1    10,610,603   $1,061   $17,092,824   $(18,905,388)  $(171,095)  $(1,982,597)
                                         
Foreign currency translation gain   -    -    -    -    -    -    482    482 
Issuance of shares and warrants from offering, net of offering costs   -    -    3,180,000    318    11,707,721    -    -    11,708,039 
Stock compensation - stock options   -    -    -    -    722,966    -    -    722,966 
Exercise of options   -    -    360,000    36    542,464    -    -    542,500 
Exercise of warrants   -         836,558    84    299,916    -    -    300,000 
Conversion of preferred stock   (436,749)        436,749    44    (44)   -    -    - 
Conversion of notes and interest             839,724    84    1,054,460    -    -    1,054,544 
                                         
Net loss   -    -    -    -    -    (1,547,796)   -    (1,547,796)
                                         
BALANCE - June 30, 2021   436,017   $1    16,263,634   $1,627   $31,420,307   $(20,453,184)  $(170,613)  $10,798,138 

 

See accompanying notes to the unaudited consolidated financial statements

 

5 

 

 

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2021   2020 
   For the six months ended June 30, 
   2021   2020 
         
CASH FLOWS FROM OPERATING ACTIVITIES          
Net Loss  $(2,754,248)  $(1,065,943)
Adjustments to reconcile net loss to net cash used in operating activities          
Depreciation expense   -    165 
Stock based compensation   1,068,941    751,552 
Change in fair value of the derivative liability   (83,670)   (37,189)
Amortization of debt discount   277,619    58,923 
Modification of warrants   -    5,861 
Changes in operating assets and liabilities          
Prepaid expenses   78,990    36,856 
Accounts payable and accrued expenses   94,278    (260,322)
           
NET CASH USED IN OPERATING ACTIVITIES   (1,318,090)   (510,097)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
           
Exercise of warrants for cash   327,125    - 
Exercise of options for cash   542,500    - 
Issuance of shares and warrants from offering, net of offering costs   11,708,039    - 
Proceeds from notes payable   100,000    - 
Repayment of notes payable   (100,000)   - 
Proceeds from PIK convertible notes   -    850,000 
Proceeds from PIK convertible notes - related party   -    50,000 
           
NET CASH PROVIDED BY FINANCING ACTIVITIES   12,577,664    900,000 
           
Effect of exchange rate on cash   2,308    (7,230)
           
NET INCREASE IN CASH   11,261,882    382,673 
           
CASH, BEGINNING OF YEAR   671,091    798,623 
           
CASH, END OF YEAR  $11,932,973   $1,181,296 
           
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION          
Cash paid for interest expense  $-   $- 
Cash paid for income taxes  $-   $- 
           
NONCASH FINANCING AND INVESTING TRANSACTIONS          
Shares issued for conversion of notes and interest  $1,054,544   $- 
Debt discount from beneficial conversion feature  $-   $104,204 
Issuance of options for settlement of accounts payable  $-   $93,950 

 

See accompanying notes to the unaudited consolidated financial statements

 

6 

 

 

PROTAGENIC THERAPEUTICS, INC & SUBSIDIARY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

June 30, 2021

 

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

 

Company Background

 

Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), is a Delaware corporation with one subsidiary named Protagenic Therapeutics Canada (2006) Inc. (“PTI Canada”), a corporation formed in 2006 under the laws of the Province of Ontario, Canada.

 

The Company was previously known as Atrinsic, Inc., a company that was once a reporting company under the Securities Exchange Act of 1934, but that, in 2012 and 2013, reorganized under Chapter 11 of the United States Bankruptcy Code and emerged from bankruptcy. On February 12, 2016, the Company acquired Protagenic Therapeutics, Inc. (“Prior Protagenic”) through a reverse merger.

 

On February 12, 2016, Protagenic Acquisition Corp., a wholly-owned subsidiary of the Company, merged (the “Merger”) with and into Prior Protagenic. Prior Protagenic was the surviving corporation of the Merger. As a result of the Merger, the Company acquired the business of Prior Protagenic and has continued the existing business operations of Prior Protagenic as a wholly-owned subsidiary. On June 17, 2016, Prior Protagenic merged with and into the Company with the Company as the surviving corporation in the merger. Immediately thereafter, the Company changed its name from Atrinsic, Inc. to Protagenic Therapeutics, Inc.

 

NOTE 2 - LIQUIDITY

 

As shown in the accompanying consolidated financial statements, the Company has incurred significant recurring losses resulting in an accumulated deficit. The Company anticipates further losses in the development of its business. The Company also had negative cash flows used in operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

Based on its cash resources as of June 30, 2021, the Company has sufficient resources to fund its operations at least until the end of the third quarter of 2023. Absent generation of sufficient revenue from the execution of the Company’s business plan and sales revenue is not anticipated before 2024, the Company will need to obtain debt or equity financing by the third quarter of 2023. Because of these factors, the Company believes that this alleviates the substantial doubt in connection with the Company’s ability to continue as a going concern.

 

NOTE 3 - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC” for interim financial information. In the opinion of the Company’s management, the accompanying consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended June 30, 2021 and 2020. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).

 

7 

 

 

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2020, which contain the audited financial statements and notes thereto, for the years ended December 31, 2020 and 2019 included within the Company’s Form 10-K filed with the SEC on March 25, 2021. The interim results for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

 

Principles of consolidation

 

The condensed consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in the condensed consolidated financial statements.

 

Reclassifications:

 

Reclassifications of prior periods have been made to conform with current year presentation

 

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include income tax provisions, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.

 

Concentrations of Credit Risk

 

The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. As of June 30, 2021, the Company has bank balances that exceeds the federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of June 30, 2021 and December 31, 2020, the Company did not have any cash equivalents.

 

Fair Value Measurements

 

ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

 

The three levels are described below:

 

Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;

 

Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;

 

8 

 

 

Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.

 

The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short term maturity of those instruments. The carrying value of long-term debt approximates fair value since the related rates of interest approximate current market rates.

 

Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.

 

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of June 30, 2021.

 

   Carrying   Fair Value Measurement Using 
   Value   Level 1   Level 2   Level 3   Total 
                          
Derivative warrants liabilities  $—   $—   $—   $—   $— 

 

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.

 

   Carrying   Fair Value Measurement Using 
   Value   Level 1   Level 2   Level 3   Total 
                          
Derivative warrants liabilities  $83,670   $—   $—   $83,670   $83,670 

 

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2021 and the year ended December 31, 2020:

 

   Fair Value Measurement Using Level 3 
   Inputs Total 
Balance, December 31, 2020  $83,670 
Change in fair value of derivative warrants liabilities   (83,670)
Balance, June 30, 2021  $- 

 

The fair value of the derivative feature of the 127,346 and 295,945 warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet dates were calculated using a Black-Scholes option model valued with the following assumptions:

 

   December 31, 2020 
Exercise price   1.25 
Risk free interest rate   0.09%
Dividend yield   0.00%
Expected volatility   169%
Contractual term   0.14 Years 

 

9 

 

 

Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement.

 

Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.

 

Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term.

 

Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants.

 

During the six months ended June 30, 2021 and 2020, the Company marked the derivative feature of the warrants to fair value and recorded a gain of $83,670 and a gain of $37,189 relating to the change in fair value, respectively. The warrants expired on February 21, 2021, resulting in the elimination of the derivative liability.

 

Derivative Liability

 

The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10-05-4 and 815-40-25. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the condensed consolidated statements of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then the related fair value is reclassified to equity.

 

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

 

Stock-Based Compensation

 

The Company accounts for stock based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or canceled during the periods reported.

 

If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.

 

Basic and Diluted Net (Loss) per Common Share

 

Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.

 

10 

 

 

   Potentially Outstanding
Dilutive Common Shares		 
   For the Six Months Ended June 30, 2021   For the Six Months Ended June 30, 2020 
         
Conversion Feature Shares          
           
Common shares issuable under the conversion feature of preferred shares   436,017    872,766 
           
Stock Options   5,493,861    4,028,162 
           
Warrants   6,132,630    3,908,258 
           
Convertible Notes   806,000    1,256,000 
           
Total potentially outstanding dilutive common shares   12,868,508    10,065,186 

 

Research and Development

 

Research and development expenses are charged to operations as incurred.

 

Foreign Currency Translation

 

The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.

 

The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the condensed consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the condensed consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the condensed consolidated statements of operations and comprehensive loss.

 

Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.

 

11 

 

 

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

 

NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses consist of the following at:

   June 30, 2021   December 31, 2020 
         
Accounting  $36,161   $36,161 
Research and development   381,702    393,496 
Other   184,724    141,860 
           
Total  $602,587   $571,517 

 

On October 1, 2019, the Company entered into an agreement with a consultant for toxicology studies. The consultant quoted a commitment of approximately $988,000 as an estimate for the study. 50% of the total price was paid upon the signing of the agreement, 35% of the total price is to be paid upon completion of the in-life study, and the remaining 15% of the total price is to be paid upon the issuance of the report. If the Company cancels the study the Company will be required to pay a cancelation fee. If the cancelation happens prior to the arrival of the test animals then the Company will need to pay between 20% and 50% of the animal fees depending on when the cancellation happens. If the cancellation occurs after the animals arrive but before the study begins then the Company will be responsible for paying 50% of the protocol price plus a fee of $7,000 per room/week for animal husbandry until the animals can be relocated or disposed of. If the Company cancels the study after it has begun then the Company will need to pay any fees for procured items for the study and any nonrecoverable expenses incurred by the consultant. As of June 30, 2021 and December 31, 2020, the Company has paid $174,106 and $174,106 to the consultant and there is a balance of $319,799 and $319,799 due, respectively.

 

NOTE 5 – NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)

 

Note Payable

 

On March 1, 2021, the Company entered into a $100,000 promissory note. This note is due on February 28, 2026 and accrues interest at a rate of 5% per annum or 7.5% per annum in the case of default. In the event that the Company completes a financing of no less than $7.5 million, then the note holder will be issued warrants valued at $25,000 with an exercise price equal to 110% of the offering cost of the common stock in the financing. These warrants will have a term of five years. During the six months ended June 30, 2021, the Company paid off the balance of this note’s principal and accrued interest.

 

As of June 30, 2021 and December 31, 2020, the Company owes $0 and $0 on the outstanding note, respectively.

 

Convertible Notes Payable

 

During the six months ended June 30, 2021 and 2020, the Company amortized $72,110 and $40,095 of the debt discount, respectively. At June 30, 2021 and December 31, 2020, the Company had an unamortized debt discount of $257,221 and $516,116, respectively.

 

During the six months ended June 30, 2021, a total of 839,724 shares of the Company’s common stock was issued for the conversion of notes and interest. A total of $990,000 in principal and $64,544 in accrued interest was converted. As part of this conversion, the Company also expensed $186,785 in unamortized debt discount related to these converted notes.

 

12 

 

 

As of June 30, 2021 and December 31, 2020, the Company owes $607,500 and $1,597,500 on the outstanding Convertible Notes, respectively.

 

     
Maturity Date of Notes for Twelve Months Ending June 30, 2021,  Amount due 
2022  $- 
2023   - 
2024   607,500 
2025   - 
2026   - 
Total  $607,500 

 

Convertible Notes Payable – Related Parties

 

During the six months ended June 30, 2021 and 2020, the Company amortized $18,724 and $18,828 of the debt discount, respectively. At June 30, 2021 and December 31, 2020, the Company had an unamortized debt discount of $88,864 and $107,588, respectively.

 

As of June 30, 2021 and December 31, 2020, the Company owes $400,000 and $400,000 on the outstanding Convertible Notes, respectively.

 

     
Maturity Date of Notes for Twelve Months Ending June 30, 2021,  Amount due 
2022  $- 
2023   - 
2024   400,000 
2025   - 
2026   - 
Total  $400,000 

 

NOTE 6 - STOCKHOLDERS’ DEFICIT

 

Common Stock

 

On April, 29, 2021, the Company completed a public offering (“the Offering”) to sell an aggregate of 3,180,000 shares of the Company’s common stock together with warrants to purchase an aggregate of 3,180,000 shares of common stock. The Company also granted the underwriters warrants to purchase an aggregate of 477,000 shares of Common Stock at the same price. Net proceeds from the Offering were approximately $11.7 million (excluding any sale of the Option Shares), after deducting underwriting discounts and commissions and public offering expenses payable by the Company.

 

During the six months ended June 30, 2021, a total of 436,749 shares of the Company’s Series B preferred stock was converted to 436,749 shares of the Company’s common stock.

 

Stock-Based Compensation

 

In connection with the consummation of the Merger completed on February 12, 2016, we adopted Prior Protagenic’s 2006 Employee, Director and Consultant Stock Plan (the “2006 Plan”). On June 17, 2016, our stockholders adopted the 2016 Plan and, as a result, we terminated the 2006 Plan. We will not grant any further awards under the 2006 Plan. All outstanding grants under the 2006 Plan will continue in effect in accordance with the terms of the particular grant and the 2006 Plan.

 

Pursuant to the 2016 Plan, the Company’s Compensation Committee may grant awards to any employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary. On each of January 1, 2017, January 1, 2019 and January 1, 2020, pursuant to an annual “evergreen” provision contained in the 2016 Plan, the number of shares reserved for future grants was increased by 564,378 shares, or a total of 1,693,134 shares. As a result of these increases, as of June 30, 2021 and December 31, 2020, the aggregate number of shares of common stock available for awards under the 2016 Plan was 4,868,623 shares and 4,868,623 shares, respectively. Options issued under the 2016 Plan are exercisable for up to ten years from the date of issuance.

 

13 

 

 

There were 5,493,861 options outstanding as of June 30, 2021. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

 

      
Exercise price  $3.65-5.60 
Expected dividend yield   0%
Risk free interest rate   0.81%-1.58%
Expected life in years   5-10 
Expected volatility   148%-158 %

 

There were 5,597,861 options outstanding as of December 31, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

 

      
Exercise price  $1.75 
Expected dividend yield   0%
Risk free interest rate   0.64%-1.61%
Expected life in years   10 
Expected volatility   140%-146%

 

The following is an analysis of the stock option grant activity under the Plan:

 

       

Weighted

Average

    

Weighted

Average

  
  Number     Exercise Price     Remaining Life  
Stock Options                      
                       
Outstanding December 31, 2020   5,597,861     $ 1.47       6.48  
Granted   546,000     $ 4.96       9.60  
Expired   (280,000 )   $ 1.00       -  
Exercised   (370,000 )   $ 1.48       -  
Outstanding June 30, 2021   5,493,861     $ 1.84       6.79  

 

A summary of the status of the Company’s nonvested options as of June 30, 2021, and changes during the six months ended June 30, 2021, is presented below:

 

Nonvested Options  Options  

Weighted-

Average
Exercise Price

 
Nonvested at December 31, 2020   862,833   $1.75 
Granted   546,000   $4.96 
Vested   (433,979)  $3.32 
Forfeited   -   $- 
Nonvested at June 30, 2021   974,854   $3.02 

 

As of June 30, 2021, the Company had 5,493,861 shares issuable under options outstanding at a weighted average exercise price of $1.84 and an intrinsic value of $5,701,038

 

The total number of options granted during the six months ended June 30, 2021 and 2020 was 546,000 and 1,387,497, respectively. The exercise price for these options was $3.65 or $5.60 per share.

 

The Company recognized compensation expense related to options issued of $722,966 and $304,148 during the three months ended June 30, 2021 and 2020, respectively, in which $721,490 and $269,408 is included in general and administrative expenses and $1,476 and $34,740 in research and development expenses, respectively. For the three months ended June 30, 2021, $528,197 of the stock compensation was related to employees and $194,769 was related to non-employees.

 

14 

 

 

The Company recognized compensation expense related to options issued of $1,068,941 and $751,552 during the six months ended June 30, 2021 and 2020, respectively, in which $1,065,988 and $595,202 is included in general and administrative expenses and $2,953 and $69,381 in research and development expenses, respectively. For the six months ended June 30, 2021, $664,400 of the stock compensation was related to employees and $404,541 was related to non-employees.

 

As of June 30, 2021, the unamortized stock option expense was $2,541,457 with $343,794 being related to employees and $2,197,663 being related to non-employees. As of June 30, 2021, the weighted average period for the unamortized stock compensation to be recognized is 3.58 years.

 

On February 25, 2021, the Company issued a total of 366,000 options to purchase shares of the Company’s common stock to five individuals, with 350,000 of these options being issued to related parties. These options had a grant date fair value of $2,009,063. These options have an exercise price of $5.60 and a term of 10 years or 5 years. 16,000 of the options vest immediately and 350,000 of the options vest monthly over 48 months.

 

On May 26, 2021, the Company issued a total of 180,000 options to purchase shares of the Company’s common stock to a related party. These options had a grant date fair value of $474,231. These options have an exercise price of $3.65, a term of 10 years, and vest immediately.

 

During the three months ended March 31, 2021, 10,000 options were exercised for 10,000 shares of the Company’s common stock. These options had an exercise price of $1.00.

 

During the three months ended June 30, 2021, the Company issued 360,000 shares of the Company’s common stock to a related party for the exercise of 360,000 options. The Company received proceeds of $532,500 from the exercise.

 

Warrants:

 

A summary of warrant issuances are as follows:

 

      

Weighted

Average

  

Weighted

Average

 
   Number   Exercise Price   Remaining Life 
Warrants               
                
Outstanding December 31, 2020   4,007,058   $1.06    1.86 
Granted   3,657,000    4.98    4.83 
Expired   (150,249)   1.25    - 
Exercised   (1,381,179)   1.13    - 
Outstanding June 30, 2021   6,132,630   $3.38    3.65 

 

As of June 30, 2021, the Company had 6,132,630 shares issuable under warrants outstanding at a weighted average exercise price of $3.38 and an intrinsic value of $4,629,869.

 

During the three months ended March 31, 2021, 373,042 warrants were exercised for 240,123 shares of the Company’s common stock. The Company received $27,125 from these exercises.

 

During the three months ended June 30, 2021, the Company issued 836,558 shares of the Company’s common stock for the net exercise of 1,008,137 warrants. 231,277 of these shares of common stock were issued to a related party. The Company received proceeds of $300,000 from the exercise.

 

15 

 

 

NOTE 7 - COLLABORATIVE AGREEMENTS

 

The Company and the University of Toronto (the “University”) entered into an agreement effective April 1, 2014 (the “New Research Agreement”) for the performance of a research project titled “Teneurin C-terminal Associated Peptide (“TCAP”) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The New Project is to perform research related to work done by Dr. David A. Lovejoy, a professor at the University and stockholder of the Company, in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, Dr. Lovejoy entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 30, 2016. In February 2017, the New Research Agreement was extended to December 31, 2017. The extension allowed for further development of the technologies and use of their applications. On April 10, 2018, the agreement was amended and the research agreement has been further extended to December 31, 2023.

 

Prior to January 1, 2016, the University has been granted 25,000 stock options which are fully vested at the exercise price of $1.00 exercisable over a ten year period which ends on April 1, 2022. As of June 30, 2021, Dr. David Lovejoy of the University has been granted 553,299 stock options, of which 435,487 are fully vested and 100,000 have expired. These have an exercise price of $1.00, $1.25 or 1.75 and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027, October 16, 2027 or on February 13, 2030.

 

The sponsorship research and development expenses pertaining to the Research Agreements were $0 and $0 for the six months ended June 30, 2021 and 2020, respectively.

 

NOTE 8 - COMMITMENTS AND CONTINGENCIES

 

Licensing Agreements

 

On July 31, 2005, the Company had entered into a Technology License Agreement (“License Agreement”) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the “Technologies”). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.

 

Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no sales revenue for the six months ended June 30, 2021 and 2020 and therefore was not subject to paying any royalties.

 

In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or Dr. Lovejoy, and/or the University, as the case may be. The Company has agreed to pay all out-of- pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment.

 

The patent applications were made in the name of Dr. Lovejoy and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the five intellectual patent properties.

 

16 

 

 

Legal Proceedings

 

From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

 

NOTE 9 – RELATED PARTY TRANSACTIONS

 

The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen. The Company does not pay any rent for the use of this space. This space is used for quarterly board meetings and our annual shareholder meeting.

 

NOTE 10- SUBSEQUENT EVENTS

 

Subsequent to the period, a total of 436,017 shares of the Company’s preferred stock was converted to 436,017 shares of the Company’s common stock.

 

On July 26, 2021, the Company issued 32,000 options to purchase share of the Company’s common stock. These options have a term of ten years, an exercise price of $2.09, and vest over 48 months.

 

17 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q and other written and oral statements we make from time to time contain certain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). You can identify these forward-looking statements by the fact they use words such as “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will,” “potential,” “opportunity,” “future” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. You can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These statements relate to, among other things, our business strategy, our research and development, our product development efforts, our ability to commercialize our product candidates, the activities of our licensees, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations, and intentions.

 

We have included more detailed descriptions of these risks and uncertainties and other risks and uncertainties applicable to our business that we believe could cause actual results to differ materially from any forward-looking statements in Part II-Item 1A “Risk Factors” of this Quarterly Report on Form 10-Q. We encourage you to read those descriptions carefully. Although we believe we have been prudent in our plans and assumptions, no assurance can be given that any goal or plan set forth in forward-looking statements can be achieved. We caution investors not to place significant reliance on forward-looking statements contained in this document; such statements need to be evaluated in light of all the information contained in this document. Furthermore, the statements speak only as of the date of this document, and we undertake no obligation to update or revise these statements.

 

The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base these estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

We expect to continue to incur significant expenses and minimal positive net cash flows from operations or negative net cash flows from operations for the foreseeable future, and those expenses and losses may fluctuate significantly from quarter-to-quarter and year-to-year. We anticipate that our expenses will fluctuate substantially as we:

 

  ● continue our ongoing preclinical studies, clinical trials and our product development activities for our pipeline of product candidates;
     
  ● seek regulatory approvals for any product candidates that successfully complete clinical trials;
     
  ● continue research and preclinical development and initiate clinical trials of our other product candidates;
     
  ● seek to discover and develop additional product candidates either internally or in partnership with other pharmaceutical companies;
     
  ● adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;
     
  ● maintain, expand and protect our intellectual property portfolio; and
     
  ● incur additional legal, accounting and other expenses in operating as a public company.

 

18 

 

 

Results of Operations

 

We are a development stage company currently performing clinical trials to obtain Food and Drug Administration (“FDA”) approval and commercialization of our product.

 

During the three months ended June 30, 2021, we incurred a loss from operations of $1,308,833 as compared to $488,943 for the three months ended June 30, 2020. The increase in the loss is due to an increase in research and development expense of $88,584 from $52,008 for the three months ended June 30, 2020 to $140,592 for the three months ended June 30, 2021, and by an increase in general and administrative expenses of $731,306 from $436,935 for the three months ended June 30, 2020 to $1,168,241 for the three months ended June 30, 2021.

 

During the six months ended June 30, 2021, we incurred a loss from operations of $2,515,023 as compared to $1,009,679 for the six months ended June 30, 2020. The increase in the loss is due to an increase in research and development expense of $614,976 from $117,967 for the six months ended June 30, 2020 to $732,943 for the six months ended June 30, 2021, and by an increase in general and administrative expenses of $890,368 from $891,712 for the six months ended June 30, 2020 to $1,782,080 for the six months ended June 30, 2021.

 

Liquidity and Going Concern

 

We continually project anticipated cash requirements, predominantly from the ongoing funding requirements of our neuropeptide drug development program. The majority of these expenses relate to paying external vendors such as Contract Research Organizations and peptide synthesizer companies. These expenses could also include business combinations, capital expenditures, and new drug development working capital requirements. As of June 30, 2021, we had cash of $11,932,973 and working capital of $11,459,553. We anticipate further losses from the development of our business. Based on its cash resources as of June 30, 2021, the Company has sufficient resources to fund its operations at least until the end of the second quarter of 2023. Absent generation of sufficient revenue from the execution of the Company’s business plan, the Company will need to obtain debt or equity financing by the third quarter of 2023. Because of these factors, the Company believes that this alleviates substantial doubt in connection with the Company’s ability to continue as a going concern.

 

Operating activities used $1,318,090 and $510,097 in cash for the six months ended June 30, 2021 and 2020, respectively. The use of cash in operating activities during the six months ended June 30, 2021, primarily comprised of $2,754,248 net loss, $1,068,941 in stock compensation expense, $83,670 of change in the fair value of the derivative liability since December 31, 2020, an increase in prepaid expenses of $78,990, and a $94,278 increase of accounts payable and accrued expenses, which included payments to tax penalties, legal and accounting professionals, payments to consultants, and other administrative expenses.

 

Investing activities provided $0 and $0 in cash for the six months ended June 30, 2021 and 2020, respectively.

 

Financing activities provided $12,577,664 and $900,000 in cash the six months ended June 30, 2021 and 2020. The cash provided by operations came from proceeds from issuance of shares and warrants from the offering net of offering costs of $11,708,039, exercise of options of $542,500, and exercise of warrants of $327,125.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

19 

 

 

Evaluation of disclosure controls and procedures

 

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act), as of June 30, 2021. Based on this evaluation, we have identified material weaknesses in our internal control over financial reporting. Due to material weaknesses, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are not effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, including this Quarterly Report on Form 10-Q, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that our disclosure and controls are not designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Material Weakness in Internal Control Over Financial Reporting

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

The material weaknesses we identified are described below:

 

  1) We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.
     
  2) Limited level of multiple reviews among those tasked with preparing the financial statements.

 

These material weaknesses could result in a material misstatement to the annual or interim condensed consolidated financial statements that would not be prevented or detected.

 

Remediation Plan

 

To address the material weakness described above the Company has engaged an independent third party to enhance our segregation of duties.

 

Since we remain a small Company, with limited segregation of duties, the third party has identified certain areas where we can layer in added controls and procedures. Management intends to implement such controls and procedures in the future.

 

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the control system are met. The design of any system of controls is also based in part on certain assumptions regarding the likelihood of certain events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Given these and other inherent limitations of control systems, these are only reasonable assurances that our controls will succeed in achieving their stated goals under all potential future conditions.

 

Changes in Internal Control over Financial Reporting

 

Other than as discussed above, there were no changes in our internal controls over financial reporting that occurred during the quarter covered by this Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

20 

 

 

Part II: Other Information

 

Item 1. Legal Proceedings

 

From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

 

Item 1A. Risk Factors

 

This Quarterly Report on Form 10-Q contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our actual future results, including our revenues, expenses, operating results, cash flows and net loss per share. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. You should carefully consider these risk factors, together with all of the other information included in this Quarterly Report on Form 10-Q as well as our other publicly available filings with the U.S. Securities and Exchange Commission, or SEC.

 

There have been no material changes to our risk factors from those disclosed under “Risk Factors” in Part I, Item 1A of the 2020 Form 10-K. The risks and uncertainties described below and in the 2020 Form 10-K are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition, or results of operations.

 

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds

 

During the three months ended March 31, 2021, 373,042 warrants were exercised for 240,123 shares of the Company’s common stock. The Company received $27,125 from these exercises.

 

During the three months ended March 31, 2021, 10,000 options were exercised for 10,000 shares of the Company’s common stock

 

During the three months ended June 30, 2021, the Company issued 836,558 shares of the Company’s common stock for the net exercise of 1,008,137 warrants. 231,277 of these shares of common stock were issued to a related party. The Company received proceeds of $300,000 from the exercise.

 

During the six months ended June 30, 2021, a total of 436,749 shares of the Company’s preferred stock was converted to 436,749 shares of the Company’s common stock.

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

21 

 

 

Item 6. Exhibits

 

The following is a complete list of exhibits filed as part of this Form 10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.

 

Exhibit   Description
     
31.1   Chief Executive Officer Certification as required under section 302 of the Sarbanes Oxley Act (€)
     
31.2   Chief Financial Officer Certification as required under section 302 of the Sarbanes Oxley Act (€)
     
32.1   Chief Executive Officer and Chief Financial Officer Certification pursuant to 18 U.S.C. section 1350 as adopted pursuant to section 906 of the Sarbanes Oxley Act *
     
101.INS   XBRL Instance Document (€)
     
101.CAL   XBRL Taxonomy Extension Schema Document (€)
     
101.SCH   XBRL Taxonomy Extension Calculation Linkbase Document (€)
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document (€)
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document (€)
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document (€)

 

(€) - Filed herewith.

 

 

(*)  -Furnished, not filed, in accordance with item 601(32)(ii) of Regulation S-K.

 

22 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

August 16, 2021 Protagenic Therapeutics, Inc.
   
  By: /s/ Alexander K. Arrow
    Chief Financial Officer

 

23 

 

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

I, Garo H. Armen, PhD, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Protagenic Therapeutics, Inc..
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

August 16, 2021   /s/ Garo H. Armen
  Name: Garo H. Armen, Ph.D.
  Title: Executive Chairman

 

 
 EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

I, Garo H. Armen, PhD, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Protagenic Therapeutics, Inc..
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

August 16, 2021   /s/ Garo H. Armen
  Name: Garo H. Armen, Ph.D.
  Title: Executive Chairman

 

 

 

 

 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Protagenic Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Garo H. Armen, Executive Chairman, and Alexander K. Arrow, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

August 16, 2021 By: /s/ Garo H. Armen
    Garo H. Armen, PhD
    Executive Chairman
    (Principal Executive Officer)

 

August 16, 2021 By: /s/ Alexander K. Arrow
    Alexander K. Arrow, MD, CFA
    Chief Financial Officer
    (Principal Financial Officer)

 

 

 

 EX-101.SCH 5 ptix-20210630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements Of Changes In Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - STOCKHOLDERS’ DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COLLABORATIVE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - STOCKHOLDERS’ DEFICIT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SCHEDULE OF MATURITY DATE OF NOTES (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SUMMARY OF WARRANT ISSUANCES (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCKHOLDERS’ DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - COLLABORATIVE AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 ptix-20210630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 ptix-20210630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 ptix-20210630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Preferred Stock [Member] Equity Components [Axis] Series B Convertible Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Measurement Input Type [Axis] Reported Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Estimate of Fair Value Measurement [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Sale of Stock [Axis] Private Placement [Member] Measurement Input, Exercise Price [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Term [Member] Antidilutive Securities [Axis] Conversion Feature Shares [Member] Equity Option [Member] Warrant [Member] Convertible Notes [Member] Title of Individual [Axis] Consultant [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Toxicology Studies [Member] Debt Instrument [Axis] Promissory Note [Member] Statistical Measurement [Axis] Maximum [Member] Unsecured Convertible Notes [Member] Convertible Notes Payable [Member] Unsecured Convertible Notes With Related Parties [Member] Convertible Notes Payable Related Party [Member] IPO [Member] Award Type [Axis] 45-day Option [Member] Series B Prefered Stock [Member] Plan Name [Axis] 2016 Plan [Member] Minimum [Member] Share-based Payment Arrangement, Option [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Research and Development Expense [Member] Employees [Member] Non-Employees [Member] 5 Individuals [Member] Related Parties [Member] Scenario [Axis] Settlement of Accrued Compensation [Member] Options Vested Over 48 Months [Member] Related Party Transaction [Axis] Options To Related Party [Member] Counterparty Name [Axis] University of Toronto [Member] Dr. David Lovejoy [Member] Research Agreements [Member] Finite-Lived Intangible Assets by Major Class [Axis] Licensing Agreements [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Prepaid expenses TOTAL CURRENT ASSETS TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) CURRENT LIABILITIES Accounts payable and accrued expenses Derivative liability TOTAL CURRENT LIABILITIES PIK convertible notes payable, net of debt discount PIK convertible notes payable, net of debt discount - related parties TOTAL LIABILITIES STOCKHOLDERS’ EQUITY (DEFICIT) Preferred stock, $0.000001 par value; 20,000,000 shares authorized; 872,766 shares issued and outstanding in the following classes: Common stock, $.0001 par value, 100,000,000 shares authorized, 16,263,634 and 10,360,480 shares issued and outstanding at June 30, 2021, and December 31, 2020 Additional paid-in-capital Accumulated deficit Accumulated other comprehensive loss TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING AND ADMINISTRATIVE EXPENSES Research and development General and administrative TOTAL OPERATING AND ADMINISTRATIVE EXPENSES LOSS FROM OPERATIONS OTHER (EXPENSE) INCOME Interest income Interest expense Change in fair value of derivative liability TOTAL OTHER INCOME (EXPENSES) LOSS BEFORE TAX INCOME TAX EXPENSE NET LOSS COMPREHENSIVE LOSS Other Comprehensive Loss - net of tax Foreign exchange translation income (loss) TOTAL COMPREHENSIVE LOSS Net loss per common share - Basic and Diluted Weighted average common shares - Basic and Diluted BALANCE Balance, shares Foreign currency translation gain Stock compensation - stock options Debt discount from beneficial conversion feature Issuance of options for settlement of accrued payroll Modification of warrants Exercise of options Exercise of options, shares Exercise of warrants Exercise of warrants, shares Issuance of shares and warrants from offering, net of offering costs Issuance of shares and warrants from offering, net of offering costs, shares Conversion of preferred stock Conversion of preferred stock,Shares Conversion of notes and interest Conversion of notes and interest, shares Net loss BALANCE Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Loss Adjustments to reconcile net loss to net cash used in operating activities Depreciation expense Stock based compensation Change in fair value of the derivative liability Amortization of debt discount Changes in operating assets and liabilities Prepaid expenses Accounts payable and accrued expenses NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Exercise of warrants for cash Exercise of options for cash Proceeds from notes payable Repayment of notes payable Proceeds from PIK convertible notes Proceeds from PIK convertible notes - related party NET CASH PROVIDED BY FINANCING ACTIVITIES Effect of exchange rate on cash NET INCREASE IN CASH CASH, BEGINNING OF YEAR CASH, END OF YEAR SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid for interest expense Cash paid for income taxes NONCASH FINANCING AND INVESTING TRANSACTIONS Shares issued for conversion of notes and interest Debt discount from beneficial conversion feature Issuance of options for settlement of accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND NATURE OF BUSINESS Liquidity LIQUIDITY Accounting Policies [Abstract] SUMMARY OF SIGNFICANT ACCOUNTING POLICIES Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Debt Disclosure [Abstract] NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) Equity [Abstract] STOCKHOLDERS’ DEFICIT COLLABORATIVE AGREEMENTS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of presentation Principles of consolidation Reclassifications Use of estimates Concentrations of Credit Risk Cash and Cash Equivalents Fair Value Measurements Derivative Liability Stock-Based Compensation Basic and Diluted Net (Loss) per Common Share Research and Development Foreign Currency Translation Recent Accounting Pronouncements SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES Schedule of Short-term Debt [Table] Short-term Debt [Line Items] SCHEDULE OF MATURITY DATE OF NOTES SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES SUMMARY OF WARRANT ISSUANCES Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Derivative warrants liabilities Balance at end Change in fair value of derivative warrants liabilities Share price Derivative liability measurement input Derivative liability measurement input, contractual term Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potentially outstanding dilutive common shares Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Fair value of derivative feature Class of warrant or right, issued Derivative, gain (loss) on derivative, net Warrant expiry date Accounting Research and development Other Total Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] Estimate for study description Estimate commitment amount Commitment cost paid Balance due amount 2022 2023 2024 2025 2026 Total Notes Payable Debt Instrument, Maturity Date Debt Instrument, Interest Rate, Stated Percentage Debt Conversion, Original Debt, Interest Rate of Debt Derivative, Fair Value, Net Convertible notes payable outstanding Debt amortized debt discount Debt unamortized debt discount Debt Conversion, Converted Instrument, Shares Issued Debt Conversion, Converted Instrument, Amount Interest Receivable SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items] Exercise price Expected dividend yield Risk free interest rate Expected life in years Expected volatility Stock Options Outstanding, Beginning Weighted Average Exercisable Price, Stock Options Outstanding, Beginning Weighted Average Remaining Life, Stock Options Outstanding, Beginning Stock Options, Granted Weighted Average Exercisable Price, Stock Options Outstanding, Granted Weighted average remaining contractual term Stock Options, Expired Weighted Average Exercisable Price, Stock Options Outstanding, Expired Stock Option, Exercised Weighted Average Exercisable Price, Stock Options Outstanding, Exercised Stock Options Outstanding, Ending Weighted Average Exercisable Price, Stock Options Outstanding, Ending Weighted average remaining life, stock options outstanding, ending Nonvested Options, Ending Balance Weighted Average Exercise Price, Ending Balance Nonvested Options, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Nonvested Options, Vested Weighted Average Exercise Price, Vested Nonvested Options, Forfeited Weighted Average Exercise Price, Forfeited Number of Warrants Outstanding, Beginning Number of Warrants Outstanding, Weighted Average Exercise Price, Beginning Number of Warrants Outstanding, Weighted Average Remaining Life Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Number of Warrants Outstanding, Weighted Average Exercise Price, Granted Number of warrants outstanding weighted average remaining life granted Number of Warrants Outstanding, Expired Number of Warrants Outstanding, Weighted Average Exercise Price, Expired Number of Warrants Outstanding, Exercised Number of Warrants Outstanding, Weighted Average Exercise Price, Exercised Number of Warrants Outstanding, Ending Number of Warrants Outstanding, Weighted Average Exercise Price, Ending Number of Warrants Outstanding, Weighted Average Remaining Life Stock Issued During Period, Shares, New Issues Class of Warrant or Right, Number of Securities Called by Warrants or Rights Proceeds from Issuance Initial Public Offering Preferred Stock, Convertible, Shares Issuable Number of additional shares grants for issuance Number of shares available for grant Stock options outstanding Stock options outstanding weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Payment Arrangement, Expense Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Unamortized stock option expense Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Stock issued during the period exercised Commom stock issued Proceeds from Stock Options Exercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Class of warrant or right, outstanding, weighted average exercise price Class of warrant or right, outstanding, intrinsic value Warrants outstanding Proceeds from warrants exercised Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Share-based compensation stock options, grants Share-based compensation weighted average exercise price Share-based payment award, expiration period Number of stock options vested Number of stock options expired Options expiration date, description Research and development expense Schedule of Finite-Lived Intangible Assets [Table] Acquired Finite-Lived Intangible Assets [Line Items] Royalty payment, percentage Up-front sub-license fees, percentage Royalty Payment on behalf of sublicensee percentage Sales revenue Interest on amounts owed under license agreement, rate Subsequent Event [Table] Subsequent Event [Line Items] Exercise price per share Series B Convertible Preferred Stock [Member] Convertible long term notes payable related party. Issuance of options for settlement of accrued payroll. StockIssued During Period Share Conversionof preferred stock. Stock Issued During Period Value Conversion of preferred stock. Issuance Of Shares And Warrants From Offering. Stock Issued During Period shares Issuance of shares and warrants from offering. Stock Issued During Period Shares Stock warrants Exercised. Modification Of Warrants. Stock Issued During Period Value Stock Warrants Exercised. Issuance of options for settlement of accounts payable. Proceeds From Notes Payable related party. Liquidity Disclosure [Text Block] Conversion Feature Shares [Member] Convertible Notes [Member] Derivative liability measurement input, contractual term. The number of warrants or rights issued during period. Accrued accounting fees current. Accrued research and development current. Estimate commitment amount. Consultant [Member] Toxicology Studies [Member] Promissory Note [Member] Unsecured Convertible Notes [Member] Convertible Notes Payable Related Party [Member] Unsecured Convertible Notes With Related Parties [Member] 5 Individuals [Member] Related Party [Member] The percentage of royalty payment of net sales. Up front sub license fees percentage. The percentage of royalty payment of net sales made on behalf of a sub-licensee. The interest rate charged per annum on any amounts owed under the license agreement and amendment. University of Toronto [Member] Options expiration date, description. Dr. David Lovejoy [Member] Number of stock options expired. Research Agreements [Member] 45-day Option [Member] Series B Prefered Stock [Member] Weighted average remaining contractual term Weighted average remaining life, stock options outstanding, ending. Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. Number of warrants outstanding, weighted average exercise price, expired. Number of warrants outstanding, weighted average exercise price, expired Weighted average remaining contractual life Weighted average remaining contractual life Number of warrants outstanding weighted average remaining life granted. 2016 Plan [Member] Employees [Member] Non-Employees [Member] Unamortized stock option expense. Related Parties [Member] Settlement of Accrued Compensation [Member] Options Vested Over 48 Months [Member] Options To Related Party [Member] Class of warrant or right, outstanding, weighted average exercise price. Class of warrant or right, outstanding, intrinsic value. Proceeds from warrants exercised. Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Other Nonoperating Expense Nonoperating Income (Expense) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Debt Instrument, Convertible, Beneficial Conversion Feature AccruedResearchAndDevelopmentCurrent Long-term Debt Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Weighted average remaining contractual life EX-101.PRE 9 ptix-20210630_pre.xml XBRL PRESENTATION FILE XML 10 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001022899 2021-01-01 2021-06-30 0001022899 2021-08-13 0001022899 2021-06-30 0001022899 2020-12-31 0001022899 us-gaap:PreferredStockMember 2021-06-30 0001022899 us-gaap:PreferredStockMember 2020-12-31 0001022899 us-gaap:PreferredStockMember 2021-06-30 0001022899 us-gaap:PreferredStockMember 2020-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-06-30 0001022899 2021-04-01 2021-06-30 0001022899 2020-04-01 2020-06-30 0001022899 2020-01-01 2020-06-30 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2019-12-31 0001022899 us-gaap:CommonStockMember 2019-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001022899 us-gaap:RetainedEarningsMember 2019-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001022899 2019-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001022899 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001022899 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001022899 2020-01-01 2020-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-03-31 0001022899 us-gaap:CommonStockMember 2020-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001022899 us-gaap:RetainedEarningsMember 2020-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001022899 2020-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-04-01 2020-06-30 0001022899 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001022899 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-06-30 0001022899 us-gaap:CommonStockMember 2020-06-30 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001022899 us-gaap:RetainedEarningsMember 2020-06-30 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001022899 2020-06-30 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-12-31 0001022899 us-gaap:CommonStockMember 2020-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001022899 us-gaap:RetainedEarningsMember 2020-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001022899 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001022899 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001022899 2021-01-01 2021-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-03-31 0001022899 us-gaap:CommonStockMember 2021-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001022899 us-gaap:RetainedEarningsMember 2021-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001022899 2021-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-04-01 2021-06-30 0001022899 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001022899 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001022899 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-06-30 0001022899 us-gaap:CommonStockMember 2021-06-30 0001022899 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001022899 us-gaap:RetainedEarningsMember 2021-06-30 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001022899 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0001022899 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001022899 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001022899 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001022899 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001022899 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:PrivatePlacementMember 2021-06-30 0001022899 us-gaap:PrivatePlacementMember 2021-01-01 2021-06-30 0001022899 us-gaap:MeasurementInputExercisePriceMember 2020-12-31 0001022899 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001022899 us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001022899 us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001022899 us-gaap:MeasurementInputExpectedTermMember 2020-01-01 2020-12-31 0001022899 us-gaap:MeasurementInputExpectedDividendRateMember 2021-06-30 0001022899 PTIX:ConversionFeatureSharesMember 2021-01-01 2021-06-30 0001022899 PTIX:ConversionFeatureSharesMember 2020-01-01 2020-06-30 0001022899 us-gaap:StockOptionMember 2021-01-01 2021-06-30 0001022899 us-gaap:StockOptionMember 2020-01-01 2020-06-30 0001022899 us-gaap:WarrantMember 2021-01-01 2021-06-30 0001022899 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001022899 PTIX:ConvertibleNotesMember 2021-01-01 2021-06-30 0001022899 PTIX:ConvertibleNotesMember 2020-01-01 2020-06-30 0001022899 2021-09-28 2021-10-01 0001022899 PTIX:ConsultantMember 2019-10-02 0001022899 PTIX:ToxicologyStudiesMember 2021-01-01 2021-06-30 0001022899 PTIX:ToxicologyStudiesMember 2020-12-30 2020-12-31 0001022899 PTIX:ToxicologyStudiesMember 2021-06-30 0001022899 PTIX:ToxicologyStudiesMember 2020-12-31 0001022899 PTIX:PromissoryNoteMember 2021-03-01 0001022899 PTIX:PromissoryNoteMember 2021-01-01 2021-06-30 0001022899 srt:MaximumMember PTIX:PromissoryNoteMember 2021-03-01 0001022899 PTIX:PromissoryNoteMember 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesMember 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesMember 2020-12-31 0001022899 PTIX:UnsecuredConvertibleNotesMember 2021-01-01 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesMember 2020-01-01 2020-06-30 0001022899 PTIX:ConvertibleNotesMember 2021-06-30 0001022899 PTIX:ConvertibleNotesMember 2020-12-31 0001022899 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-06-30 0001022899 us-gaap:ConvertibleNotesPayableMember 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2021-01-01 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2020-01-01 2020-06-30 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2021-06-30 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2020-12-31 0001022899 PTIX:ConvertibleNotesPayableRelatedPartyMember 2021-01-01 2021-06-30 0001022899 PTIX:ConvertibleNotesPayableRelatedPartyMember 2021-06-30 0001022899 us-gaap:IPOMember 2021-04-28 2021-04-29 0001022899 us-gaap:IPOMember 2021-04-29 0001022899 PTIX:FourtyFiveDayOptionMember us-gaap:IPOMember 2021-04-29 0001022899 2021-04-28 2021-04-29 0001022899 PTIX:SeriesBPreferedStockMember 2021-06-30 0001022899 us-gaap:CommonStockMember 2021-06-30 0001022899 PTIX:TwoThousandSixteenPlanMember 2017-01-01 2017-01-02 0001022899 PTIX:TwoThousandSixteenPlanMember 2017-01-02 0001022899 PTIX:TwoThousandSixteenPlanMember 2020-12-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2021-06-30 0001022899 srt:MinimumMember 2021-06-30 0001022899 srt:MaximumMember 2021-06-30 0001022899 srt:MinimumMember 2021-01-01 2021-06-30 0001022899 srt:MaximumMember 2021-01-01 2021-06-30 0001022899 2020-01-01 2020-12-31 0001022899 srt:MinimumMember 2020-01-01 2020-12-31 0001022899 srt:MaximumMember 2020-01-01 2020-12-31 0001022899 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001022899 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001022899 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001022899 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001022899 PTIX:EmployeesMember 2020-04-01 2020-06-30 0001022899 PTIX:NonEmployeesMember 2020-04-01 2020-06-30 0001022899 us-gaap:StockOptionMember 2021-01-01 2021-06-30 0001022899 us-gaap:StockOptionMember 2020-01-01 2020-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001022899 PTIX:NonEmployeesMember 2021-01-01 2021-06-30 0001022899 us-gaap:StockOptionMember 2021-06-30 0001022899 PTIX:EmployeesMember 2021-06-30 0001022899 PTIX:NonEmployeesMember 2021-06-30 0001022899 PTIX:FiveIndividualsMember us-gaap:EmployeeStockOptionMember 2021-02-24 2021-02-25 0001022899 PTIX:RelatedPartiesMember us-gaap:EmployeeStockOptionMember 2020-02-24 2020-02-25 0001022899 PTIX:SettlementOfAccruedCompensationMember us-gaap:EmployeeStockOptionMember 2020-02-24 2020-02-25 0001022899 srt:MaximumMember PTIX:SettlementOfAccruedCompensationMember us-gaap:EmployeeStockOptionMember 2020-02-24 2020-02-25 0001022899 srt:MinimumMember PTIX:SettlementOfAccruedCompensationMember us-gaap:EmployeeStockOptionMember 2020-02-24 2020-02-25 0001022899 PTIX:OptionsVestedOverFourtyEightMonthsMember us-gaap:EmployeeStockOptionMember 2021-02-24 2021-02-25 0001022899 PTIX:OptionsVestedOverFourtyEightMonthsMember us-gaap:EmployeeStockOptionMember 2020-02-24 2020-02-25 0001022899 PTIX:SettlementOfAccruedCompensationMember us-gaap:EmployeeStockOptionMember 2021-05-25 2021-05-26 0001022899 PTIX:OptionsToRelatedPartyMember 2021-06-30 0001022899 PTIX:OptionsToRelatedPartyMember 2021-01-01 2021-06-30 0001022899 us-gaap:WarrantMember 2021-06-30 0001022899 us-gaap:WarrantMember 2021-03-31 0001022899 us-gaap:WarrantMember 2021-04-01 2021-06-30 0001022899 PTIX:OptionsToRelatedPartyMember us-gaap:CommonStockMember 2021-06-30 0001022899 PTIX:UniversityOfTorontoMember 2015-01-01 2015-12-31 0001022899 PTIX:UniversityOfTorontoMember 2015-12-31 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember 2021-06-30 0001022899 PTIX:DrDavidLovejoyMember srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-06-30 0001022899 PTIX:DrDavidLovejoyMember srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-06-30 0001022899 PTIX:ResearchAgreementsMember 2021-01-01 2021-06-30 0001022899 PTIX:ResearchAgreementsMember 2020-01-01 2020-06-30 0001022899 us-gaap:LicensingAgreementsMember 2021-06-30 0001022899 us-gaap:SubsequentEventMember 2021-08-16 0001022899 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-08-16 0001022899 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-07-25 2021-07-26 0001022899 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-07-26 iso4217:USD shares iso4217:USD shares pure 0001022899 false --12-31 Q2 Protagenic Therapeutics, Inc.\new 10-Q true 2021-06-30 2021 false 000-51353 DE 06-1390025 149 Fifth Avenue Suite 500 New York NY 10010 (212) 994-8200 Common Stock, par value $0.0001 PTIX NASDAQ Yes Yes Non-accelerated Filer true false false 16699651 11932973 671091 129167 208156 12062140 879247 12062140 879247 602587 571517 83670 602587 655187 350279 1081384 311136 292412 1264002 2028983 0.000001 0.000001 20000000 20000000 872766 872766 872766 872766 0.000001 0.000001 2000000 2000000 0 0 0 0 0.000001 0.000001 18000000 18000000 436017 436017 872766 872766 1 1 1 1 100000000 100000000 16263634 16263634 10360480 10360480 1627 1036 31420307 16719749 -20453184 -17698936 -170613 -171586 10798138 -1149736 12062140 879247 140592 52008 732943 117967 1168241 436935 1782080 891712 1308833 488943 2515023 1009679 -1308833 -488943 -2515023 -1009679 227 93 232 477 239190 54944 323127 93930 -23560 83670 37189 -238963 -78411 -239225 -56264 -1547796 -567354 -2754248 -1065943 -1547796 -567354 -2754248 -1065943 482 1084 973 -1335 -1547314 -566270 -2753275 -1067278 -0.11 -0.06 -0.22 -0.10 14487277 10261419 12488906 10261419 872766 1 10261419 1026 14687172 -15150201 -172364 -634366 -2419 -2419 360436 360436 89204 89204 93950 93950 5861 5861 839724 84 1054460 1054544 -498589 -498589 872766 1 10261419 1026 15236623 -15648790 -174783 -585923 1084 1084 304148 304148 86968 86968 15000 15000 -567354 -567354 872766 1 10261419 1026 15642739 -16216144 -173699 -746077 872766 1 10360480 1036 16719749 -17698936 -171586 -1149736 491 491 345975 345975 10000 1 -1 240123 24 27101 27125 -1206452 -1206452 872766 1 10610603 1061 17092824 -18905388 -171095 -1982597 872766 1 10610603 1061 17092824 -18905388 -171095 -1982597 482 482 3180000 318 11707721 11708039 722966 722966 360000 36 542464 542500 836558 84 299916 300000 -436749 436749 44 -44 839724 84 1054460 1054544 -1547796 -1547796 436017 1 16263634 1627 31420307 -20453184 -170613 10798138 436017 1 16263634 1627 31420307 -20453184 -170613 10798138 -2754248 -1065943 165 1068941 751552 83670 37189 277619 58923 5861 -78990 -36856 94278 -260322 -1318090 -510097 327125 542500 11708039 100000 100000 850000 50000 12577664 900000 2308 -7230 11261882 382673 671091 798623 11932973 1181296 1054544 104204 93950 <p id="xdx_802_eus-gaap--NatureOfOperations_zojpjbLhYS8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 1 – <span id="xdx_828_zcTGHk7wSql9">ORGANIZATION AND NATURE OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Company Background</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), is a Delaware corporation with one subsidiary named Protagenic Therapeutics Canada (2006) Inc. (“PTI Canada”), a corporation formed in 2006 under the laws of the Province of Ontario, Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company was previously known as Atrinsic, Inc., a company that was once a reporting company under the Securities Exchange Act of 1934, but that, in 2012 and 2013, reorganized under Chapter 11 of the United States Bankruptcy Code and emerged from bankruptcy. On February 12, 2016, the Company acquired Protagenic Therapeutics, Inc. (“Prior Protagenic”) through a reverse merger.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On February 12, 2016, Protagenic Acquisition Corp., a wholly-owned subsidiary of the Company, merged (the “Merger”) with and into Prior Protagenic. Prior Protagenic was the surviving corporation of the Merger. As a result of the Merger, the Company acquired the business of Prior Protagenic and has continued the existing business operations of Prior Protagenic as a wholly-owned subsidiary. On June 17, 2016, Prior Protagenic merged with and into the Company with the Company as the surviving corporation in the merger. Immediately thereafter, the Company changed its name from Atrinsic, Inc. to Protagenic Therapeutics, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_80D_ecustom--LiquidityDisclosureTextBlock_z4Qgh6rgXKgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 2 - <span id="xdx_828_z5jJznku8xn5">LIQUIDITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As shown in the accompanying consolidated financial statements, the Company has incurred significant recurring losses resulting in an accumulated deficit. The Company anticipates further losses in the development of its business. The Company also had negative cash flows used in operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Based on its cash resources as of June 30, 2021, the Company has sufficient resources to fund its operations at least until the end of the third quarter of 2023. Absent generation of sufficient revenue from the execution of the Company’s business plan and sales revenue is not anticipated before 2024, the Company will need to obtain debt or equity financing by the third quarter of 2023. Because of these factors, the Company believes that this alleviates the substantial doubt in connection with the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zEvlHBQKeAU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 3 - <span id="xdx_82E_zBpPjWHYoile">SUMMARY OF SIGNFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zigtocXXqVf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zU6N820PUxKf">Basis of presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC” for interim financial information. In the opinion of the Company’s management, the accompanying consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended June 30, 2021 and 2020. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2020, which contain the audited financial statements and notes thereto, for the years ended December 31, 2020 and 2019 included within the Company’s Form 10-K filed with the SEC on March 25, 2021. The interim results for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zKmuY3z62ak6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_860_zTaGoOyQ2Koj">Principles of consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The condensed consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in the condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zR05x4F4JZe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_860_zhq06BdJIEP8">Reclassifications</span>:</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Reclassifications of prior periods have been made to conform with current year presentation</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--UseOfEstimates_z6ZdVXN6Ocyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_zYfadowqzd0h">Use of estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include income tax provisions, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_z9zyvzryZ3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_861_zmVP5xTPUAP6">Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. As of June 30, 2021, the Company has bank balances that exceeds the federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVE0UmOiI6x9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zL27ArwTWZW3">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of June 30, 2021 and December 31, 2020, the Company did <span title="Cash equivalents"><span title="Cash equivalents">not</span></span> have any cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zzAMcjRqXlNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zRn0jSuk6Tsi">Fair Value Measurements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The three levels are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short term maturity of those instruments. The carrying value of long-term debt approximates fair value since the related rates of interest approximate current market rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of June 30, 2021.</span></p> <p id="xdx_893_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zG2W2gtntKgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_z0xlFvPFvllh" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Carrying</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Derivative warrants liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0728">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0730">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0732">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0734">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0736">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Carrying</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Derivative warrants liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities">83,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0740">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0742">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities">83,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities">83,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zJHWBnOWdDo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2021 and the year ended December 31, 2020:</span></p> <p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zRkOwF8jdxfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zghHbtGkZuWh" style="display: none">SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom">Fair Value Measurement Using Level 3</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Inputs Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance, December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c20201231_pp0p0" style="width: 16%; text-align: right" title="Balance at beginning">83,670</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative warrants liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c20210101__20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of derivative warrants liabilities">(83,670</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance, June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zsL7VJIBoJa3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of the derivative feature of the <span id="xdx_908_eus-gaap--DerivativeFairValueOfDerivativeNet_c20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp0p0" title="Fair value of derivative feature">127,346</span> and <span title="Fair value of derivative feature"><span id="xdx_90A_ecustom--ClassOfWarrantOrRightIssued_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Class of warrant or right, issued">295,945</span></span> warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet dates were calculated using a Black-Scholes option model valued with the following assumptions:</span></p> <p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zCcBp9KWUC14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BB_z8HGOYNaLJik" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMMTWI6q8Qnd" style="width: 16%; text-align: right" title="Share price">1.25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfjn7jI3rSh3" style="text-align: right" title="Derivative liability measurement input">0.09</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uUSDPShares_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z0ncAKnbjUo2" style="text-align: right" title="Derivative liability measurement input">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zjK4IP30iI13" style="text-align: right" title="Derivative liability measurement input">169</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_ecustom--DerivativeLiabilityMeasurementInputContractualTerm_dtY_c20200101__20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zFaVSAvzMLgj" title="Derivative liability measurement input, contractual term">0.14</span> Years</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A8_zr2FeLFcycCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Dividend yield: The Company uses a <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1HwxBeJnOy5" title="Derivative liability measurement input">0</span>% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2021 and 2020, the Company marked the derivative feature of the warrants to fair value and recorded a gain of $<span id="xdx_90C_eus-gaap--DerivativeGainLossOnDerivativeNet_c20210101__20210630_pp0p0" title="Derivative, gain (loss) on derivative, net">83,670</span> and a gain of $<span id="xdx_90A_eus-gaap--DerivativeGainLossOnDerivativeNet_c20200101__20200630_pp0p0" title="Derivative, gain (loss) on derivative, net">37,189</span> relating to the change in fair value, respectively. The warrants expired on <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630_zm8CyI3WWiag" title="Warrant expiry date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zP1U0uLRxqP" title="Warrant expiry date">February 21, 2021</span></span>, resulting in the elimination of the derivative liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_843_eus-gaap--DerivativesPolicyTextBlock_zCjnZVLF3t0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_zT1Un9GNTYml">Derivative Liability</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10-05-4 and 815-40-25. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the condensed consolidated statements of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then the related fair value is reclassified to equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zpPZm1Pc2Ljj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zMJFVzPZxGJ7">Stock-Based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company accounts for stock based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or canceled during the periods reported.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_zCXhEpZ573P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zbXItdeq6fGg">Basic and Diluted Net (Loss) per Common Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqpYA1U4xUs1" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B1_zbWwTGQAjG42" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Potentially Outstanding<br/> Dilutive Common Shares</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">For the Six Months Ended June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">For the Six Months Ended June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Conversion Feature Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Common shares issuable under the conversion feature of preferred shares</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConversionFeatureSharesMember_pdd" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares">436,017</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConversionFeatureSharesMember_pdd" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares">872,766</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Stock Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">5,493,861</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">4,028,162</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr5ZbgV4L9Z9" style="text-align: right" title="Total potentially outstanding dilutive common shares">6,132,630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">3,908,258</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Convertible Notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially outstanding dilutive common shares">806,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially outstanding dilutive common shares">1,256,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total potentially outstanding dilutive common shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">12,868,508</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">10,065,186</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zrQ72kSt9hUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zk8a2oEBKbZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_867_z8iVKJMCaVl8">Research and Development</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research and development expenses are charged to operations as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z2QfuOBrRP44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zeQMeQ3SFnr6">Foreign Currency Translation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the condensed consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the condensed consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the condensed consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0fo8Ar4prFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zOaneAWuOhOa">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zigtocXXqVf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zU6N820PUxKf">Basis of presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC” for interim financial information. In the opinion of the Company’s management, the accompanying consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended June 30, 2021 and 2020. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2020, which contain the audited financial statements and notes thereto, for the years ended December 31, 2020 and 2019 included within the Company’s Form 10-K filed with the SEC on March 25, 2021. The interim results for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zKmuY3z62ak6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_860_zTaGoOyQ2Koj">Principles of consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The condensed consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in the condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zR05x4F4JZe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_860_zhq06BdJIEP8">Reclassifications</span>:</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Reclassifications of prior periods have been made to conform with current year presentation</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--UseOfEstimates_z6ZdVXN6Ocyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_zYfadowqzd0h">Use of estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include income tax provisions, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_z9zyvzryZ3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_861_zmVP5xTPUAP6">Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. As of June 30, 2021, the Company has bank balances that exceeds the federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVE0UmOiI6x9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zL27ArwTWZW3">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of June 30, 2021 and December 31, 2020, the Company did <span title="Cash equivalents"><span title="Cash equivalents">not</span></span> have any cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zzAMcjRqXlNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zRn0jSuk6Tsi">Fair Value Measurements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The three levels are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short term maturity of those instruments. The carrying value of long-term debt approximates fair value since the related rates of interest approximate current market rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of June 30, 2021.</span></p> <p id="xdx_893_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zG2W2gtntKgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_z0xlFvPFvllh" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Carrying</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Derivative warrants liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0728">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0730">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0732">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0734">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0736">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Carrying</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Derivative warrants liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities">83,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0740">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0742">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities">83,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities">83,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zJHWBnOWdDo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2021 and the year ended December 31, 2020:</span></p> <p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zRkOwF8jdxfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zghHbtGkZuWh" style="display: none">SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom">Fair Value Measurement Using Level 3</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Inputs Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance, December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c20201231_pp0p0" style="width: 16%; text-align: right" title="Balance at beginning">83,670</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative warrants liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c20210101__20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of derivative warrants liabilities">(83,670</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance, June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zsL7VJIBoJa3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of the derivative feature of the <span id="xdx_908_eus-gaap--DerivativeFairValueOfDerivativeNet_c20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp0p0" title="Fair value of derivative feature">127,346</span> and <span title="Fair value of derivative feature"><span id="xdx_90A_ecustom--ClassOfWarrantOrRightIssued_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Class of warrant or right, issued">295,945</span></span> warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet dates were calculated using a Black-Scholes option model valued with the following assumptions:</span></p> <p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zCcBp9KWUC14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BB_z8HGOYNaLJik" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMMTWI6q8Qnd" style="width: 16%; text-align: right" title="Share price">1.25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfjn7jI3rSh3" style="text-align: right" title="Derivative liability measurement input">0.09</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uUSDPShares_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z0ncAKnbjUo2" style="text-align: right" title="Derivative liability measurement input">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zjK4IP30iI13" style="text-align: right" title="Derivative liability measurement input">169</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_ecustom--DerivativeLiabilityMeasurementInputContractualTerm_dtY_c20200101__20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zFaVSAvzMLgj" title="Derivative liability measurement input, contractual term">0.14</span> Years</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A8_zr2FeLFcycCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Dividend yield: The Company uses a <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1HwxBeJnOy5" title="Derivative liability measurement input">0</span>% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2021 and 2020, the Company marked the derivative feature of the warrants to fair value and recorded a gain of $<span id="xdx_90C_eus-gaap--DerivativeGainLossOnDerivativeNet_c20210101__20210630_pp0p0" title="Derivative, gain (loss) on derivative, net">83,670</span> and a gain of $<span id="xdx_90A_eus-gaap--DerivativeGainLossOnDerivativeNet_c20200101__20200630_pp0p0" title="Derivative, gain (loss) on derivative, net">37,189</span> relating to the change in fair value, respectively. The warrants expired on <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630_zm8CyI3WWiag" title="Warrant expiry date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zP1U0uLRxqP" title="Warrant expiry date">February 21, 2021</span></span>, resulting in the elimination of the derivative liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zG2W2gtntKgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_z0xlFvPFvllh" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Carrying</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Derivative warrants liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0728">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0730">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0732">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0734">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0736">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Carrying</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Derivative warrants liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities">83,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0740">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0742">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities">83,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--EstimateOfFairValueFairValueDisclosureMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrants liabilities">83,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 83670 83670 83670 <p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zRkOwF8jdxfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zghHbtGkZuWh" style="display: none">SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom">Fair Value Measurement Using Level 3</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Inputs Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance, December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c20201231_pp0p0" style="width: 16%; text-align: right" title="Balance at beginning">83,670</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative warrants liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c20210101__20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of derivative warrants liabilities">(83,670</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance, June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 83670 -83670 127346 295945 <p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zCcBp9KWUC14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BB_z8HGOYNaLJik" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMMTWI6q8Qnd" style="width: 16%; text-align: right" title="Share price">1.25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfjn7jI3rSh3" style="text-align: right" title="Derivative liability measurement input">0.09</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uUSDPShares_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z0ncAKnbjUo2" style="text-align: right" title="Derivative liability measurement input">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zjK4IP30iI13" style="text-align: right" title="Derivative liability measurement input">169</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_ecustom--DerivativeLiabilityMeasurementInputContractualTerm_dtY_c20200101__20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zFaVSAvzMLgj" title="Derivative liability measurement input, contractual term">0.14</span> Years</span></td><td style="text-align: left"> </td></tr> </table> 1.25 0.0009 0.0000 1.69 P0Y1M20D 0 83670 37189 2021-02-21 2021-02-21 <p id="xdx_843_eus-gaap--DerivativesPolicyTextBlock_zCjnZVLF3t0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_zT1Un9GNTYml">Derivative Liability</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10-05-4 and 815-40-25. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the condensed consolidated statements of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then the related fair value is reclassified to equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zpPZm1Pc2Ljj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zMJFVzPZxGJ7">Stock-Based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company accounts for stock based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or canceled during the periods reported.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_zCXhEpZ573P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zbXItdeq6fGg">Basic and Diluted Net (Loss) per Common Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqpYA1U4xUs1" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B1_zbWwTGQAjG42" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Potentially Outstanding<br/> Dilutive Common Shares</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">For the Six Months Ended June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">For the Six Months Ended June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Conversion Feature Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Common shares issuable under the conversion feature of preferred shares</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConversionFeatureSharesMember_pdd" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares">436,017</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConversionFeatureSharesMember_pdd" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares">872,766</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Stock Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">5,493,861</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">4,028,162</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr5ZbgV4L9Z9" style="text-align: right" title="Total potentially outstanding dilutive common shares">6,132,630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">3,908,258</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Convertible Notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially outstanding dilutive common shares">806,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially outstanding dilutive common shares">1,256,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total potentially outstanding dilutive common shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">12,868,508</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">10,065,186</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zrQ72kSt9hUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqpYA1U4xUs1" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B1_zbWwTGQAjG42" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Potentially Outstanding<br/> Dilutive Common Shares</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">For the Six Months Ended June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">For the Six Months Ended June 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Conversion Feature Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Common shares issuable under the conversion feature of preferred shares</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConversionFeatureSharesMember_pdd" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares">436,017</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConversionFeatureSharesMember_pdd" style="width: 16%; text-align: right" title="Total potentially outstanding dilutive common shares">872,766</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Stock Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">5,493,861</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">4,028,162</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr5ZbgV4L9Z9" style="text-align: right" title="Total potentially outstanding dilutive common shares">6,132,630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">3,908,258</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Convertible Notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially outstanding dilutive common shares">806,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially outstanding dilutive common shares">1,256,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total potentially outstanding dilutive common shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">12,868,508</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630_pdd" style="text-align: right" title="Total potentially outstanding dilutive common shares">10,065,186</td><td style="text-align: left"> </td></tr> </table> 436017 872766 5493861 4028162 6132630 3908258 806000 1256000 12868508 10065186 <p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zk8a2oEBKbZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_867_z8iVKJMCaVl8">Research and Development</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research and development expenses are charged to operations as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z2QfuOBrRP44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zeQMeQ3SFnr6">Foreign Currency Translation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the condensed consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the condensed consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the condensed consolidated statements of operations and comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0fo8Ar4prFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zOaneAWuOhOa">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zfSTtvbGfDNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 4 - <span id="xdx_821_zKjmkI9JT9x4">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_znKZ7ldxKHrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Accounts payable and accrued expenses consist of the following at:</span></p> <p style="font: 8.5pt Segoe UI,sans-serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B3_zwYXq3JydQXl" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20210630_zVEYBN7j7KMi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20201231_zIY56hs7RXlh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_ecustom--AccruedAccountingFeesCurrent_iI_maAPAALzHPL_zx45SC2No3s8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Accounting</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">36,161</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">36,161</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedResearchAndDevelopmentCurrent_iI_maAPAALzHPL_zFpBsML9tq66" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">381,702</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">393,496</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maAPAALzHPL_zQxwwM1pRdp5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">184,724</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">141,860</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_mtAPAALzHPL_zmT8yKKseRh6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">602,587</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">571,517</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zpZ5SI1E1bhf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--RegistrationPaymentArrangementEventToTransferConsideration_c20210928__20211001_z3lOCQuxqHKk" title="Estimate for study description">On October 1, 2019, the Company entered into an agreement with a consultant for toxicology studies. The consultant quoted a commitment of approximately $<span id="xdx_900_ecustom--EstimateCommitmentAmount_c20191002__srt--TitleOfIndividualAxis__custom--ConsultantMember_pp0p0" title="Estimate commitment amount">988,000</span> as an estimate for the study. 50% of the total price was paid upon the signing of the agreement, 35% of the total price is to be paid upon completion of the in-life study, and the remaining 15% of the total price is to be paid upon the issuance of the report. If the Company cancels the study the Company will be required to pay a cancelation fee. If the cancelation happens prior to the arrival of the test animals then the Company will need to pay between 20% and 50% of the animal fees depending on when the cancellation happens. If the cancellation occurs after the animals arrive but before the study begins then the Company will be responsible for paying 50% of the protocol price plus a fee of $7,000 per room/week for animal husbandry until the animals can be relocated or disposed of. If the Company cancels the study after it has begun then the Company will need to pay any fees for procured items for the study and any nonrecoverable expenses incurred by the consultant.</span> As of June 30, 2021 and December 31, 2020, the Company has paid $<span title="Commitment cost paid"><span id="xdx_902_eus-gaap--RegistrationPaymentArrangementGainsAndLosses_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--ToxicologyStudiesMember_pp0p0" title="Commitment cost paid">174,106</span></span> and $<span title="Commitment cost paid"><span id="xdx_902_eus-gaap--RegistrationPaymentArrangementGainsAndLosses_c20201230__20201231__us-gaap--TypeOfArrangementAxis__custom--ToxicologyStudiesMember_pp0p0" title="Commitment cost paid">174,106</span></span> to the consultant and there is a balance of $<span title="Balance due amount"><span id="xdx_903_eus-gaap--RegistrationPaymentArrangementAccrualCarryingValue_c20210630__us-gaap--TypeOfArrangementAxis__custom--ToxicologyStudiesMember_pp0p0" title="Balance due amount">319,799</span></span> and $<span id="xdx_906_eus-gaap--RegistrationPaymentArrangementAccrualCarryingValue_c20201231__us-gaap--TypeOfArrangementAxis__custom--ToxicologyStudiesMember_pp0p0">319,799</span> due, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_znKZ7ldxKHrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Accounts payable and accrued expenses consist of the following at:</span></p> <p style="font: 8.5pt Segoe UI,sans-serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B3_zwYXq3JydQXl" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20210630_zVEYBN7j7KMi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20201231_zIY56hs7RXlh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_ecustom--AccruedAccountingFeesCurrent_iI_maAPAALzHPL_zx45SC2No3s8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Accounting</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">36,161</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">36,161</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedResearchAndDevelopmentCurrent_iI_maAPAALzHPL_zFpBsML9tq66" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">381,702</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">393,496</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maAPAALzHPL_zQxwwM1pRdp5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">184,724</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">141,860</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_mtAPAALzHPL_zmT8yKKseRh6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">602,587</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">571,517</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 36161 36161 381702 393496 184724 141860 602587 571517 On October 1, 2019, the Company entered into an agreement with a consultant for toxicology studies. The consultant quoted a commitment of approximately $988,000 as an estimate for the study. 50% of the total price was paid upon the signing of the agreement, 35% of the total price is to be paid upon completion of the in-life study, and the remaining 15% of the total price is to be paid upon the issuance of the report. If the Company cancels the study the Company will be required to pay a cancelation fee. If the cancelation happens prior to the arrival of the test animals then the Company will need to pay between 20% and 50% of the animal fees depending on when the cancellation happens. If the cancellation occurs after the animals arrive but before the study begins then the Company will be responsible for paying 50% of the protocol price plus a fee of $7,000 per room/week for animal husbandry until the animals can be relocated or disposed of. If the Company cancels the study after it has begun then the Company will need to pay any fees for procured items for the study and any nonrecoverable expenses incurred by the consultant. 988000 174106 174106 319799 319799 <p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_z9NW33DSr4vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 5 – <span id="xdx_822_z8EDqR7mBZXk">NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Note Payable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On March 1, 2021, the Company entered into a $<span id="xdx_90E_eus-gaap--NotesPayable_c20210301__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_pp0p0">100,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">promissory note. This note is due on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember">February 28, 2026</span></span> <span style="font: 10pt Times New Roman, Times, Serif">and accrues interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210301__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zaoToyfo6ry3">5</span></span><span style="font: 10pt Times New Roman, Times, Serif">% per annum or <span id="xdx_90C_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_pdd">7.5</span></span><span style="font: 10pt Times New Roman, Times, Serif">% per annum in the case of default. In the event that the Company completes a financing of no less than $<span id="xdx_907_eus-gaap--NotesPayable_iI_pn5n6_c20210301__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--RangeAxis__srt--MaximumMember_zY5IkX0qqLIh">7.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million, then the note holder will be issued warrants valued at $<span id="xdx_908_eus-gaap--DerivativeFairValueOfDerivativeNet_c20210630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_pp0p0">25,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">with an exercise price equal to <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zsFA6G8m35M6">110</span></span><span style="font: 10pt Times New Roman, Times, Serif">% of the offering cost of the common stock in the financing. These warrants will have a term of five years. During the six months ended June 30, 2021, the Company paid off the balance of this note’s principal and accrued interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021 and December 31, 2020, the Company owes $<span id="xdx_903_eus-gaap--ConvertibleNotesPayable_c20210630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesMember_pp0p0">0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_c20201231__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesMember_pp0p0">0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">on the outstanding note, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Convertible Notes Payable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2021 and 2020, the Company amortized $<span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesMember_z3bZ9ikTZDC4" title="Debt amortized debt discount">72,110</span> and $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20200101__20200630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesMember_z2KvL4ptjwyk">40,095</span> of the debt discount, respectively. At June 30, 2021 and December 31, 2020, the Company had an unamortized debt discount of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210630_zixww9GAwTT1" title="Debt unamortized debt discount">257,221</span> and $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20201231_zHB3pXsDpjFl">516,116</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2021, a total of <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210630_zXFRSwqFqpA8">839,724</span> shares of the Company’s common stock was issued for the conversion of notes and interest. A total of $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210630_z4we1rma8bDj">990,000</span> in principal and $<span id="xdx_903_eus-gaap--InterestReceivable_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesMember_zes4utt29Rt5">64,544</span> in accrued interest was converted. As part of this conversion, the Company also expensed $<span title="Debt unamortized debt discount"><span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesMember_z6KrLDwUbs1e" title="Debt unamortized debt discount">186,785</span></span> in unamortized debt discount related to these converted notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021 and December 31, 2020, the Company owes $<span title="Convertible notes payable outstanding"><span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zAmLdpnGQJZ" title="Convertible notes payable outstanding">607,500</span></span> and $<span title="Convertible notes payable outstanding"><span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zpbHxUkNvB73" title="Convertible notes payable outstanding">1,597,500</span></span> on the outstanding Convertible Notes, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zo3mGkTntFE1" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span><span id="xdx_8BC_z48uydp8uyha">SCHEDULE OF MATURITY DATE OF NOTES</span></span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210630_zCXNmUudfxE9" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Maturity Date of Notes for Twelve Months Ending June 30, 2021,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount due</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_maLTDzHng_zXpcNl3SpvWj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left">2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_maLTDzHng_zTDgMLXAtWu" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2023</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0873"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_maLTDzHng_zz94HdKMvfI6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">607,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_maLTDzHng_zIyW6E8b97og" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2025</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0877"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_maLTDzHng_zQT9qnUvWTag" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0879"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LongTermDebt_iTI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_mtLTDzHng_zugnktnmJyo7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">607,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Convertible Notes Payable – Related Parties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2021 and 2020, the Company amortized $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_zgYxCtoh0ab8">18,724</span> and $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20200101__20200630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_z7HWEuq0I4J5">18,828</span> of the debt discount, respectively. At June 30, 2021 and December 31, 2020, the Company had an unamortized debt discount of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_zDrgO81K2wdk">88,864</span> and $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20201231__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_zfYLCfwQLVn9">107,588</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021 and December 31, 2020, the Company owes $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_zddCQYn9x9v1" title="Convertible notes payable outstanding">400,000</span> and $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_zMnA4unssig5">400,000</span> on the outstanding Convertible Notes, respectively.</span></p> <p id="xdx_895_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_zmNMvCF5XXz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BF_zH7GqQ3LdrB1" style="display: none">SCHEDULE OF MATURITY DATE OF NOTES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210630_zVEdHkJGvjI5" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Maturity Date of Notes for Twelve Months Ending June 30, 2021,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount due</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zrgS41uXGOLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left">2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zXFwXFc9Agrk" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2023</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0894"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zq43SghudP79" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zgxDQGvmfZga" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2025</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0898"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zwKSh4cIAbxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0900"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_mtLTDzvPK_z4Qsoi8p6jgl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">400,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zoM0DmOlLaQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 100000 2026-02-28 0.05 7.5 7500000 25000 1.10 0 0 72110 40095 257221 516116 839724 990000 64544 186785 607500 1597500 <p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zo3mGkTntFE1" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span><span id="xdx_8BC_z48uydp8uyha">SCHEDULE OF MATURITY DATE OF NOTES</span></span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210630_zCXNmUudfxE9" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Maturity Date of Notes for Twelve Months Ending June 30, 2021,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount due</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_maLTDzHng_zXpcNl3SpvWj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left">2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_maLTDzHng_zTDgMLXAtWu" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2023</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0873"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_maLTDzHng_zz94HdKMvfI6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">607,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_maLTDzHng_zIyW6E8b97og" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2025</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0877"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_maLTDzHng_zQT9qnUvWTag" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0879"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LongTermDebt_iTI_pp0p0_hus-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_mtLTDzHng_zugnktnmJyo7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">607,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Convertible Notes Payable – Related Parties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2021 and 2020, the Company amortized $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_zgYxCtoh0ab8">18,724</span> and $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20200101__20200630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_z7HWEuq0I4J5">18,828</span> of the debt discount, respectively. At June 30, 2021 and December 31, 2020, the Company had an unamortized debt discount of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_zDrgO81K2wdk">88,864</span> and $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20201231__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_zfYLCfwQLVn9">107,588</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021 and December 31, 2020, the Company owes $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_zddCQYn9x9v1" title="Convertible notes payable outstanding">400,000</span> and $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertibleNotesWithRelatedPartiesMember_zMnA4unssig5">400,000</span> on the outstanding Convertible Notes, respectively.</span></p> <p id="xdx_895_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_zmNMvCF5XXz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BF_zH7GqQ3LdrB1" style="display: none">SCHEDULE OF MATURITY DATE OF NOTES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210630_zVEdHkJGvjI5" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Maturity Date of Notes for Twelve Months Ending June 30, 2021,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount due</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zrgS41uXGOLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left">2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zXFwXFc9Agrk" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2023</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0894"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zq43SghudP79" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zgxDQGvmfZga" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2025</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0898"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zwKSh4cIAbxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0900"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_mtLTDzvPK_z4Qsoi8p6jgl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">400,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 607500 607500 18724 18828 88864 107588 400000 400000 <p id="xdx_895_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_zmNMvCF5XXz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BF_zH7GqQ3LdrB1" style="display: none">SCHEDULE OF MATURITY DATE OF NOTES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210630_zVEdHkJGvjI5" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Maturity Date of Notes for Twelve Months Ending June 30, 2021,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount due</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zrgS41uXGOLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left">2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zXFwXFc9Agrk" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2023</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0894"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zq43SghudP79" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zgxDQGvmfZga" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2025</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0898"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_maLTDzvPK_zwKSh4cIAbxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0900"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableRelatedPartyMember_mtLTDzvPK_z4Qsoi8p6jgl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">400,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 400000 400000 <p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zzBHP4XbogMb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 6 - <span id="xdx_82D_z8I5ca3ML4wb">STOCKHOLDERS’ DEFICIT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On April, 29, 2021, the Company completed a public offering (“the Offering”) to sell an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210428__20210429__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zau1yMgRfh4i">3,180,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company’s common stock together with warrants to purchase an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210429__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zmT11CHlKpz5">3,180,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock. The Company also granted the underwriters warrants to purchase an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210429__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--AwardTypeAxis__custom--FourtyFiveDayOptionMember_zXJuItxDL55">477,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Common Stock at the same price. Net proceeds from the Offering were approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20210428__20210429_zCG0ximFBpXb">11.7 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million (excluding any sale of the Option Shares), after deducting underwriting discounts and commissions and public offering expenses payable by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2021, a total of <span id="xdx_903_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--SeriesBPreferedStockMember_zBCmzF2Pn7S7">436,749</span> shares of the Company’s Series B preferred stock was converted to <span id="xdx_901_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20210630__us-gaap--DebtInstrumentAxis__us-gaap--CommonStockMember_zkQGxB7Ylc6l">436,749</span> shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock-Based Compensation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In connection with the consummation of the Merger completed on February 12, 2016, we adopted Prior Protagenic’s 2006 Employee, Director and Consultant Stock Plan (the “2006 Plan”). On June 17, 2016, our stockholders adopted the 2016 Plan and, as a result, we terminated the 2006 Plan. We will not grant any further awards under the 2006 Plan. All outstanding grants under the 2006 Plan will continue in effect in accordance with the terms of the particular grant and the 2006 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant to the 2016 Plan, the Company’s Compensation Committee may grant awards to any employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary. On each of January 1, 2017, January 1, 2019 and January 1, 2020, pursuant to an annual “evergreen” provision contained in the 2016 Plan, the number of shares reserved for future grants was increased by <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20170101__20170102__us-gaap--PlanNameAxis__custom--TwoThousandSixteenPlanMember_pdd" title="Number of additional shares grants for issuance">564,378</span> shares, or a total of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20170102__us-gaap--PlanNameAxis__custom--TwoThousandSixteenPlanMember_pdd" title="Number of shares available for grant">1,693,134</span> shares. As a result of these increases, as of June 30, 2021 and December 31, 2020, the aggregate number of shares of common stock available for awards under the 2016 Plan was <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenPlanMember_pdd" title="Number of shares available for grant">4,868,623</span> shares and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210630__us-gaap--PlanNameAxis__custom--TwoThousandSixteenPlanMember_pdd" title="Number of shares available for grant">4,868,623</span> shares, respectively. Options issued under the 2016 Plan are exercisable for up to ten years from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210630_pdd">5,493,861 </span></span><span style="font: 10pt Times New Roman, Times, Serif">options outstanding as of June 30, 2021. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:</span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdX2gaoYDpGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BB_zilycndE2K05" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20210630__srt--RangeAxis__srt--MinimumMember_ztaoDlGD4xKc" title="Exercise price">3.65</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20210630__srt--RangeAxis__srt--MaximumMember_zAOr7aWvqfm4" title="Exercise price">5.60</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20210101__20210630_zO6HiWnUdP52" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__srt--RangeAxis__srt--MinimumMember_zoKMiwm9nCFb" style="font: 10pt Times New Roman, Times, Serif">0.81</span><span style="font: 10pt Times New Roman, Times, Serif">%-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__srt--RangeAxis__srt--MaximumMember_zDkMWv4Ifo17">1.58</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__srt--RangeAxis__srt--MinimumMember_zqD3rgXU4OWk" title="Expected life in years">5</span>-<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__srt--RangeAxis__srt--MaximumMember_zZ62vuCDCpR4" title="Expected life in years">10</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__srt--RangeAxis__srt--MinimumMember_zgi3tgfqqOQi" style="font: 10pt Times New Roman, Times, Serif">148</span><span style="font: 10pt Times New Roman, Times, Serif">%-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__srt--RangeAxis__srt--MaximumMember_zlF988iVLjX8">158</span></span></td><td style="text-align: left"> %</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20201231_pdd" title="Stock options outstanding">5,597,861</span> options outstanding as of December 31, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20201231_zyyh5cPDqmD9" style="width: 16%; text-align: right" title="Exercise price">1.75</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_z9Toq6s0IN05" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zP7amf6JiE77" title="Risk free interest rate">0.64</span>%-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_z18QVdaEMSr7" title="Risk free interest rate">1.61</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zQbmvi3RJpl3" title="Expected life in years">10</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_z9m0B5u3Nz8k" title="Expected volatility">140</span>%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zxv7wZ2j2HB7" title="Expected volatility">146</span></span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AE_zgo9yVCHAFR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPdKMcDC337j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following is an analysis of the stock option grant activity under the Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B8_zi2jwuxOsq25" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining Life</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 51%"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock Options </i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding December 31, 2020 </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630_zvqs31BBdHZd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Beginning"><span style="font: 10pt Times New Roman, Times, Serif">5,597,861</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_zF9bGprSESZd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercisable Price, Stock Options Outstanding, Beginning"><span style="font: 10pt Times New Roman, Times, Serif">1.47</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zZrssqGSBx4h" title="Weighted Average Remaining Life, Stock Options Outstanding, Beginning">6.48</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options, Granted"><span style="font: 10pt Times New Roman, Times, Serif">546,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercisable Price, Stock Options Outstanding, Granted"><span style="font: 10pt Times New Roman, Times, Serif">4.96</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20210101__20210630_zUV74k6HYVj4" style="font: 10pt Times New Roman, Times, Serif">9.60</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20210630_zK5lTQmJvFF3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options, Expired"><span style="font: 10pt Times New Roman, Times, Serif">(280,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercisable Price, Stock Options Outstanding, Expired"><span style="font: 10pt Times New Roman, Times, Serif">1.00</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercised </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20210630_zCMEMavrAg8k" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Option, Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(370,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercisable Price, Stock Options Outstanding, Exercised"><span style="font: 10pt Times New Roman, Times, Serif">1.48</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding June 30, 2021 </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630_zzC7RO4Kfw0i" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Ending"><span style="font: 10pt Times New Roman, Times, Serif">5,493,861</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_zLHjY5INEkti" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercisable Price, Stock Options Outstanding, Ending"><span style="font: 10pt Times New Roman, Times, Serif">1.84</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20210630_zZYtACyormNc" style="font: 10pt Times New Roman, Times, Serif">6.79</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zX6ixZ6xmNab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A summary of the status of the Company’s nonvested options as of June 30, 2021, and changes during the six months ended June 30, 2021, is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zoPstLuwbdb7" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B0_z48K3Wa41RVl" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average<br/> Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Nonvested at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c20201231_pdd" style="width: 16%; text-align: right" title="Nonvested Options, Beginning Balance">862,833</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_dtY_c20201231_zMNNZHD6BLe6" title="Weighted Average Exercise Price, Beginning Balance">1.75</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630_zLS7Kn5rypjj" style="text-align: right" title="Nonvested Options, Granted">546,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dtY_c20210101__20210630_zdvFz4DUc3">4.96</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20210101__20210630_zHXCWaawEts8" style="text-align: right" title="Nonvested Options, Vested">(433,979</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span title="Weighted Average Exercise Price, Beginning Balance"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_dtY_c20210101__20210630_zmQ0numFJSR8" title="Weighted Average Exercise Price, Vested">3.32</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20210101__20210630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_dtY_c20210101__20210630_zEiekspvGaKj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Nonvested at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20210630_zyXLYGbTk3Pl" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Options, Ending Balance">974,854</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_dtY_c20210630_zphgT9dICya9" title="Weighted Average Exercise Price, Ending Balance">3.02</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zu6mGHSWpHRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021, the Company had <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630_zncrUNuAmaz9">5,493,861 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares issuable under options outstanding at a weighted average exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210630_pdd">1.84 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and an intrinsic value of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20210630_pp0p0">5,701,038</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The total number of options granted during the six months ended June 30, 2021 and 2020 was <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd">546,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdvREDxYaxw6">1,387,497</span></span><span style="font: 10pt Times New Roman, Times, Serif">, respectively. The exercise price for these options was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4NJGFXU2Qll">3.65</span> or $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQYCcdgrmu96">5.60 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognized compensation expense related to options issued of $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqU79I8s1dKg">722,966 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8XxXMd1PhCe">304,148 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the three months ended June 30, 2021 and 2020, respectively, in which $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7LDd2e3eKje">721,490 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZka9uUTR1Kl">269,408 </span></span><span style="font: 10pt Times New Roman, Times, Serif">is included in general and administrative expenses and $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXq2lKniwCta">1,476 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zWwWFvtd4BXi">34,740 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in research and development expenses, respectively. For the three months ended June 30, 2021, $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDbGzewDJRfg">528,197 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the stock compensation was related to employees and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__srt--TitleOfIndividualAxis__custom--NonEmployeesMember_ztynWmkoXOC9">194,769 </span></span><span style="font: 10pt Times New Roman, Times, Serif">was related to non-employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognized compensation expense related to options issued of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGykBWOILrgl">1,068,941 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zXmvMqxXp8Sj">751,552 </span></span><span style="font: 10pt Times New Roman, Times, Serif">during the six months ended June 30, 2021 and 2020, respectively, in which $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYugIRKOVdDl">1,065,988 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zg9hliLWLr16">595,202 </span></span><span style="font: 10pt Times New Roman, Times, Serif">is included in general and administrative expenses and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zMAp6foLdnFi">2,953 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuMygqSwJ7t3">69,381 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in research and development expenses, respectively. For the six months ended June 30, 2021, $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm6VU26IMFJi">664,400 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the stock compensation was related to employees and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__srt--TitleOfIndividualAxis__custom--NonEmployeesMember_zF33DfZIkV2b">404,541 </span></span><span style="font: 10pt Times New Roman, Times, Serif">was related to non-employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021, the unamortized stock option expense was $<span id="xdx_90A_ecustom--UnamortizedStockOptionExpense_c20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Unamortized stock option expense">2,541,457</span> with $<span id="xdx_905_ecustom--UnamortizedStockOptionExpense_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember_pp0p0" title="Unamortized stock option expense">343,794</span> being related to employees and $<span id="xdx_902_ecustom--UnamortizedStockOptionExpense_c20210630__srt--TitleOfIndividualAxis__custom--NonEmployeesMember_pp0p0" title="Unamortized stock option expense">2,197,663</span> being related to non-employees. As of June 30, 2021, the weighted average period for the unamortized stock compensation to be recognized is 3.58 years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On February 25, 2021, the Company issued a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210224__20210225__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__custom--FiveIndividualsMember_zhgmeHCnZuG4">366,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">options to purchase shares of the Company’s common stock to five individuals, with <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200224__20200225__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__custom--RelatedPartiesMember_pdd">350,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of these options being issued to related parties. These options had a grant date fair value of $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200224__20200225__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--SettlementOfAccruedCompensationMember_z5kzFMSc4Qm">2,009,063</span></span><span style="font: 10pt Times New Roman, Times, Serif">. These options have an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200224__20200225__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--SettlementOfAccruedCompensationMember_znEoJQVIX4s2">5.60 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and a term of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200224__20200225__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--SettlementOfAccruedCompensationMember__srt--RangeAxis__srt--MaximumMember_zRS1D5FJhJx5">10</span> years or <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200224__20200225__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--SettlementOfAccruedCompensationMember__srt--RangeAxis__srt--MinimumMember_zC9RtfVgWwH2">5</span> years.</span><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210224__20210225__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--OptionsVestedOverFourtyEightMonthsMember_zeRwg3IN3MB">16,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the options vest immediately and <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20200224__20200225__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--OptionsVestedOverFourtyEightMonthsMember_z0GNt1DY3Vxb">350,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the options vest monthly over 48 months. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On May 26, 2021, the Company issued a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210525__20210526__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--SettlementOfAccruedCompensationMember_zXw7P0wcLYhc">180,000</span> options to purchase shares of the Company’s common stock to a related party. These options had a grant date fair value of $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210525__20210526__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--SettlementOfAccruedCompensationMember_z0FhrTtBdKDk">474,231</span>. These options have an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210525__20210526__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--SettlementOfAccruedCompensationMember_zga3ANJHMF4g">3.65</span>, a term of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210525__20210526__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--StatementScenarioAxis__custom--SettlementOfAccruedCompensationMember_zQrdd3MP0yA">10</span> years, and vest immediately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the three months ended March 31, 2021, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210630__us-gaap--RelatedPartyTransactionAxis__custom--OptionsToRelatedPartyMember_pdd" title="Stock options outstanding">10,000</span> options were exercised for <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20210630__us-gaap--RelatedPartyTransactionAxis__custom--OptionsToRelatedPartyMember_pdd" title="Stock issued during the period exercised">10,000</span> shares of the Company’s common stock. These options had an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210630__us-gaap--RelatedPartyTransactionAxis__custom--OptionsToRelatedPartyMember_pdd" title="Stock options outstanding weighted average exercise price">1.00</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2021, the Company issued <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGZHcOmVRk8c" title="Commom stock issued">360,000</span> shares of the Company’s common stock to a related party for the exercise of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0p0_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPY0GqVlQxy3">360,000</span> options. The Company received proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromStockOptionsExercised_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx9ReVvnraBi">532,500</span> from the exercise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Warrants:</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zy32bnKFy3ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A summary of warrant issuances are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zd7f8kmyBt3g" style="display: none">SUMMARY OF WARRANT ISSUANCES</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Remaining Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic">Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Outstanding December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630_zhbMIGAWglPc" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">4,007,058</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_z0zE74RuHuti" style="width: 14%; text-align: right" title="Number of Warrants Outstanding, Weighted Average Exercise Price, Beginning">1.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20210101__20210630_zk6QI1vfSSd" title="Number of Warrants Outstanding, Weighted Average Remaining Life">1.86</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630_zfQPsZx42smf" style="text-align: right">3,657,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630_zMYDBGauLem6" style="text-align: right" title="Number of Warrants Outstanding, Weighted Average Exercise Price, Granted">4.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--NumberOfWarrantsOutstandingWeightedAverageRemainingLifeGranted_dtY_c20210101__20210630_zhcVojofxp2b">4.83</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20210630_zVACsfhJtTRe" style="text-align: right" title="Number of Warrants Outstanding, Expired">(150,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Number of Warrants Outstanding, Weighted Average Exercise Price, Expired">1.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20210630_zeIcpWnS0zm5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised">(1,381,179</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Weighted Average Exercise Price, Exercised">1.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630_z1xJOsjJO39e" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending">6,132,630</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_zc60Fnvwm8k3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Weighted Average Exercise Price, Ending">3.38</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20210630_z6wpbveZBlna" title="Number of Warrants Outstanding, Weighted Average Remaining Life">3.65</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zUuFJselIZ67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021, the Company had <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUg8IDnwsGoe">6,132,630 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares issuable under warrants outstanding at a weighted average exercise price of $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingWeightedAverageExercisePrice_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztgmGMQn4zZe">3.38 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and an intrinsic value of $<span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOR5ShHbG1Qj">4,629,869</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the three months ended March 31, 2021, <span title="Warrants outstanding"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUmt6LuVirL8" title="Warrants outstanding">373,042</span></span> warrants were exercised for <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmbN1ItOUcn6" title="Warrants outstanding">240,123</span> shares of the Company’s common stock. The Company received $<span id="xdx_90F_ecustom--ProceedsFromWarrantsExercised_pp0p0_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziUqHjQgxEC2" title="Proceeds from warrants exercised">27,125</span> from these exercises.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2021, the Company issued <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7P8ROewx6kf">836,558</span> shares of the Company’s common stock for the net exercise of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOJdJz2IPG07">1,008,137</span> warrants. <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20210630__us-gaap--RelatedPartyTransactionAxis__custom--OptionsToRelatedPartyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziJGobAg0MJa">231,277</span> of these shares of common stock were issued to a related party. The Company received proceeds of $<span id="xdx_90B_ecustom--ProceedsFromWarrantsExercised_pp0p0_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPe8SYmb8ARj">300,000</span> from the exercise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 3180000 3180000 477000 11700000 436749 436749 564378 1693134 4868623 4868623 5493861 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdX2gaoYDpGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BB_zilycndE2K05" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20210630__srt--RangeAxis__srt--MinimumMember_ztaoDlGD4xKc" title="Exercise price">3.65</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20210630__srt--RangeAxis__srt--MaximumMember_zAOr7aWvqfm4" title="Exercise price">5.60</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20210101__20210630_zO6HiWnUdP52" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__srt--RangeAxis__srt--MinimumMember_zoKMiwm9nCFb" style="font: 10pt Times New Roman, Times, Serif">0.81</span><span style="font: 10pt Times New Roman, Times, Serif">%-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__srt--RangeAxis__srt--MaximumMember_zDkMWv4Ifo17">1.58</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__srt--RangeAxis__srt--MinimumMember_zqD3rgXU4OWk" title="Expected life in years">5</span>-<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__srt--RangeAxis__srt--MaximumMember_zZ62vuCDCpR4" title="Expected life in years">10</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__srt--RangeAxis__srt--MinimumMember_zgi3tgfqqOQi" style="font: 10pt Times New Roman, Times, Serif">148</span><span style="font: 10pt Times New Roman, Times, Serif">%-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__srt--RangeAxis__srt--MaximumMember_zlF988iVLjX8">158</span></span></td><td style="text-align: left"> %</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20201231_pdd" title="Stock options outstanding">5,597,861</span> options outstanding as of December 31, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20201231_zyyh5cPDqmD9" style="width: 16%; text-align: right" title="Exercise price">1.75</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_z9Toq6s0IN05" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zP7amf6JiE77" title="Risk free interest rate">0.64</span>%-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_z18QVdaEMSr7" title="Risk free interest rate">1.61</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zQbmvi3RJpl3" title="Expected life in years">10</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_z9m0B5u3Nz8k" title="Expected volatility">140</span>%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zxv7wZ2j2HB7" title="Expected volatility">146</span></span></td><td style="text-align: left">%</td></tr> </table> 3.65 5.60 0 0.0081 0.0158 P5Y P10Y 1.48 1.58 5597861 1.75 0 0.0064 0.0161 P10Y 1.40 1.46 <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPdKMcDC337j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following is an analysis of the stock option grant activity under the Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B8_zi2jwuxOsq25" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining Life</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 51%"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock Options </i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding December 31, 2020 </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630_zvqs31BBdHZd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Beginning"><span style="font: 10pt Times New Roman, Times, Serif">5,597,861</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_zF9bGprSESZd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercisable Price, Stock Options Outstanding, Beginning"><span style="font: 10pt Times New Roman, Times, Serif">1.47</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zZrssqGSBx4h" title="Weighted Average Remaining Life, Stock Options Outstanding, Beginning">6.48</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options, Granted"><span style="font: 10pt Times New Roman, Times, Serif">546,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercisable Price, Stock Options Outstanding, Granted"><span style="font: 10pt Times New Roman, Times, Serif">4.96</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20210101__20210630_zUV74k6HYVj4" style="font: 10pt Times New Roman, Times, Serif">9.60</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20210630_zK5lTQmJvFF3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options, Expired"><span style="font: 10pt Times New Roman, Times, Serif">(280,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercisable Price, Stock Options Outstanding, Expired"><span style="font: 10pt Times New Roman, Times, Serif">1.00</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercised </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20210630_zCMEMavrAg8k" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Option, Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(370,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercisable Price, Stock Options Outstanding, Exercised"><span style="font: 10pt Times New Roman, Times, Serif">1.48</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding June 30, 2021 </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630_zzC7RO4Kfw0i" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Ending"><span style="font: 10pt Times New Roman, Times, Serif">5,493,861</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_zLHjY5INEkti" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercisable Price, Stock Options Outstanding, Ending"><span style="font: 10pt Times New Roman, Times, Serif">1.84</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20210630_zZYtACyormNc" style="font: 10pt Times New Roman, Times, Serif">6.79</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 5597861 1.47 P6Y5M23D 546000 4.96 P9Y7M6D 280000 1.00 370000 1.48 5493861 1.84 P6Y9M14D <p id="xdx_895_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zoPstLuwbdb7" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B0_z48K3Wa41RVl" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average<br/> Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Nonvested at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c20201231_pdd" style="width: 16%; text-align: right" title="Nonvested Options, Beginning Balance">862,833</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_dtY_c20201231_zMNNZHD6BLe6" title="Weighted Average Exercise Price, Beginning Balance">1.75</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630_zLS7Kn5rypjj" style="text-align: right" title="Nonvested Options, Granted">546,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dtY_c20210101__20210630_zdvFz4DUc3">4.96</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20210101__20210630_zHXCWaawEts8" style="text-align: right" title="Nonvested Options, Vested">(433,979</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span title="Weighted Average Exercise Price, Beginning Balance"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_dtY_c20210101__20210630_zmQ0numFJSR8" title="Weighted Average Exercise Price, Vested">3.32</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20210101__20210630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_dtY_c20210101__20210630_zEiekspvGaKj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Nonvested at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20210630_zyXLYGbTk3Pl" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Options, Ending Balance">974,854</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_dtY_c20210630_zphgT9dICya9" title="Weighted Average Exercise Price, Ending Balance">3.02</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 862833 1.75 546000 4.96 433979 3.32 974854 3.02 5493861 1.84 5701038 546000 1387497 3.65 5.60 722966 304148 721490 269408 1476 34740 528197 194769 1068941 751552 1065988 595202 2953 69381 664400 404541 2541457 343794 2197663 366000 350000 2009063 5.60 P10Y P5Y 16000 350000 180000 474231 3.65 P10Y 10000 10000 1.00 360000 360000 532500 <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zy32bnKFy3ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A summary of warrant issuances are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zd7f8kmyBt3g" style="display: none">SUMMARY OF WARRANT ISSUANCES</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Remaining Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic">Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Outstanding December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630_zhbMIGAWglPc" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">4,007,058</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_z0zE74RuHuti" style="width: 14%; text-align: right" title="Number of Warrants Outstanding, Weighted Average Exercise Price, Beginning">1.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20210101__20210630_zk6QI1vfSSd" title="Number of Warrants Outstanding, Weighted Average Remaining Life">1.86</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630_zfQPsZx42smf" style="text-align: right">3,657,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630_zMYDBGauLem6" style="text-align: right" title="Number of Warrants Outstanding, Weighted Average Exercise Price, Granted">4.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--NumberOfWarrantsOutstandingWeightedAverageRemainingLifeGranted_dtY_c20210101__20210630_zhcVojofxp2b">4.83</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20210630_zVACsfhJtTRe" style="text-align: right" title="Number of Warrants Outstanding, Expired">(150,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Number of Warrants Outstanding, Weighted Average Exercise Price, Expired">1.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20210630_zeIcpWnS0zm5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised">(1,381,179</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Weighted Average Exercise Price, Exercised">1.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630_z1xJOsjJO39e" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending">6,132,630</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_zc60Fnvwm8k3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Weighted Average Exercise Price, Ending">3.38</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20210101__20210630_z6wpbveZBlna" title="Number of Warrants Outstanding, Weighted Average Remaining Life">3.65</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4007058 1.06 P1Y10M9D 3657000 4.98 P4Y9M29D 150249 1.25 1381179 1.13 6132630 3.38 P3Y7M24D 6132630 3.38 4629869 373042 240123 27125 836558 1008137 231277 300000 <p id="xdx_803_eus-gaap--CollaborativeArrangementDisclosureTextBlock_zkiyXXRvnbDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 7 - <span id="xdx_820_zcaFRrbIfvq6">COLLABORATIVE AGREEMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company and the University of Toronto (the “University”) entered into an agreement effective April 1, 2014 (the “New Research Agreement”) for the performance of a research project titled “Teneurin C-terminal Associated Peptide (“TCAP”) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The New Project is to perform research related to work done by Dr. David A. Lovejoy, a professor at the University and stockholder of the Company, in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, Dr. Lovejoy entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 30, 2016. In February 2017, the New Research Agreement was extended to December 31, 2017. The extension allowed for further development of the technologies and use of their applications. On April 10, 2018, the agreement was amended and the research agreement has been further extended to December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Prior to January 1, 2016, the University has been granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20150101__20151231__srt--CounterpartyNameAxis__custom--UniversityOfTorontoMember_pdd" title="Share-based compensation stock options, grants">25,000</span> stock options which are fully vested at the exercise price of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20151231__srt--CounterpartyNameAxis__custom--UniversityOfTorontoMember_pdd" title="Share-based compensation weighted average exercise price">1.00</span> exercisable over a <span title="Share-based payment award, expiration period"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20150101__20151231__srt--CounterpartyNameAxis__custom--UniversityOfTorontoMember_zgr99uMEbVa" title="Share-based payment award, expiration period">ten year</span></span> period which ends on April 1, 2022. As of June 30, 2021, Dr. David Lovejoy of the University has been granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20210630__srt--CounterpartyNameAxis__custom--DrDavidLovejoyMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share-based compensation stock options, grants">553,299</span> stock options, of which <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210101__20210630__srt--CounterpartyNameAxis__custom--DrDavidLovejoyMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Number of stock options vested">435,487</span> are fully vested and <span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpirationNumberOfShares_c20210101__20210630__srt--CounterpartyNameAxis__custom--DrDavidLovejoyMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Number of stock options expired">100,000</span> have expired. <span id="xdx_906_ecustom--OptionsExpirationDateDescription_c20210101__20210630__srt--CounterpartyNameAxis__custom--DrDavidLovejoyMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember" title="Options expiration date, description">These have an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__srt--CounterpartyNameAxis__custom--DrDavidLovejoyMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share-based compensation weighted average exercise price">1.00</span>, $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__srt--CounterpartyNameAxis__custom--DrDavidLovejoyMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Share-based compensation weighted average exercise price">1.25</span> or <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210630__srt--CounterpartyNameAxis__custom--DrDavidLovejoyMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Share-based compensation weighted average exercise price">1.75</span> and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027, October 16, 2027 or on February 13, 2030.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The sponsorship research and development expenses pertaining to the Research Agreements were $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementsMember_pp0p0" title="Research and development expense">0</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--ResearchAgreementsMember_pp0p0" title="Research and development expense">0</span> for the six months ended June 30, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 25000 1.00 P10Y 553299 435487 100000 These have an exercise price of $1.00, $1.25 or 1.75 and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027, October 16, 2027 or on February 13, 2030. 1.00 1.25 1.75 0 0 <p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zemGgwhalP97" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 8 - <span id="xdx_82F_z1NLOnhpqY37">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Licensing Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On July 31, 2005, the Company had entered into a Technology License Agreement (“License Agreement”) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the “Technologies”). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of <span id="xdx_90F_ecustom--RoyaltyPaymentPercentage_iI_pid_dp_uPure_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zxBRG7t9tGG8" title="Royalty payment, percentage">2.5</span>% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University <span id="xdx_908_ecustom--UpFrontSubLicenseFeesPercentage_iI_pid_dp_uPure_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zAXBROWn01qf" title="Up-front sub-license fees, percentage">10</span>% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, <span id="xdx_900_ecustom--RoyaltyPaymentOnBehalfOfSublicenseePercentage_iI_c20210630_zUWoi4yYxnqj" title="Royalty Payment on behalf of sublicensee percentage">2.5</span>% of net sales by the sub-licensee of all products based on the Technologies. The Company had <span id="xdx_902_eus-gaap--Revenues_pp0p0_do_c20210101__20210630_zdJCczWpSbae" title="Sales revenue"><span id="xdx_90C_eus-gaap--Revenues_pp0p0_do_c20200101__20200630_zO7qQdScIoF7" title="Sales revenue">no</span></span> sales revenue for the six months ended June 30, 2021 and 2020 and therefore was not subject to paying any royalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at <span id="xdx_903_ecustom--InterestOnAmountsOwedUnderLicenseAgreementRate_iI_pid_dp_uPure_c20210630_zdWDmjlYzP3j" title="Interest on amounts owed under license agreement, rate">3</span>% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or Dr. Lovejoy, and/or the University, as the case may be. The Company has agreed to pay all out-of- pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the <span title="Royalty payment on behalf of sub-licensee, percentage"><span id="xdx_909_ecustom--RoyaltyPaymentPercentage_iI_pid_dp_uPure_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zIddz8oazq5b" title="Royalty payment, percentage">2.5</span></span>% royalty payment owed to the University under the License Agreement and amendment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The patent applications were made in the name of Dr. Lovejoy and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the five intellectual patent properties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Legal Proceedings</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 0.025 0.10 2.5 0 0 0.03 0.025 <p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zDEZhiZCuGx9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 9 – <span id="xdx_826_zSa1uNOdPMa2">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen. The Company does not pay any rent for the use of this space. This space is used for quarterly board meetings and our annual shareholder meeting.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zepW1PJ8ntFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 10- <span id="xdx_824_zfAkW1nR1Yde">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Subsequent to the period, a total of <span id="xdx_901_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20210816__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgLx4sa5XHGl">436,017</span> shares of the Company’s preferred stock was converted to <span id="xdx_90B_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20210816__us-gaap--DebtInstrumentAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNMfoXFCQhs">436,017</span> shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On July 26, 2021, the Company issued <span title="Option to purchase shares of common stock"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210725__20210726__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEyDLiCu1tCl" title="Option to purchase shares of common stock">32,000</span></span> options to purchase share of the Company’s common stock. These options have a term of ten years, an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210726__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0dijMXREqtd" title="Exercise price per share">2.09</span>, and vest over 48 months.</span></p> 436017 436017 32000 2.09 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
 6 Months Ended
Jun. 30, 2021
Aug. 13, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2021  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --12-31  
Entity File Number 000-51353  
Entity Registrant Name Protagenic Therapeutics, Inc.\new  
Entity Central Index Key 0001022899  
Entity Tax Identification Number 06-1390025  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 149 Fifth Avenue  
Entity Address, Address Line Two Suite 500  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10010  
City Area Code (212)  
Local Phone Number 994-8200  
Title of 12(b) Security Common Stock, par value $0.0001  
Trading Symbol PTIX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   16,699,651
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets - USD ($)
Jun. 30, 2021
Dec. 31, 2020
CURRENT ASSETS    
Cash $ 11,932,973 $ 671,091
Prepaid expenses 129,167 208,156
TOTAL CURRENT ASSETS 12,062,140 879,247
TOTAL ASSETS 12,062,140 879,247
CURRENT LIABILITIES    
Accounts payable and accrued expenses 602,587 571,517
Derivative liability 83,670
TOTAL CURRENT LIABILITIES 602,587 655,187
PIK convertible notes payable, net of debt discount 350,279 1,081,384
PIK convertible notes payable, net of debt discount - related parties 311,136 292,412
TOTAL LIABILITIES 1,264,002 2,028,983
STOCKHOLDERS’ EQUITY (DEFICIT)    
Preferred stock, $0.000001 par value; 20,000,000 shares authorized; 872,766 shares issued and outstanding in the following classes:
Common stock, $.0001 par value, 100,000,000 shares authorized, 16,263,634 and 10,360,480 shares issued and outstanding at June 30, 2021, and December 31, 2020 1,627 1,036
Additional paid-in-capital 31,420,307 16,719,749
Accumulated deficit (20,453,184) (17,698,936)
Accumulated other comprehensive loss (170,613) (171,586)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) 10,798,138 (1,149,736)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) 12,062,140 879,247
Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY (DEFICIT)    
Preferred stock, $0.000001 par value; 20,000,000 shares authorized; 872,766 shares issued and outstanding in the following classes:
Series B Convertible Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY (DEFICIT)    
Preferred stock, $0.000001 par value; 20,000,000 shares authorized; 872,766 shares issued and outstanding in the following classes: $ 1 $ 1
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2021
Dec. 31, 2020
Preferred stock, par value $ 0.000001 $ 0.000001
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, shares issued 872,766 872,766
Preferred stock, shares outstanding 872,766 872,766
Common stock, par value $ 1 $ 1
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 16,263,634 10,360,480
Common stock, shares outstanding 16,263,634 10,360,480
Series B Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.000001 $ 0.000001
Preferred stock, shares authorized 18,000,000 18,000,000
Preferred stock, shares issued 436,017 872,766
Preferred stock, shares outstanding 436,017 872,766
Preferred Stock [Member]    
Preferred stock, par value $ 0.000001 $ 0.000001
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
OPERATING AND ADMINISTRATIVE EXPENSES        
Research and development $ 140,592 $ 52,008 $ 732,943 $ 117,967
General and administrative 1,168,241 436,935 1,782,080 891,712
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES 1,308,833 488,943 2,515,023 1,009,679
LOSS FROM OPERATIONS (1,308,833) (488,943) (2,515,023) (1,009,679)
OTHER (EXPENSE) INCOME        
Interest income 227 93 232 477
Interest expense (239,190) (54,944) (323,127) (93,930)
Change in fair value of derivative liability (23,560) 83,670 37,189
TOTAL OTHER INCOME (EXPENSES) (238,963) (78,411) (239,225) (56,264)
LOSS BEFORE TAX (1,547,796) (567,354) (2,754,248) (1,065,943)
INCOME TAX EXPENSE
NET LOSS (1,547,796) (567,354) (2,754,248) (1,065,943)
Other Comprehensive Loss - net of tax        
Foreign exchange translation income (loss) 482 1,084 973 (1,335)
TOTAL COMPREHENSIVE LOSS $ (1,547,314) $ (566,270) $ (2,753,275) $ (1,067,278)
Net loss per common share - Basic and Diluted $ (0.11) $ (0.06) $ (0.22) $ (0.10)
Weighted average common shares - Basic and Diluted 14,487,277 10,261,419 12,488,906 10,261,419
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements Of Changes In Stockholders' Deficit (Unaudited) - USD ($)
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
BALANCE at Dec. 31, 2019 $ 1 $ 1,026 $ 14,687,172 $ (15,150,201) $ (172,364) $ (634,366)
Balance, shares at Dec. 31, 2019 872,766 10,261,419        
Foreign currency translation gain (2,419) (2,419)
Stock compensation - stock options 360,436 360,436
Debt discount from beneficial conversion feature 89,204 89,204
Issuance of options for settlement of accrued payroll 93,950 93,950
Modification of warrants 5,861 5,861
Conversion of notes and interest   $ 84 1,054,460 1,054,544
Conversion of notes and interest, shares   839,724        
Net loss (498,589) (498,589)
BALANCE at Mar. 31, 2020 $ 1 $ 1,026 15,236,623 (15,648,790) (174,783) (585,923)
Balance, shares at Mar. 31, 2020 872,766 10,261,419        
BALANCE at Dec. 31, 2019 $ 1 $ 1,026 14,687,172 (15,150,201) (172,364) (634,366)
Balance, shares at Dec. 31, 2019 872,766 10,261,419        
Modification of warrants           5,861
Issuance of shares and warrants from offering, net of offering costs          
Net loss           (1,065,943)
BALANCE at Jun. 30, 2020 $ 1 $ 1,026 15,642,739 (16,216,144) (173,699) (746,077)
Balance, shares at Jun. 30, 2020 872,766 10,261,419        
BALANCE at Mar. 31, 2020 $ 1 $ 1,026 15,236,623 (15,648,790) (174,783) (585,923)
Balance, shares at Mar. 31, 2020 872,766 10,261,419        
Foreign currency translation gain 1,084 1,084
Stock compensation - stock options 304,148 304,148
Debt discount from beneficial conversion feature 86,968 86,968
Issuance of options for settlement of accrued payroll 15,000 15,000
Net loss (567,354) (567,354)
BALANCE at Jun. 30, 2020 $ 1 $ 1,026 15,642,739 (16,216,144) (173,699) (746,077)
Balance, shares at Jun. 30, 2020 872,766 10,261,419        
BALANCE at Dec. 31, 2020 $ 1 $ 1,036 16,719,749 (17,698,936) (171,586) (1,149,736)
Balance, shares at Dec. 31, 2020 872,766 10,360,480        
Foreign currency translation gain 491 491
Stock compensation - stock options 345,975 345,975
Exercise of options $ 1 (1)
Exercise of options, shares   10,000        
Exercise of warrants $ 24 27,101 27,125
Exercise of warrants, shares   240,123        
Net loss (1,206,452) (1,206,452)
BALANCE at Mar. 31, 2021 $ 1 $ 1,061 17,092,824 (18,905,388) (171,095) (1,982,597)
Balance, shares at Mar. 31, 2021 872,766 10,610,603        
BALANCE at Dec. 31, 2020 $ 1 $ 1,036 16,719,749 (17,698,936) (171,586) (1,149,736)
Balance, shares at Dec. 31, 2020 872,766 10,360,480        
Modification of warrants          
Exercise of options, shares           370,000
Issuance of shares and warrants from offering, net of offering costs           $ 11,708,039
Net loss           (2,754,248)
BALANCE at Jun. 30, 2021 $ 1 $ 1,627 31,420,307 (20,453,184) (170,613) 10,798,138
Balance, shares at Jun. 30, 2021 436,017 16,263,634        
BALANCE at Mar. 31, 2021 $ 1 $ 1,061 17,092,824 (18,905,388) (171,095) (1,982,597)
Balance, shares at Mar. 31, 2021 872,766 10,610,603        
Foreign currency translation gain 482 482
Stock compensation - stock options 722,966 722,966
Exercise of options $ 36 542,464 542,500
Exercise of options, shares   360,000        
Exercise of warrants   $ 84 299,916 300,000
Exercise of warrants, shares   836,558        
Issuance of shares and warrants from offering, net of offering costs $ 318 11,707,721 11,708,039
Issuance of shares and warrants from offering, net of offering costs, shares   3,180,000        
Conversion of preferred stock   $ 44 (44)
Conversion of preferred stock,Shares (436,749) 436,749        
Conversion of notes and interest   $ 84 1,054,460 1,054,544
Conversion of notes and interest, shares   839,724        
Net loss (1,547,796) (1,547,796)
BALANCE at Jun. 30, 2021 $ 1 $ 1,627 $ 31,420,307 $ (20,453,184) $ (170,613) $ 10,798,138
Balance, shares at Jun. 30, 2021 436,017 16,263,634        
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Cash Flows - USD ($)
 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES    
Net Loss $ (2,754,248) $ (1,065,943)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation expense 165
Stock based compensation 1,068,941 751,552
Change in fair value of the derivative liability (83,670) (37,189)
Amortization of debt discount 277,619 58,923
Modification of warrants 5,861
Changes in operating assets and liabilities    
Prepaid expenses 78,990 36,856
Accounts payable and accrued expenses 94,278 (260,322)
NET CASH USED IN OPERATING ACTIVITIES (1,318,090) (510,097)
CASH FLOWS FROM FINANCING ACTIVITIES    
Exercise of warrants for cash 327,125
Exercise of options for cash 542,500
Issuance of shares and warrants from offering, net of offering costs 11,708,039
Proceeds from notes payable 100,000
Repayment of notes payable (100,000)
Proceeds from PIK convertible notes 850,000
Proceeds from PIK convertible notes - related party 50,000
NET CASH PROVIDED BY FINANCING ACTIVITIES 12,577,664 900,000
Effect of exchange rate on cash 2,308 (7,230)
NET INCREASE IN CASH 11,261,882 382,673
CASH, BEGINNING OF YEAR 671,091 798,623
CASH, END OF YEAR 11,932,973 1,181,296
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION    
Cash paid for interest expense
Cash paid for income taxes
NONCASH FINANCING AND INVESTING TRANSACTIONS    
Shares issued for conversion of notes and interest 1,054,544
Debt discount from beneficial conversion feature 104,204
Issuance of options for settlement of accounts payable $ 93,950
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND NATURE OF BUSINESS
 6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND NATURE OF BUSINESS

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

 

Company Background

 

Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), is a Delaware corporation with one subsidiary named Protagenic Therapeutics Canada (2006) Inc. (“PTI Canada”), a corporation formed in 2006 under the laws of the Province of Ontario, Canada.

 

The Company was previously known as Atrinsic, Inc., a company that was once a reporting company under the Securities Exchange Act of 1934, but that, in 2012 and 2013, reorganized under Chapter 11 of the United States Bankruptcy Code and emerged from bankruptcy. On February 12, 2016, the Company acquired Protagenic Therapeutics, Inc. (“Prior Protagenic”) through a reverse merger.

 

On February 12, 2016, Protagenic Acquisition Corp., a wholly-owned subsidiary of the Company, merged (the “Merger”) with and into Prior Protagenic. Prior Protagenic was the surviving corporation of the Merger. As a result of the Merger, the Company acquired the business of Prior Protagenic and has continued the existing business operations of Prior Protagenic as a wholly-owned subsidiary. On June 17, 2016, Prior Protagenic merged with and into the Company with the Company as the surviving corporation in the merger. Immediately thereafter, the Company changed its name from Atrinsic, Inc. to Protagenic Therapeutics, Inc.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.2
LIQUIDITY
 6 Months Ended
Jun. 30, 2021
Liquidity  
LIQUIDITY

NOTE 2 - LIQUIDITY

 

As shown in the accompanying consolidated financial statements, the Company has incurred significant recurring losses resulting in an accumulated deficit. The Company anticipates further losses in the development of its business. The Company also had negative cash flows used in operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

Based on its cash resources as of June 30, 2021, the Company has sufficient resources to fund its operations at least until the end of the third quarter of 2023. Absent generation of sufficient revenue from the execution of the Company’s business plan and sales revenue is not anticipated before 2024, the Company will need to obtain debt or equity financing by the third quarter of 2023. Because of these factors, the Company believes that this alleviates the substantial doubt in connection with the Company’s ability to continue as a going concern.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNFICANT ACCOUNTING POLICIES
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNFICANT ACCOUNTING POLICIES

NOTE 3 - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC” for interim financial information. In the opinion of the Company’s management, the accompanying consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended June 30, 2021 and 2020. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).

 

 

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2020, which contain the audited financial statements and notes thereto, for the years ended December 31, 2020 and 2019 included within the Company’s Form 10-K filed with the SEC on March 25, 2021. The interim results for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

 

Principles of consolidation

 

The condensed consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in the condensed consolidated financial statements.

 

Reclassifications:

 

Reclassifications of prior periods have been made to conform with current year presentation

 

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include income tax provisions, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.

 

Concentrations of Credit Risk

 

The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. As of June 30, 2021, the Company has bank balances that exceeds the federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of June 30, 2021 and December 31, 2020, the Company did not have any cash equivalents.

 

Fair Value Measurements

 

ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

 

The three levels are described below:

 

Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;

 

Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;

 

 

Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.

 

The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short term maturity of those instruments. The carrying value of long-term debt approximates fair value since the related rates of interest approximate current market rates.

 

Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.

 

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of June 30, 2021.

 

   Carrying   Fair Value Measurement Using 
   Value   Level 1   Level 2   Level 3   Total 
                          
Derivative warrants liabilities  $—   $—   $—   $—   $— 

 

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.

 

   Carrying   Fair Value Measurement Using 
   Value   Level 1   Level 2   Level 3   Total 
                          
Derivative warrants liabilities  $83,670   $—   $—   $83,670   $83,670 

 

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2021 and the year ended December 31, 2020:

 

   Fair Value Measurement Using Level 3 
   Inputs Total 
Balance, December 31, 2020  $83,670 
Change in fair value of derivative warrants liabilities   (83,670)
Balance, June 30, 2021  $- 

 

The fair value of the derivative feature of the 127,346 and 295,945 warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet dates were calculated using a Black-Scholes option model valued with the following assumptions:

 

   December 31, 2020 
Exercise price   1.25 
Risk free interest rate   0.09%
Dividend yield   0.00%
Expected volatility   169%
Contractual term   0.14 Years 

 

 

Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement.

 

Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.

 

Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term.

 

Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants.

 

During the six months ended June 30, 2021 and 2020, the Company marked the derivative feature of the warrants to fair value and recorded a gain of $83,670 and a gain of $37,189 relating to the change in fair value, respectively. The warrants expired on February 21, 2021, resulting in the elimination of the derivative liability.

 

Derivative Liability

 

The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10-05-4 and 815-40-25. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the condensed consolidated statements of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then the related fair value is reclassified to equity.

 

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

 

Stock-Based Compensation

 

The Company accounts for stock based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or canceled during the periods reported.

 

If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.

 

Basic and Diluted Net (Loss) per Common Share

 

Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.

 

 

   Potentially Outstanding
Dilutive Common Shares		 
   For the Six Months Ended June 30, 2021   For the Six Months Ended June 30, 2020 
         
Conversion Feature Shares          
           
Common shares issuable under the conversion feature of preferred shares   436,017    872,766 
           
Stock Options   5,493,861    4,028,162 
           
Warrants   6,132,630    3,908,258 
           
Convertible Notes   806,000    1,256,000 
           
Total potentially outstanding dilutive common shares   12,868,508    10,065,186 

 

Research and Development

 

Research and development expenses are charged to operations as incurred.

 

Foreign Currency Translation

 

The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.

 

The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the condensed consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the condensed consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the condensed consolidated statements of operations and comprehensive loss.

 

Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.

 

 

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.2
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
 6 Months Ended
Jun. 30, 2021
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses consist of the following at:

   June 30, 2021   December 31, 2020 
         
Accounting  $36,161   $36,161 
Research and development   381,702    393,496 
Other   184,724    141,860 
           
Total  $602,587   $571,517 

 

On October 1, 2019, the Company entered into an agreement with a consultant for toxicology studies. The consultant quoted a commitment of approximately $988,000 as an estimate for the study. 50% of the total price was paid upon the signing of the agreement, 35% of the total price is to be paid upon completion of the in-life study, and the remaining 15% of the total price is to be paid upon the issuance of the report. If the Company cancels the study the Company will be required to pay a cancelation fee. If the cancelation happens prior to the arrival of the test animals then the Company will need to pay between 20% and 50% of the animal fees depending on when the cancellation happens. If the cancellation occurs after the animals arrive but before the study begins then the Company will be responsible for paying 50% of the protocol price plus a fee of $7,000 per room/week for animal husbandry until the animals can be relocated or disposed of. If the Company cancels the study after it has begun then the Company will need to pay any fees for procured items for the study and any nonrecoverable expenses incurred by the consultant. As of June 30, 2021 and December 31, 2020, the Company has paid $174,106 and $174,106 to the consultant and there is a balance of $319,799 and $319,799 due, respectively.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.2
NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)
 6 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)

NOTE 5 – NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)

 

Note Payable

 

On March 1, 2021, the Company entered into a $100,000 promissory note. This note is due on February 28, 2026 and accrues interest at a rate of 5% per annum or 7.5% per annum in the case of default. In the event that the Company completes a financing of no less than $7.5 million, then the note holder will be issued warrants valued at $25,000 with an exercise price equal to 110% of the offering cost of the common stock in the financing. These warrants will have a term of five years. During the six months ended June 30, 2021, the Company paid off the balance of this note’s principal and accrued interest.

 

As of June 30, 2021 and December 31, 2020, the Company owes $0 and $0 on the outstanding note, respectively.

 

Convertible Notes Payable

 

During the six months ended June 30, 2021 and 2020, the Company amortized $72,110 and $40,095 of the debt discount, respectively. At June 30, 2021 and December 31, 2020, the Company had an unamortized debt discount of $257,221 and $516,116, respectively.

 

During the six months ended June 30, 2021, a total of 839,724 shares of the Company’s common stock was issued for the conversion of notes and interest. A total of $990,000 in principal and $64,544 in accrued interest was converted. As part of this conversion, the Company also expensed $186,785 in unamortized debt discount related to these converted notes.

 

 

As of June 30, 2021 and December 31, 2020, the Company owes $607,500 and $1,597,500 on the outstanding Convertible Notes, respectively.

 

     
Maturity Date of Notes for Twelve Months Ending June 30, 2021,  Amount due 
2022  $- 
2023   - 
2024   607,500 
2025   - 
2026   - 
Total  $607,500 

 

Convertible Notes Payable – Related Parties

 

During the six months ended June 30, 2021 and 2020, the Company amortized $18,724 and $18,828 of the debt discount, respectively. At June 30, 2021 and December 31, 2020, the Company had an unamortized debt discount of $88,864 and $107,588, respectively.

 

As of June 30, 2021 and December 31, 2020, the Company owes $400,000 and $400,000 on the outstanding Convertible Notes, respectively.

 

     
Maturity Date of Notes for Twelve Months Ending June 30, 2021,  Amount due 
2022  $- 
2023   - 
2024   400,000 
2025   - 
2026   - 
Total  $400,000 

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ DEFICIT
 6 Months Ended
Jun. 30, 2021
Equity [Abstract]  
STOCKHOLDERS’ DEFICIT

NOTE 6 - STOCKHOLDERS’ DEFICIT

 

Common Stock

 

On April, 29, 2021, the Company completed a public offering (“the Offering”) to sell an aggregate of 3,180,000 shares of the Company’s common stock together with warrants to purchase an aggregate of 3,180,000 shares of common stock. The Company also granted the underwriters warrants to purchase an aggregate of 477,000 shares of Common Stock at the same price. Net proceeds from the Offering were approximately $11.7 million (excluding any sale of the Option Shares), after deducting underwriting discounts and commissions and public offering expenses payable by the Company.

 

During the six months ended June 30, 2021, a total of 436,749 shares of the Company’s Series B preferred stock was converted to 436,749 shares of the Company’s common stock.

 

Stock-Based Compensation

 

In connection with the consummation of the Merger completed on February 12, 2016, we adopted Prior Protagenic’s 2006 Employee, Director and Consultant Stock Plan (the “2006 Plan”). On June 17, 2016, our stockholders adopted the 2016 Plan and, as a result, we terminated the 2006 Plan. We will not grant any further awards under the 2006 Plan. All outstanding grants under the 2006 Plan will continue in effect in accordance with the terms of the particular grant and the 2006 Plan.

 

Pursuant to the 2016 Plan, the Company’s Compensation Committee may grant awards to any employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary. On each of January 1, 2017, January 1, 2019 and January 1, 2020, pursuant to an annual “evergreen” provision contained in the 2016 Plan, the number of shares reserved for future grants was increased by 564,378 shares, or a total of 1,693,134 shares. As a result of these increases, as of June 30, 2021 and December 31, 2020, the aggregate number of shares of common stock available for awards under the 2016 Plan was 4,868,623 shares and 4,868,623 shares, respectively. Options issued under the 2016 Plan are exercisable for up to ten years from the date of issuance.

 

 

There were 5,493,861 options outstanding as of June 30, 2021. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

 

      
Exercise price  $3.65-5.60 
Expected dividend yield   0%
Risk free interest rate   0.81%-1.58%
Expected life in years   5-10 
Expected volatility   148%-158 %

 

There were 5,597,861 options outstanding as of December 31, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

 

      
Exercise price  $1.75 
Expected dividend yield   0%
Risk free interest rate   0.64%-1.61%
Expected life in years   10 
Expected volatility   140%-146%

 

The following is an analysis of the stock option grant activity under the Plan:

 

       

Weighted

Average

    

Weighted

Average

  
  Number     Exercise Price     Remaining Life  
Stock Options                      
                       
Outstanding December 31, 2020   5,597,861     $ 1.47       6.48  
Granted   546,000     $ 4.96       9.60  
Expired   (280,000 )   $ 1.00       -  
Exercised   (370,000 )   $ 1.48       -  
Outstanding June 30, 2021   5,493,861     $ 1.84       6.79  

 

A summary of the status of the Company’s nonvested options as of June 30, 2021, and changes during the six months ended June 30, 2021, is presented below:

 

Nonvested Options  Options  

Weighted-

Average
Exercise Price

 
Nonvested at December 31, 2020   862,833   $1.75 
Granted   546,000   $4.96 
Vested   (433,979)  $3.32 
Forfeited   -   $- 
Nonvested at June 30, 2021   974,854   $3.02 

 

As of June 30, 2021, the Company had 5,493,861 shares issuable under options outstanding at a weighted average exercise price of $1.84 and an intrinsic value of $5,701,038

 

The total number of options granted during the six months ended June 30, 2021 and 2020 was 546,000 and 1,387,497, respectively. The exercise price for these options was $3.65 or $5.60 per share.

 

The Company recognized compensation expense related to options issued of $722,966 and $304,148 during the three months ended June 30, 2021 and 2020, respectively, in which $721,490 and $269,408 is included in general and administrative expenses and $1,476 and $34,740 in research and development expenses, respectively. For the three months ended June 30, 2021, $528,197 of the stock compensation was related to employees and $194,769 was related to non-employees.

 

 

The Company recognized compensation expense related to options issued of $1,068,941 and $751,552 during the six months ended June 30, 2021 and 2020, respectively, in which $1,065,988 and $595,202 is included in general and administrative expenses and $2,953 and $69,381 in research and development expenses, respectively. For the six months ended June 30, 2021, $664,400 of the stock compensation was related to employees and $404,541 was related to non-employees.

 

As of June 30, 2021, the unamortized stock option expense was $2,541,457 with $343,794 being related to employees and $2,197,663 being related to non-employees. As of June 30, 2021, the weighted average period for the unamortized stock compensation to be recognized is 3.58 years.

 

On February 25, 2021, the Company issued a total of 366,000 options to purchase shares of the Company’s common stock to five individuals, with 350,000 of these options being issued to related parties. These options had a grant date fair value of $2,009,063. These options have an exercise price of $5.60 and a term of 10 years or 5 years. 16,000 of the options vest immediately and 350,000 of the options vest monthly over 48 months.

 

On May 26, 2021, the Company issued a total of 180,000 options to purchase shares of the Company’s common stock to a related party. These options had a grant date fair value of $474,231. These options have an exercise price of $3.65, a term of 10 years, and vest immediately.

 

During the three months ended March 31, 2021, 10,000 options were exercised for 10,000 shares of the Company’s common stock. These options had an exercise price of $1.00.

 

During the three months ended June 30, 2021, the Company issued 360,000 shares of the Company’s common stock to a related party for the exercise of 360,000 options. The Company received proceeds of $532,500 from the exercise.

 

Warrants:

 

A summary of warrant issuances are as follows:

 

      

Weighted

Average

  

Weighted

Average

 
   Number   Exercise Price   Remaining Life 
Warrants               
                
Outstanding December 31, 2020   4,007,058   $1.06    1.86 
Granted   3,657,000    4.98    4.83 
Expired   (150,249)   1.25    - 
Exercised   (1,381,179)   1.13    - 
Outstanding June 30, 2021   6,132,630   $3.38    3.65 

 

As of June 30, 2021, the Company had 6,132,630 shares issuable under warrants outstanding at a weighted average exercise price of $3.38 and an intrinsic value of $4,629,869.

 

During the three months ended March 31, 2021, 373,042 warrants were exercised for 240,123 shares of the Company’s common stock. The Company received $27,125 from these exercises.

 

During the three months ended June 30, 2021, the Company issued 836,558 shares of the Company’s common stock for the net exercise of 1,008,137 warrants. 231,277 of these shares of common stock were issued to a related party. The Company received proceeds of $300,000 from the exercise.

 

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.2
COLLABORATIVE AGREEMENTS
 6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
COLLABORATIVE AGREEMENTS

NOTE 7 - COLLABORATIVE AGREEMENTS

 

The Company and the University of Toronto (the “University”) entered into an agreement effective April 1, 2014 (the “New Research Agreement”) for the performance of a research project titled “Teneurin C-terminal Associated Peptide (“TCAP”) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The New Project is to perform research related to work done by Dr. David A. Lovejoy, a professor at the University and stockholder of the Company, in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, Dr. Lovejoy entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 30, 2016. In February 2017, the New Research Agreement was extended to December 31, 2017. The extension allowed for further development of the technologies and use of their applications. On April 10, 2018, the agreement was amended and the research agreement has been further extended to December 31, 2023.

 

Prior to January 1, 2016, the University has been granted 25,000 stock options which are fully vested at the exercise price of $1.00 exercisable over a ten year period which ends on April 1, 2022. As of June 30, 2021, Dr. David Lovejoy of the University has been granted 553,299 stock options, of which 435,487 are fully vested and 100,000 have expired. These have an exercise price of $1.00, $1.25 or 1.75 and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027, October 16, 2027 or on February 13, 2030.

 

The sponsorship research and development expenses pertaining to the Research Agreements were $0 and $0 for the six months ended June 30, 2021 and 2020, respectively.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 8 - COMMITMENTS AND CONTINGENCIES

 

Licensing Agreements

 

On July 31, 2005, the Company had entered into a Technology License Agreement (“License Agreement”) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the “Technologies”). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.

 

Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no sales revenue for the six months ended June 30, 2021 and 2020 and therefore was not subject to paying any royalties.

 

In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or Dr. Lovejoy, and/or the University, as the case may be. The Company has agreed to pay all out-of- pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment.

 

The patent applications were made in the name of Dr. Lovejoy and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the five intellectual patent properties.

 

 

Legal Proceedings

 

From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS
 6 Months Ended
Jun. 30, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 9 – RELATED PARTY TRANSACTIONS

 

The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen. The Company does not pay any rent for the use of this space. This space is used for quarterly board meetings and our annual shareholder meeting.

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.2
SUBSEQUENT EVENTS
 6 Months Ended
Jun. 30, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 10- SUBSEQUENT EVENTS

 

Subsequent to the period, a total of 436,017 shares of the Company’s preferred stock was converted to 436,017 shares of the Company’s common stock.

 

On July 26, 2021, the Company issued 32,000 options to purchase share of the Company’s common stock. These options have a term of ten years, an exercise price of $2.09, and vest over 48 months.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Policies)
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Basis of presentation

Basis of presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC” for interim financial information. In the opinion of the Company’s management, the accompanying consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended June 30, 2021 and 2020. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).

 

 

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2020, which contain the audited financial statements and notes thereto, for the years ended December 31, 2020 and 2019 included within the Company’s Form 10-K filed with the SEC on March 25, 2021. The interim results for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

 
Principles of consolidation

Principles of consolidation

 

The condensed consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in the condensed consolidated financial statements.

 
Reclassifications

Reclassifications:

 

Reclassifications of prior periods have been made to conform with current year presentation

 
Use of estimates

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include income tax provisions, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.

 
Concentrations of Credit Risk

Concentrations of Credit Risk

 

The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. As of June 30, 2021, the Company has bank balances that exceeds the federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of June 30, 2021 and December 31, 2020, the Company did not have any cash equivalents.

 
Fair Value Measurements

Fair Value Measurements

 

ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

 

The three levels are described below:

 

Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;

 

Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;

 

 

Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.

 

The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short term maturity of those instruments. The carrying value of long-term debt approximates fair value since the related rates of interest approximate current market rates.

 

Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.

 

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of June 30, 2021.

 

   Carrying   Fair Value Measurement Using 
   Value   Level 1   Level 2   Level 3   Total 
                          
Derivative warrants liabilities  $—   $—   $—   $—   $— 

 

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.

 

   Carrying   Fair Value Measurement Using 
   Value   Level 1   Level 2   Level 3   Total 
                          
Derivative warrants liabilities  $83,670   $—   $—   $83,670   $83,670 

 

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2021 and the year ended December 31, 2020:

 

   Fair Value Measurement Using Level 3 
   Inputs Total 
Balance, December 31, 2020  $83,670 
Change in fair value of derivative warrants liabilities   (83,670)
Balance, June 30, 2021  $- 

 

The fair value of the derivative feature of the 127,346 and 295,945 warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet dates were calculated using a Black-Scholes option model valued with the following assumptions:

 

   December 31, 2020 
Exercise price   1.25 
Risk free interest rate   0.09%
Dividend yield   0.00%
Expected volatility   169%
Contractual term   0.14 Years 

 

 

Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement.

 

Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.

 

Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term.

 

Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants.

 

During the six months ended June 30, 2021 and 2020, the Company marked the derivative feature of the warrants to fair value and recorded a gain of $83,670 and a gain of $37,189 relating to the change in fair value, respectively. The warrants expired on February 21, 2021, resulting in the elimination of the derivative liability.

 
Derivative Liability

Derivative Liability

 

The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10-05-4 and 815-40-25. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the condensed consolidated statements of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then the related fair value is reclassified to equity.

 

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company accounts for stock based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or canceled during the periods reported.

 

If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.

 
Basic and Diluted Net (Loss) per Common Share

Basic and Diluted Net (Loss) per Common Share

 

Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.

 

 

   Potentially Outstanding
Dilutive Common Shares		 
   For the Six Months Ended June 30, 2021   For the Six Months Ended June 30, 2020 
         
Conversion Feature Shares          
           
Common shares issuable under the conversion feature of preferred shares   436,017    872,766 
           
Stock Options   5,493,861    4,028,162 
           
Warrants   6,132,630    3,908,258 
           
Convertible Notes   806,000    1,256,000 
           
Total potentially outstanding dilutive common shares   12,868,508    10,065,186 

 
Research and Development

Research and Development

 

Research and development expenses are charged to operations as incurred.

 
Foreign Currency Translation

Foreign Currency Translation

 

The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.

 

The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the condensed consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the condensed consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the condensed consolidated statements of operations and comprehensive loss.

 

Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.

 

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Tables)
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS

 

   Carrying   Fair Value Measurement Using 
   Value   Level 1   Level 2   Level 3   Total 
                          
Derivative warrants liabilities  $—   $—   $—   $—   $— 

 

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.

 

   Carrying   Fair Value Measurement Using 
   Value   Level 1   Level 2   Level 3   Total 
                          
Derivative warrants liabilities  $83,670   $—   $—   $83,670   $83,670 
SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION

 

   Fair Value Measurement Using Level 3 
   Inputs Total 
Balance, December 31, 2020  $83,670 
Change in fair value of derivative warrants liabilities   (83,670)
Balance, June 30, 2021  $- 
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES

 

   December 31, 2020 
Exercise price   1.25 
Risk free interest rate   0.09%
Dividend yield   0.00%
Expected volatility   169%
Contractual term   0.14 Years 
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

 

   Potentially Outstanding
Dilutive Common Shares		 
   For the Six Months Ended June 30, 2021   For the Six Months Ended June 30, 2020 
         
Conversion Feature Shares          
           
Common shares issuable under the conversion feature of preferred shares   436,017    872,766 
           
Stock Options   5,493,861    4,028,162 
           
Warrants   6,132,630    3,908,258 
           
Convertible Notes   806,000    1,256,000 
           
Total potentially outstanding dilutive common shares   12,868,508    10,065,186 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.2
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)
 6 Months Ended
Jun. 30, 2021
Payables and Accruals [Abstract]  
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following at:

   June 30, 2021   December 31, 2020 
         
Accounting  $36,161   $36,161 
Research and development   381,702    393,496 
Other   184,724    141,860 
           
Total  $602,587   $571,517 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.21.2
NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Tables)
 6 Months Ended
Jun. 30, 2021
Convertible Notes Payable [Member]  
Short-term Debt [Line Items]  
SCHEDULE OF MATURITY DATE OF NOTES
     
Maturity Date of Notes for Twelve Months Ending June 30, 2021,  Amount due 
2022  $- 
2023   - 
2024   607,500 
2025   - 
2026   - 
Total  $607,500 

 

Convertible Notes Payable – Related Parties

 

During the six months ended June 30, 2021 and 2020, the Company amortized $18,724 and $18,828 of the debt discount, respectively. At June 30, 2021 and December 31, 2020, the Company had an unamortized debt discount of $88,864 and $107,588, respectively.

 

As of June 30, 2021 and December 31, 2020, the Company owes $400,000 and $400,000 on the outstanding Convertible Notes, respectively.

 

     
Maturity Date of Notes for Twelve Months Ending June 30, 2021,  Amount due 
2022  $- 
2023   - 
2024   400,000 
2025   - 
2026   - 
Total  $400,000 
Convertible Notes Payable Related Party [Member]  
Short-term Debt [Line Items]  
SCHEDULE OF MATURITY DATE OF NOTES

 

     
Maturity Date of Notes for Twelve Months Ending June 30, 2021,  Amount due 
2022  $- 
2023   - 
2024   400,000 
2025   - 
2026   - 
Total  $400,000 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ DEFICIT (Tables)
 6 Months Ended
Jun. 30, 2021
Equity [Abstract]  
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS

 

      
Exercise price  $3.65-5.60 
Expected dividend yield   0%
Risk free interest rate   0.81%-1.58%
Expected life in years   5-10 
Expected volatility   148%-158 %

 

There were 5,597,861 options outstanding as of December 31, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

 

      
Exercise price  $1.75 
Expected dividend yield   0%
Risk free interest rate   0.64%-1.61%
Expected life in years   10 
Expected volatility   140%-146%
SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY

The following is an analysis of the stock option grant activity under the Plan:

 

       

Weighted

Average

    

Weighted

Average

  
  Number     Exercise Price     Remaining Life  
Stock Options                      
                       
Outstanding December 31, 2020   5,597,861     $ 1.47       6.48  
Granted   546,000     $ 4.96       9.60  
Expired   (280,000 )   $ 1.00       -  
Exercised   (370,000 )   $ 1.48       -  
Outstanding June 30, 2021   5,493,861     $ 1.84       6.79  
SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES

Nonvested Options  Options  

Weighted-

Average
Exercise Price

 
Nonvested at December 31, 2020   862,833   $1.75 
Granted   546,000   $4.96 
Vested   (433,979)  $3.32 
Forfeited   -   $- 
Nonvested at June 30, 2021   974,854   $3.02 
SUMMARY OF WARRANT ISSUANCES

A summary of warrant issuances are as follows:

 

      

Weighted

Average

  

Weighted

Average

 
   Number   Exercise Price   Remaining Life 
Warrants               
                
Outstanding December 31, 2020   4,007,058   $1.06    1.86 
Granted   3,657,000    4.98    4.83 
Expired   (150,249)   1.25    - 
Exercised   (1,381,179)   1.13    - 
Outstanding June 30, 2021   6,132,630   $3.38    3.65 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Reported Value Measurement [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative warrants liabilities $ 83,670
Estimate of Fair Value Measurement [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative warrants liabilities 83,670
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative warrants liabilities
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative warrants liabilities
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative warrants liabilities $ 83,670
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION (Details) - USD ($)
 6 Months Ended
Jun. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Balance at end $ 83,670
Change in fair value of derivative warrants liabilities $ (83,670)  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details)
 12 Months Ended
Dec. 31, 2020
$ / shares
Jun. 30, 2021
Measurement Input, Exercise Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Share price $ 1.25  
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 0.0009  
Measurement Input, Expected Dividend Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 0.0000 0
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 1.69  
Measurement Input, Expected Term [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input, contractual term 1 month 20 days  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares
 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially outstanding dilutive common shares 12,868,508 10,065,186
Conversion Feature Shares [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially outstanding dilutive common shares 436,017 872,766
Equity Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially outstanding dilutive common shares 5,493,861 4,028,162
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially outstanding dilutive common shares 6,132,630 3,908,258
Convertible Notes [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially outstanding dilutive common shares 806,000 1,256,000
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Details Narrative)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
shares
Jun. 30, 2020
USD ($)
Dec. 31, 2020
$ / shares
Subsidiary, Sale of Stock [Line Items]          
Derivative, gain (loss) on derivative, net $ (23,560) $ 83,670 $ 37,189  
Warrant expiry date Feb. 21, 2021   Feb. 21, 2021    
Measurement Input, Expected Dividend Rate [Member]          
Subsidiary, Sale of Stock [Line Items]          
Derivative liability measurement input 0   0   0.0000
Warrant expiry date Feb. 21, 2021   Feb. 21, 2021    
Private Placement [Member]          
Subsidiary, Sale of Stock [Line Items]          
Fair value of derivative feature $ 127,346   $ 127,346    
Class of warrant or right, issued | shares     295,945    
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Accounting $ 36,161 $ 36,161
Research and development 381,702 393,496
Other 184,724 141,860
Total $ 602,587 $ 571,517
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.21.2
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative) - USD ($)
 6 Months Ended
Oct. 01, 2021
Dec. 31, 2020
Jun. 30, 2021
Oct. 02, 2019
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]        
Estimate for study description On October 1, 2019, the Company entered into an agreement with a consultant for toxicology studies. The consultant quoted a commitment of approximately $988,000 as an estimate for the study. 50% of the total price was paid upon the signing of the agreement, 35% of the total price is to be paid upon completion of the in-life study, and the remaining 15% of the total price is to be paid upon the issuance of the report. If the Company cancels the study the Company will be required to pay a cancelation fee. If the cancelation happens prior to the arrival of the test animals then the Company will need to pay between 20% and 50% of the animal fees depending on when the cancellation happens. If the cancellation occurs after the animals arrive but before the study begins then the Company will be responsible for paying 50% of the protocol price plus a fee of $7,000 per room/week for animal husbandry until the animals can be relocated or disposed of. If the Company cancels the study after it has begun then the Company will need to pay any fees for procured items for the study and any nonrecoverable expenses incurred by the consultant.      
Toxicology Studies [Member]        
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]        
Commitment cost paid   $ 174,106 $ 174,106  
Balance due amount   $ 319,799 $ 319,799  
Consultant [Member]        
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]        
Estimate commitment amount       $ 988,000
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF MATURITY DATE OF NOTES (Details)
Jun. 30, 2021
USD ($)
Convertible Notes Payable [Member]  
Short-term Debt [Line Items]  
2022
2023
2024 607,500
2025
2026
Total 607,500
Convertible Notes Payable Related Party [Member]  
Short-term Debt [Line Items]  
2022
2023
2024 400,000
2025
2026
Total $ 400,000
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.2
NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Details Narrative) - USD ($)
 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Mar. 01, 2021
Dec. 31, 2020
Short-term Debt [Line Items]        
Debt amortized debt discount $ 277,619 $ 58,923    
Debt unamortized debt discount $ 257,221     $ 516,116
Debt Conversion, Converted Instrument, Shares Issued 839,724      
Debt Conversion, Converted Instrument, Amount $ 990,000      
Promissory Note [Member]        
Short-term Debt [Line Items]        
Notes Payable     $ 100,000  
Debt Instrument, Maturity Date Feb. 28, 2026      
Debt Instrument, Interest Rate, Stated Percentage 110.00%   5.00%  
Debt Conversion, Original Debt, Interest Rate of Debt 750.00%      
Derivative, Fair Value, Net $ 25,000      
Promissory Note [Member] | Maximum [Member]        
Short-term Debt [Line Items]        
Notes Payable     $ 7,500,000  
Unsecured Convertible Notes [Member]        
Short-term Debt [Line Items]        
Convertible notes payable outstanding 0     0
Debt amortized debt discount 72,110 40,095    
Debt unamortized debt discount 186,785      
Interest Receivable 64,544      
Convertible Notes [Member]        
Short-term Debt [Line Items]        
Convertible notes payable outstanding 607,500     1,597,500
Unsecured Convertible Notes With Related Parties [Member]        
Short-term Debt [Line Items]        
Convertible notes payable outstanding 400,000     400,000
Debt amortized debt discount 18,724 $ 18,828    
Debt unamortized debt discount $ 88,864     $ 107,588
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) - $ / shares
 6 Months Ended 12 Months Ended
Jun. 30, 2021
Dec. 31, 2020
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]    
Exercise price   $ 1.75
Expected dividend yield 0.00% 0.00%
Expected life in years   10 years
Minimum [Member]    
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]    
Exercise price $ 3.65  
Risk free interest rate 0.81% 0.64%
Expected life in years 5 years  
Expected volatility 148.00% 140.00%
Maximum [Member]    
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]    
Exercise price $ 5.60  
Risk free interest rate 1.58% 1.61%
Expected life in years 10 years  
Expected volatility 158.00% 146.00%
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details)
 6 Months Ended
Jun. 30, 2021
$ / shares
shares
Equity [Abstract]  
Stock Options Outstanding, Beginning | shares 5,597,861
Weighted Average Exercisable Price, Stock Options Outstanding, Beginning | $ / shares $ 1.47
Weighted Average Remaining Life, Stock Options Outstanding, Beginning 6 years 5 months 23 days
Stock Options, Granted | shares 546,000
Weighted Average Exercisable Price, Stock Options Outstanding, Granted | $ / shares $ 4.96
Weighted average remaining contractual term 9 years 7 months 6 days
Stock Options, Expired | shares (280,000)
Weighted Average Exercisable Price, Stock Options Outstanding, Expired | $ / shares $ 1.00
Stock Option, Exercised | shares (370,000)
Weighted Average Exercisable Price, Stock Options Outstanding, Exercised | $ / shares $ 1.48
Stock Options Outstanding, Ending | shares 5,493,861
Weighted Average Exercisable Price, Stock Options Outstanding, Ending | $ / shares $ 1.84
Weighted average remaining life, stock options outstanding, ending 6 years 9 months 14 days
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details) - $ / shares
 6 Months Ended
Jun. 30, 2021
Dec. 31, 2020
Equity [Abstract]    
Nonvested Options, Ending Balance 974,854 862,833
Weighted Average Exercise Price, Ending Balance $ 3.02 $ 1.75
Nonvested Options, Granted 546,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 4.96  
Nonvested Options, Vested (433,979)  
Weighted Average Exercise Price, Vested $ 3.32  
Nonvested Options, Forfeited  
Weighted Average Exercise Price, Forfeited  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF WARRANT ISSUANCES (Details)
 6 Months Ended
Jun. 30, 2021
$ / shares
shares
Equity [Abstract]  
Number of Warrants Outstanding, Beginning | shares 4,007,058
Number of Warrants Outstanding, Weighted Average Exercise Price, Beginning | $ / shares $ 1.06
Number of Warrants Outstanding, Weighted Average Remaining Life 1 year 10 months 9 days
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted | shares 3,657,000
Number of Warrants Outstanding, Weighted Average Exercise Price, Granted | $ / shares $ 4.98
Number of warrants outstanding weighted average remaining life granted 4 years 9 months 29 days
Number of Warrants Outstanding, Expired | shares (150,249)
Number of Warrants Outstanding, Weighted Average Exercise Price, Expired | $ / shares $ 1.25
Number of Warrants Outstanding, Exercised | shares (1,381,179)
Number of Warrants Outstanding, Weighted Average Exercise Price, Exercised | $ / shares $ 1.13
Number of Warrants Outstanding, Ending | shares 6,132,630
Number of Warrants Outstanding, Weighted Average Exercise Price, Ending | $ / shares $ 3.38
Number of Warrants Outstanding, Weighted Average Remaining Life 3 years 7 months 24 days
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
May 26, 2021
Apr. 29, 2021
Feb. 25, 2021
Feb. 25, 2020
Jan. 02, 2017
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]                      
Proceeds from Issuance Initial Public Offering   $ 11,700,000                  
Stock options outstanding           5,493,861     5,493,861   5,597,861
Stock options outstanding weighted average exercise price           $ 1.84     $ 1.84   $ 1.47
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value           $ 5,701,038     $ 5,701,038    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                 546,000    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price                 $ 4.96    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term                 6 years 5 months 23 days    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares                 433,979    
Stock issued during the period exercised                 370,000    
Commom stock issued           16,263,634     16,263,634   10,360,480
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number           6,132,630     6,132,630   4,007,058
Common Stock [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Stock issued during the period exercised           360,000 10,000        
Commom stock issued           360,000     360,000    
Proceeds from Stock Options Exercised           $ 532,500          
Warrants outstanding           836,558 240,123   836,558    
Proceeds from warrants exercised           $ 300,000 $ 27,125        
Warrant [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Stock issued during the period exercised           1,008,137          
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number           6,132,630     6,132,630    
Class of warrant or right, outstanding, weighted average exercise price           $ 3.38     $ 3.38    
Class of warrant or right, outstanding, intrinsic value           $ 4,629,869     $ 4,629,869    
Warrants outstanding             373,042        
Options To Related Party [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Stock options outstanding           10,000     10,000    
Stock options outstanding weighted average exercise price           $ 1.00     $ 1.00    
Stock issued during the period exercised                 10,000    
Options To Related Party [Member] | Common Stock [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Warrants outstanding           231,277     231,277    
Employees [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Payment Arrangement, Expense               $ 528,197      
Unamortized stock option expense           $ 343,794     $ 343,794    
Non-Employees [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Payment Arrangement, Expense               194,769 404,541    
Unamortized stock option expense           $ 2,197,663     $ 2,197,663    
2016 Plan [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Number of additional shares grants for issuance         564,378            
Number of shares available for grant         1,693,134 4,868,623     4,868,623   4,868,623
Series B Prefered Stock [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Preferred Stock, Convertible, Shares Issuable           436,749     436,749    
Common Stock [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Preferred Stock, Convertible, Shares Issuable           436,749     436,749    
Share-based Payment Arrangement, Option [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                 546,000    
Share-based Payment Arrangement, Expense           $ 722,966   304,148 $ 664,400 $ 1,387,497  
Share-based Payment Arrangement, Option [Member] | Settlement of Accrued Compensation [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 180,000                    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 3.65     $ 5.60              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value $ 474,231     $ 2,009,063              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 10 years                    
Share-based Payment Arrangement, Option [Member] | Options Vested Over 48 Months [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares     16,000 350,000              
Share-based Payment Arrangement, Option [Member] | 5 Individuals [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     366,000                
Share-based Payment Arrangement, Option [Member] | Related Parties [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross       350,000              
Share-based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Payment Arrangement, Expense           721,490   269,408 1,065,988 595,202  
Share-based Payment Arrangement, Option [Member] | Research and Development Expense [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Payment Arrangement, Expense           1,476   $ 34,740 2,953 $ 69,381  
Share-based Payment Arrangement, Option [Member] | Minimum [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price                   $ 3.65  
Share-based Payment Arrangement, Option [Member] | Minimum [Member] | Settlement of Accrued Compensation [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term       5 years              
Share-based Payment Arrangement, Option [Member] | Maximum [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price                   $ 5.60  
Share-based Payment Arrangement, Option [Member] | Maximum [Member] | Settlement of Accrued Compensation [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term       10 years              
Equity Option [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Share-based Payment Arrangement, Expense                 1,068,941 $ 751,552  
Unamortized stock option expense           $ 2,541,457     $ 2,541,457    
IPO [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Stock Issued During Period, Shares, New Issues   3,180,000                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   3,180,000                  
IPO [Member] | 45-day Option [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   477,000                  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.21.2
COLLABORATIVE AGREEMENTS (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2015
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of stock options vested     433,979    
Research and development expense $ 140,592 $ 52,008 $ 732,943 $ 117,967  
Research Agreements [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expense     $ 0 $ 0  
University of Toronto [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Share-based compensation stock options, grants         25,000
Share-based compensation weighted average exercise price         $ 1.00
Share-based payment award, expiration period         10 years
Dr. David Lovejoy [Member] | Share-based Payment Arrangement, Option [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Share-based compensation stock options, grants     553,299    
Share-based compensation weighted average exercise price $ 1.00   $ 1.00    
Number of stock options vested     435,487    
Number of stock options expired     100,000    
Options expiration date, description     These have an exercise price of $1.00, $1.25 or 1.75 and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027, October 16, 2027 or on February 13, 2030.    
Dr. David Lovejoy [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Share-based compensation weighted average exercise price 1.25   $ 1.25    
Dr. David Lovejoy [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Share-based compensation weighted average exercise price $ 1.75   $ 1.75    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Acquired Finite-Lived Intangible Assets [Line Items]    
Royalty Payment on behalf of sublicensee percentage 250.00%  
Sales revenue $ 0 $ 0
Interest on amounts owed under license agreement, rate 3.00%  
Licensing Agreements [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Royalty payment, percentage 2.50%  
Up-front sub-license fees, percentage 10.00%  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.21.2
SUBSEQUENT EVENTS (Details Narrative) - $ / shares
 6 Months Ended
Jul. 26, 2021
Jun. 30, 2021
Aug. 16, 2021
Subsequent Event [Line Items]      
Stock Options, Granted   546,000  
Common Stock [Member]      
Subsequent Event [Line Items]      
Preferred Stock, Convertible, Shares Issuable   436,749  
Subsequent Event [Member]      
Subsequent Event [Line Items]      
Preferred Stock, Convertible, Shares Issuable     436,017
Subsequent Event [Member] | Common Stock [Member]      
Subsequent Event [Line Items]      
Stock Options, Granted 32,000    
Exercise price per share $ 2.09    
Subsequent Event [Member] | Common Stock [Member]      
Subsequent Event [Line Items]      
Preferred Stock, Convertible, Shares Issuable     436,017
EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 185 297 1 false 55 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://protagenic.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://protagenic.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://protagenic.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements Of Changes In Stockholders' Deficit (Unaudited) Sheet http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit Consolidated Statements Of Changes In Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://protagenic.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS Sheet http://protagenic.com/role/OrganizationAndNatureOfBusiness ORGANIZATION AND NATURE OF BUSINESS Notes 7 false false R8.htm 00000008 - Disclosure - LIQUIDITY Sheet http://protagenic.com/role/Liquidity LIQUIDITY Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES Sheet http://protagenic.com/role/SummaryOfSignficantAccountingPolicies SUMMARY OF SIGNFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://protagenic.com/role/AccountsPayableAndAccruedExpenses ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 10 false false R11.htm 00000011 - Disclosure - NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) Notes http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotes NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) Notes 11 false false R12.htm 00000012 - Disclosure - STOCKHOLDERS??? DEFICIT Sheet http://protagenic.com/role/StockholdersDeficit STOCKHOLDERS??? DEFICIT Notes 12 false false R13.htm 00000013 - Disclosure - COLLABORATIVE AGREEMENTS Sheet http://protagenic.com/role/CollaborativeAgreements COLLABORATIVE AGREEMENTS Notes 13 false false R14.htm 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://protagenic.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 00000015 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://protagenic.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 15 false false R16.htm 00000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://protagenic.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 00000017 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Policies) Sheet http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Tables) Sheet http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesTables SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Tables) Tables http://protagenic.com/role/SummaryOfSignficantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://protagenic.com/role/AccountsPayableAndAccruedExpensesTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://protagenic.com/role/AccountsPayableAndAccruedExpenses 19 false false R20.htm 00000020 - Disclosure - NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Tables) Notes http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesTables NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Tables) Tables http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotes 20 false false R21.htm 00000021 - Disclosure - STOCKHOLDERS??? DEFICIT (Tables) Sheet http://protagenic.com/role/StockholdersDeficitTables STOCKHOLDERS??? DEFICIT (Tables) Tables http://protagenic.com/role/StockholdersDeficit 21 false false R22.htm 00000022 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) Sheet http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) Details 22 false false R23.htm 00000023 - Disclosure - SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION (Details) Sheet http://protagenic.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION (Details) Details 23 false false R24.htm 00000024 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details) Sheet http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details) Details 24 false false R25.htm 00000025 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Sheet http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Details 25 false false R26.htm 00000026 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Details Narrative) Details http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Sheet http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Details 27 false false R28.htm 00000028 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative) Sheet http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative) Details http://protagenic.com/role/AccountsPayableAndAccruedExpensesTables 28 false false R29.htm 00000029 - Disclosure - SCHEDULE OF MATURITY DATE OF NOTES (Details) Notes http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails SCHEDULE OF MATURITY DATE OF NOTES (Details) Details 29 false false R30.htm 00000030 - Disclosure - NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Details Narrative) Notes http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Details Narrative) Details http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesTables 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) Sheet http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) Details 31 false false R32.htm 00000032 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details) Sheet http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details) Details 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details) Sheet http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details) Details 33 false false R34.htm 00000034 - Disclosure - SUMMARY OF WARRANT ISSUANCES (Details) Sheet http://protagenic.com/role/SummaryOfWarrantIssuancesDetails SUMMARY OF WARRANT ISSUANCES (Details) Details 34 false false R35.htm 00000035 - Disclosure - STOCKHOLDERS??? DEFICIT (Details Narrative) Sheet http://protagenic.com/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS??? DEFICIT (Details Narrative) Details http://protagenic.com/role/StockholdersDeficitTables 35 false false R36.htm 00000036 - Disclosure - COLLABORATIVE AGREEMENTS (Details Narrative) Sheet http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative COLLABORATIVE AGREEMENTS (Details Narrative) Details http://protagenic.com/role/CollaborativeAgreements 36 false false R37.htm 00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://protagenic.com/role/CommitmentsAndContingencies 37 false false R38.htm 00000038 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://protagenic.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://protagenic.com/role/SubsequentEvents 38 false false All Reports Book All Reports form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ptix-20210630.xsd ptix-20210630_cal.xml ptix-20210630_def.xml ptix-20210630_lab.xml ptix-20210630_pre.xml http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 18, "contextCount": 185, "dts": { "calculationLink": { "local": [ "ptix-20210630_cal.xml" ] }, "definitionLink": { "local": [ "ptix-20210630_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "ptix-20210630_lab.xml" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "ptix-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml" ] }, "schema": { "local": [ "ptix-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 392, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 107, "http://protagenic.com/20210630": 27, "http://xbrl.sec.gov/dei/2021": 5, "total": 139 }, "keyCustom": 36, "keyStandard": 261, "memberCustom": 22, "memberStandard": 27, "nsprefix": "PTIX", "nsuri": "http://protagenic.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://protagenic.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES", "role": "http://protagenic.com/role/AccountsPayableAndAccruedExpenses", "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)", "role": "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotes", "shortName": "NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - STOCKHOLDERS\u2019 DEFICIT", "role": "http://protagenic.com/role/StockholdersDeficit", "shortName": "STOCKHOLDERS\u2019 DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - COLLABORATIVE AGREEMENTS", "role": "http://protagenic.com/role/CollaborativeAgreements", "shortName": "COLLABORATIVE AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://protagenic.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://protagenic.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS", "role": "http://protagenic.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Policies)", "role": "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Tables)", "role": "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)", "role": "http://protagenic.com/role/AccountsPayableAndAccruedExpensesTables", "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "role": "http://protagenic.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-06-30_us-gaap_ConvertibleNotesPayableMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Tables)", "role": "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesTables", "shortName": "NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-06-30_us-gaap_ConvertibleNotesPayableMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Tables)", "role": "http://protagenic.com/role/StockholdersDeficitTables", "shortName": "STOCKHOLDERS\u2019 DEFICIT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)", "role": "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "shortName": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION (Details)", "role": "http://protagenic.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails", "shortName": "SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_MeasurementInputExercisePriceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details)", "role": "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails", "shortName": "SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_MeasurementInputExercisePriceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "role": "http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-04-012020-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-06-30_us-gaap_PrivatePlacementMember", "decimals": "INF", "lang": null, "name": "PTIX:ClassOfWarrantOrRightIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "PTIX:AccruedAccountingFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)", "role": "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails", "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "PTIX:AccruedAccountingFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-09-282021-10-01", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RegistrationPaymentArrangementEventToTransferConsideration", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)", "role": "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative", "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-09-282021-10-01", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RegistrationPaymentArrangementEventToTransferConsideration", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SCHEDULE OF MATURITY DATE OF NOTES (Details)", "role": "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails", "shortName": "SCHEDULE OF MATURITY DATE OF NOTES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://protagenic.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Details Narrative)", "role": "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "shortName": "NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)", "role": "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "shortName": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details)", "role": "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "shortName": "SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "lang": "en-US", "name": "PTIX:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details)", "role": "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails", "shortName": "SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SUMMARY OF WARRANT ISSUANCES (Details)", "role": "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails", "shortName": "SUMMARY OF WARRANT ISSUANCES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "lang": null, "name": "PTIX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-282021-04-29", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "role": "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-282021-04-29", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - COLLABORATIVE AGREEMENTS (Details Narrative)", "role": "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "shortName": "COLLABORATIVE AGREEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-06-30_custom_ResearchAgreementsMember", "decimals": "0", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "PTIX:RoyaltyPaymentOnBehalfOfSublicenseePercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "PTIX:RoyaltyPaymentOnBehalfOfSublicenseePercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://protagenic.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-08-16_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockConvertibleSharesIssuable", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "role": "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-31_custom_SeriesBConvertiblePreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements Of Changes In Stockholders' Deficit (Unaudited)", "role": "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit", "shortName": "Consolidated Statements Of Changes In Stockholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember", "decimals": "0", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "role": "http://protagenic.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-06-30", "decimals": "0", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS", "role": "http://protagenic.com/role/OrganizationAndNatureOfBusiness", "shortName": "ORGANIZATION AND NATURE OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "PTIX:LiquidityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - LIQUIDITY", "role": "http://protagenic.com/role/Liquidity", "shortName": "LIQUIDITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "PTIX:LiquidityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES", "role": "http://protagenic.com/role/SummaryOfSignficantAccountingPolicies", "shortName": "SUMMARY OF SIGNFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 55, "tag": { "PTIX_AccruedAccountingFeesCurrent": { "auth_ref": [], "calculation": { "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued accounting fees current.", "label": "Accounting" } } }, "localname": "AccruedAccountingFeesCurrent", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "PTIX_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development current.", "label": "AccruedResearchAndDevelopmentCurrent", "verboseLabel": "Research and development" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "PTIX_ClassOfWarrantOrRightIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights issued during period.", "label": "Class of warrant or right, issued" } } }, "localname": "ClassOfWarrantOrRightIssued", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PTIX_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant [Member]", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_ConversionFeatureSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Feature Shares [Member]", "label": "Conversion Feature Shares [Member]" } } }, "localname": "ConversionFeatureSharesMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "PTIX_ConvertibleLongTermNotesPayableRelatedParty": { "auth_ref": [], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible long term notes payable related party.", "label": "PIK convertible notes payable, net of debt discount - related parties" } } }, "localname": "ConvertibleLongTermNotesPayableRelatedParty", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "PTIX_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes [Member]", "label": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "PTIX_ConvertibleNotesPayableRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes Payable Related Party [Member]", "label": "Convertible Notes Payable Related Party [Member]" } } }, "localname": "ConvertibleNotesPayableRelatedPartyMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesTables", "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails" ], "xbrltype": "domainItemType" }, "PTIX_DerivativeLiabilityMeasurementInputContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative liability measurement input, contractual term.", "label": "Derivative liability measurement input, contractual term" } } }, "localname": "DerivativeLiabilityMeasurementInputContractualTerm", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails" ], "xbrltype": "durationItemType" }, "PTIX_DisclosureLiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity" } } }, "localname": "DisclosureLiquidityAbstract", "nsuri": "http://protagenic.com/20210630", "xbrltype": "stringItemType" }, "PTIX_DrDavidLovejoyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dr. David Lovejoy [Member]", "label": "Dr. David Lovejoy [Member]" } } }, "localname": "DrDavidLovejoyMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees [Member]", "label": "Employees [Member]" } } }, "localname": "EmployeesMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_EstimateCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimate commitment amount.", "label": "Estimate commitment amount" } } }, "localname": "EstimateCommitmentAmount", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PTIX_FiveIndividualsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5 Individuals [Member]", "label": "5 Individuals [Member]" } } }, "localname": "FiveIndividualsMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_FourtyFiveDayOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "45-day Option [Member]", "label": "45-day Option [Member]" } } }, "localname": "FourtyFiveDayOptionMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_InterestOnAmountsOwedUnderLicenseAgreementRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The interest rate charged per annum on any amounts owed under the license agreement and amendment.", "label": "Interest on amounts owed under license agreement, rate" } } }, "localname": "InterestOnAmountsOwedUnderLicenseAgreementRate", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "PTIX_IssuanceOfOptionsForSettlementOfAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of options for settlement of accounts payable.", "label": "Issuance of options for settlement of accounts payable" } } }, "localname": "IssuanceOfOptionsForSettlementOfAccountsPayable", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PTIX_IssuanceOfOptionsForSettlementOfAccruedPayroll": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of options for settlement of accrued payroll.", "label": "Issuance of options for settlement of accrued payroll" } } }, "localname": "IssuanceOfOptionsForSettlementOfAccruedPayroll", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "PTIX_IssuanceOfSharesAndWarrantsFromOffering": { "auth_ref": [], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance Of Shares And Warrants From Offering.", "label": "Issuance of shares and warrants from offering, net of offering costs" } } }, "localname": "IssuanceOfSharesAndWarrantsFromOffering", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows", "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "PTIX_LiquidityDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity Disclosure [Text Block]", "label": "LIQUIDITY" } } }, "localname": "LiquidityDisclosureTextBlock", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/Liquidity" ], "xbrltype": "textBlockItemType" }, "PTIX_ModificationOfWarrants": { "auth_ref": [], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Modification Of Warrants.", "label": "Modification of warrants" } } }, "localname": "ModificationOfWarrants", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows", "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "PTIX_NonEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Employees [Member]", "label": "Non-Employees [Member]" } } }, "localname": "NonEmployeesMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_NumberOfWarrantsOutstandingWeightedAverageRemainingLifeGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants outstanding weighted average remaining life granted.", "label": "Number of warrants outstanding weighted average remaining life granted" } } }, "localname": "NumberOfWarrantsOutstandingWeightedAverageRemainingLifeGranted", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "durationItemType" }, "PTIX_OptionsExpirationDateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options expiration date, description.", "label": "Options expiration date, description" } } }, "localname": "OptionsExpirationDateDescription", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "PTIX_OptionsToRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options To Related Party [Member]", "label": "Options To Related Party [Member]" } } }, "localname": "OptionsToRelatedPartyMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_OptionsVestedOverFourtyEightMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options Vested Over 48 Months [Member]", "label": "Options Vested Over 48 Months [Member]" } } }, "localname": "OptionsVestedOverFourtyEightMonthsMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_ProceedsFromNotesPayablerelatedparty": { "auth_ref": [], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Notes Payable related party.", "label": "Proceeds from PIK convertible notes - related party" } } }, "localname": "ProceedsFromNotesPayablerelatedparty", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PTIX_ProceedsFromWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds from warrants exercised.", "label": "Proceeds from warrants exercised" } } }, "localname": "ProceedsFromWarrantsExercised", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PTIX_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member]", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_RelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Parties [Member]", "label": "Related Parties [Member]" } } }, "localname": "RelatedPartiesMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_ResearchAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research Agreements [Member]", "label": "Research Agreements [Member]" } } }, "localname": "ResearchAgreementsMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_RoyaltyPaymentOnBehalfOfSublicenseePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of royalty payment of net sales made on behalf of a sub-licensee.", "label": "Royalty Payment on behalf of sublicensee percentage" } } }, "localname": "RoyaltyPaymentOnBehalfOfSublicenseePercentage", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "PTIX_RoyaltyPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of royalty payment of net sales.", "label": "Royalty payment, percentage" } } }, "localname": "RoyaltyPaymentPercentage", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "PTIX_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Convertible Preferred Stock [Member]", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "PTIX_SeriesBPreferedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Prefered Stock [Member]", "label": "Series B Prefered Stock [Member]" } } }, "localname": "SeriesBPreferedStockMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_SettlementOfAccruedCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement of Accrued Compensation [Member]", "label": "Settlement of Accrued Compensation [Member]" } } }, "localname": "SettlementOfAccruedCompensationMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants outstanding, weighted average exercise price, expired", "label": "Number of Warrants Outstanding, Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "perShareItemType" }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants outstanding, weighted average exercise price, expired.", "label": "Number of Warrants Outstanding, Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "perShareItemType" }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.", "label": "Number of Warrants Outstanding, Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "perShareItemType" }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.", "label": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan", "periodEndLabel": "Number of Warrants Outstanding, Weighted Average Exercise Price, Ending", "periodStartLabel": "Number of Warrants Outstanding, Weighted Average Exercise Price, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "perShareItemType" }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual life", "label": "Number of Warrants Outstanding, Weighted Average Remaining Life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "durationItemType" }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual life", "label": "Weighted average remaining contractual life", "verboseLabel": "Number of Warrants Outstanding, Weighted Average Remaining Life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "durationItemType" }, "PTIX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, outstanding, weighted average exercise price.", "label": "Class of warrant or right, outstanding, weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingWeightedAverageExercisePrice", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "PTIX_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, outstanding, intrinsic value.", "label": "Class of warrant or right, outstanding, intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PTIX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term", "label": "Weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "PTIX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpirationNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock options expired.", "label": "Number of stock options expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpirationNumberOfShares", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PTIX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining life, stock options outstanding, ending.", "label": "Weighted average remaining life, stock options outstanding, ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "PTIX_StockIssuedDuringPeriodShareConversionofpreferredstock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "StockIssued During Period Share Conversionof preferred stock.", "label": "Conversion of preferred stock,Shares" } } }, "localname": "StockIssuedDuringPeriodShareConversionofpreferredstock", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "PTIX_StockIssuedDuringPeriodSharesStockwarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Shares Stock warrants Exercised.", "label": "Exercise of warrants, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockwarrantsExercised", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "PTIX_StockIssuedDuringPeriodValueConversionofpreferredstock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Value Conversion of preferred stock.", "label": "Conversion of preferred stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionofpreferredstock", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "PTIX_StockIssuedDuringPeriodValueStockWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Value Stock Warrants Exercised.", "label": "Exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "PTIX_StockIssuedDuringPeriodsharesIssuanceofsharesandwarrantsfromoffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period shares Issuance of shares and warrants from offering.", "label": "Issuance of shares and warrants from offering, net of offering costs, shares" } } }, "localname": "StockIssuedDuringPeriodsharesIssuanceofsharesandwarrantsfromoffering", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "PTIX_ToxicologyStudiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Toxicology Studies [Member]", "label": "Toxicology Studies [Member]" } } }, "localname": "ToxicologyStudiesMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_TwoThousandSixteenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2016 Plan [Member]", "label": "2016 Plan [Member]" } } }, "localname": "TwoThousandSixteenPlanMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_UnamortizedStockOptionExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unamortized stock option expense.", "label": "Unamortized stock option expense" } } }, "localname": "UnamortizedStockOptionExpense", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PTIX_UniversityOfTorontoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "University of Toronto [Member]", "label": "University of Toronto [Member]" } } }, "localname": "UniversityOfTorontoMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_UnsecuredConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unsecured Convertible Notes [Member]", "label": "Unsecured Convertible Notes [Member]" } } }, "localname": "UnsecuredConvertibleNotesMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_UnsecuredConvertibleNotesWithRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unsecured Convertible Notes With Related Parties [Member]", "label": "Unsecured Convertible Notes With Related Parties [Member]" } } }, "localname": "UnsecuredConvertibleNotesWithRelatedPartiesMember", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PTIX_UpFrontSubLicenseFeesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Up front sub license fees percentage.", "label": "Up-front sub-license fees, percentage" } } }, "localname": "UpFrontSubLicenseFeesPercentage", "nsuri": "http://protagenic.com/20210630", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r416", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://protagenic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r39", "r41", "r90", "r91", "r183", "r216" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r182", "r215", "r246", "r248", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r392", "r393", "r404", "r405" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r182", "r215", "r246", "r248", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r392", "r393", "r404", "r405" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r182", "r215", "r236", "r246", "r248", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r392", "r393", "r404", "r405" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r182", "r215", "r236", "r246", "r248", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r392", "r393", "r404", "r405" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r40", "r41", "r90", "r91", "r183", "r216" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r103", "r107", "r247" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r103", "r107", "r165", "r247", "r355" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r148", "r346" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses", "verboseLabel": "Total" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r44", "r45", "r46", "r385", "r398", "r399" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r43", "r46", "r52", "r53", "r54", "r95", "r96", "r97", "r302", "r394", "r395", "r427" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r17", "r282", "r352" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r95", "r96", "r97", "r279", "r280", "r281", "r311" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r228", "r231", "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Debt discount from beneficial conversion feature" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r249", "r251", "r285", "r286" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock compensation - stock options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r251", "r276", "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r63", "r73", "r202", "r339" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount", "verboseLabel": "Debt amortized debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total potentially outstanding dilutive common shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative", "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r88", "r134", "r137", "r143", "r150", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r299", "r303", "r323", "r350", "r352", "r372", "r382" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r36", "r88", "r150", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r299", "r303", "r323", "r350", "r352" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r252", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r23", "r352", "r400", "r401" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r76" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r69", "r75", "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "CASH, END OF YEAR", "periodStartLabel": "CASH, BEGINNING OF YEAR" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r69", "r329" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NONCASH FINANCING AND INVESTING TRANSACTIONS" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r85", "r88", "r108", "r109", "r110", "r112", "r114", "r118", "r119", "r120", "r150", "r168", "r172", "r173", "r174", "r177", "r178", "r212", "r213", "r218", "r222", "r323", "r422" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r295", "r296", "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "COLLABORATIVE AGREEMENTS" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r162", "r163", "r164", "r166", "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r95", "r96", "r311" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Commom stock issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16", "r352" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.0001 par value, 100,000,000 shares authorized, 16,263,634 and 10,360,480 shares issued and outstanding at June 30, 2021, and December 31, 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r48", "r50", "r51", "r58", "r378", "r389" ], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "TOTAL COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r124", "r380" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r83", "r301" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r32" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "PIK convertible notes payable, net of debt discount" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r13", "r374", "r383", "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible notes payable outstanding" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r11", "r373", "r381", "r402" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesTables", "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r78", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r78", "r80" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtInterestRateOfDebt": { "auth_ref": [ "r78", "r80" ], "lang": { "en-us": { "role": { "documentation": "The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Interest Rate of Debt" } } }, "localname": "DebtConversionOriginalDebtInterestRateOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r84", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r196", "r203", "r204", "r205", "r211" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r12", "r13", "r87", "r93", "r179", "r180", "r181", "r182", "r183", "r184", "r186", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r207", "r208", "r209", "r210", "r340", "r373", "r374", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesTables", "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Debt Instrument, Convertible, Beneficial Conversion Feature", "verboseLabel": "Debt discount from beneficial conversion feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r30", "r180" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r31", "r182", "r316" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r32", "r87", "r93", "r179", "r180", "r181", "r182", "r183", "r184", "r186", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r207", "r208", "r209", "r210", "r340" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesTables", "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r192", "r339", "r341" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r73", "r159" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Fair value of derivative feature", "verboseLabel": "Derivative, Fair Value, Net" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r309" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in fair value of derivative liability", "negatedLabel": "Change in fair value of the derivative liability", "verboseLabel": "Derivative, gain (loss) on derivative, net" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows", "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r37", "r38", "r41", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative warrants liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative liability measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails", "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r92", "r305", "r306", "r307", "r308", "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Liability" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per common share - Basic and Diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r115", "r116" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and Diluted Net (Loss) per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r329" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r52", "r53", "r54", "r95", "r96", "r97", "r99", "r104", "r106", "r117", "r151", "r228", "r231", "r279", "r280", "r281", "r290", "r291", "r311", "r331", "r332", "r333", "r334", "r335", "r336", "r394", "r395", "r396", "r427" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r194", "r207", "r208", "r320" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r194", "r207", "r208", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r314", "r357", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r194", "r237", "r238", "r243", "r245", "r314", "r357" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r194", "r207", "r208", "r237", "r238", "r243", "r245", "r314", "r358" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r194", "r207", "r208", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r314", "r359" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r317", "r319" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Change in fair value of derivative warrants liabilities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r317" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Balance at end" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r194", "r207", "r208", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r357", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r154", "r155", "r157", "r158", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r154", "r156" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r61" ], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r56", "r134", "r136", "r139", "r142", "r144", "r371", "r376", "r379", "r390" ], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "LOSS BEFORE TAX" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r89", "r105", "r106", "r133", "r288", "r292", "r293", "r391" ], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "INCOME TAX EXPENSE" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r72" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r72" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r68", "r70", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest expense" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r88", "r138", "r150", "r168", "r169", "r170", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r300", "r303", "r304", "r323", "r350", "r351" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r88", "r150", "r323", "r352", "r375", "r387" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r29", "r88", "r150", "r168", "r169", "r170", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r300", "r303", "r304", "r323", "r350", "r351", "r352" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r193", "r206", "r207", "r208", "r374", "r384" ], "calculation": { "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r93", "r167", "r198" ], "calculation": { "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r93", "r167", "r198" ], "calculation": { "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r93", "r167", "r198" ], "calculation": { "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r93", "r167", "r198" ], "calculation": { "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r93", "r167", "r198" ], "calculation": { "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails", "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails", "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails", "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r121", "r130" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "ORGANIZATION AND NATURE OF BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/OrganizationAndNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r71", "r74" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r47", "r49", "r54", "r57", "r74", "r88", "r98", "r100", "r101", "r102", "r103", "r105", "r106", "r111", "r134", "r136", "r139", "r142", "r144", "r150", "r168", "r169", "r170", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r312", "r323", "r377", "r388" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "NET LOSS", "verboseLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows", "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit", "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "TOTAL OTHER INCOME (EXPENSES)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER (EXPENSE) INCOME" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r13", "r374", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "TOTAL OPERATING AND ADMINISTRATIVE EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING AND ADMINISTRATIVE EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r134", "r136", "r139", "r142", "r144" ], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r28" ], "calculation": { "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r42", "r44", "r327", "r328", "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation gain" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r42" ], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign exchange translation income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Loss - net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r64" ], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Interest expense" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r60" ], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Interest income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r252", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "Preferred Stock, Convertible, Shares Issuable" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15", "r212" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15", "r212" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15", "r352" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.000001 par value; 20,000,000 shares authorized; 872,766 shares issued and outstanding in the following classes:" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r5", "r152", "r153" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r66" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Exercise of options for cash" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r66" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Exercise of warrants for cash" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r66" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from PIK convertible notes" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r66" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from notes payable" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r65", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RegistrationPaymentArrangementAccrualCarryingValue": { "auth_ref": [ "r325" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of the balance sheet date of the liability representing the obligation under the registration payment arrangement.", "label": "Balance due amount" } } }, "localname": "RegistrationPaymentArrangementAccrualCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RegistrationPaymentArrangementEventToTransferConsideration": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Describes the event or circumstance that would trigger the transfer of consideration under the registration payment arrangement.", "label": "Estimate for study description" } } }, "localname": "RegistrationPaymentArrangementEventToTransferConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RegistrationPaymentArrangementGainsAndLosses": { "auth_ref": [ "r326" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The decrease (gain) or increase (loss) in the carrying amount of the registration payment obligation that was recognized in earnings during the period.", "label": "Commitment cost paid" } } }, "localname": "RegistrationPaymentArrangementGainsAndLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r244", "r344", "r345", "r347" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r342", "r343", "r345", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r67" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayment of notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r287", "r367", "r406" ], "calculation": { "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r231", "r282", "r352", "r386", "r397", "r399" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r95", "r96", "r97", "r99", "r104", "r106", "r151", "r279", "r280", "r281", "r290", "r291", "r311", "r394", "r396" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r55", "r88", "r131", "r132", "r135", "r140", "r141", "r145", "r146", "r147", "r150", "r168", "r169", "r170", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r323", "r379" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Sales revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r154", "r156", "r369" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "SCHEDULE OF MATURITY DATE OF NOTES" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r257", "r266", "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesTables", "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r232", "r250" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SUMMARY OF WARRANT ISSUANCES" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r72" ], "calculation": { "http://protagenic.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Number of Warrants Outstanding, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Number of Warrants Outstanding, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r258", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Warrants Outstanding, Ending", "periodStartLabel": "Number of Warrants Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SummaryOfWarrantIssuancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Number of additional shares grants for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based compensation weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Stock Options, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based compensation stock options, grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Stock Options, Granted", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Nonvested Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails", "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r259", "r277" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Stock options outstanding", "periodEndLabel": "Stock Options Outstanding, Ending", "periodStartLabel": "Stock Options Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Stock options outstanding weighted average exercise price", "periodEndLabel": "Weighted Average Exercisable Price, Stock Options Outstanding, Ending", "periodStartLabel": "Weighted Average Exercisable Price, Stock Options Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r250", "r254" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercisable Price, Stock Options Outstanding, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercisable Price, Stock Options Outstanding, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercisable Price, Stock Options Outstanding, Granted", "verboseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based payment award, expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r271", "r283" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Nonvested Options, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "Nonvested Options, Forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Weighted Average Exercise Price, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Life, Stock Options Outstanding, Beginning", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r256" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Nonvested Options, Vested", "verboseLabel": "Number of stock options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative", "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Weighted Average Exercise Price, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationNonvestedSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesDetailsNarrative", "http://protagenic.com/role/NotePayableAndConvertibleNotePayablePikNotesTables", "http://protagenic.com/role/ScheduleOfMaturityDateOfNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r82", "r94" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r15", "r16", "r85", "r88", "r108", "r109", "r110", "r112", "r114", "r118", "r119", "r120", "r150", "r168", "r172", "r173", "r174", "r177", "r178", "r212", "r213", "r218", "r222", "r228", "r323", "r422" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r34", "r52", "r53", "r54", "r95", "r96", "r97", "r99", "r104", "r106", "r117", "r151", "r228", "r231", "r279", "r280", "r281", "r290", "r291", "r311", "r331", "r332", "r333", "r334", "r335", "r336", "r394", "r395", "r396", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r95", "r96", "r97", "r117", "r368" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/BalanceSheetsParenthetical", "http://protagenic.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r78", "r79", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Shares issued for conversion of notes and interest" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r33", "r197", "r228", "r229", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of notes and interest, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r228", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r228", "r231", "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercise of options, shares", "negatedLabel": "Stock Option, Exercised", "verboseLabel": "Stock issued during the period exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r34", "r228", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of notes and interest" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r34", "r228", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r20", "r21", "r88", "r149", "r150", "r323", "r352" ], "calculation": { "http://protagenic.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "BALANCE", "periodStartLabel": "BALANCE", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets", "http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r86", "r213", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r231", "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r337", "r354" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r337", "r354" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r337", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r337", "r354" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r353", "r356" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StockholdersDeficitDetailsNarrative", "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative", "http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r122", "r123", "r125", "r126", "r127", "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://protagenic.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrant expiry date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/SummaryOfSignficantAccountingPoliciesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average common shares - Basic and Diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r349": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r356": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r407": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r408": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r409": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r410": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r411": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r412": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r413": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r414": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r415": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r416": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r417": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r418": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r419": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r420": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r421": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r422": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r423": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r424": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r425": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r426": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 56 0001493152-21-020241-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-020241-xbrl.zip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